Development of ultrasound and photoacoustic imaging tools for tracking of cells and particles by Kubelick, Kelsey P.
DEVELOPMENT OF ULTRASOUND AND PHOTOACOUSTIC 




























In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 
Wallace H. Coulter  












COPYRIGHT © 2019 BY KELSEY PAIGE KUBELICK 
DEVELOPMENT OF ULTRASOUND AND PHOTOACOUSTIC 



















Dr. Stanislav Y. Emelianov, Advisor 
School of Electrical and Computer 
Engineering  
The Wallace H. Coulter 
Department of Biomedical Engineering 
Georgia Institute of Technology 
Emory University School of Medicine 
 Dr. Eleanor Donnelly 
School of Medicine 




Dr. C. Ross Ethier 
The Wallace H. Coulter 
Department of Biomedical Engineering 
Georgia Institute of Technology 
Emory University School of Medicine 
 Dr. Andrés García 
The George W. Woodruff 
School of Mechanical Engineering 




Dr. Francisco Robles 
The Wallace H. Coulter 
Department of Biomedical Engineering 
School of Electrical and Computer 
Engineering 
Georgia Institute of Technology 
Emory University School of Medicine 
 Dr. Krishnendu Roy 
The Wallace H. Coulter 
Department of Biomedical Engineering 
Georgia Institute of Technology 
Emory University School of Medicine 
   
  Date Approved:  December 13, 2019 
 







My family frequently uses the saying, “Be thankful for what you have.  Be thankful 
for what you don’t have.”  Reflecting on the last five years, I am thankful for all of the 
wonderful opportunities and lessons learned throughout graduate school.  Most 
importantly, I am thankful for the support of countless colleagues, friends, and family. 
I would like to acknowledge the incredible support of my advisor, Stanislav 
Emelianov.  I could not have succeeded without his guidance.  I am most thankful for his 
encouragement to pursue research directions and interests outside of my comfort zone.  
While I loved living in Austin, it was a wonderful experience, opportunity, challenge, and 
change to relocate to Atlanta.  Furthermore, I would like to thank all members, past and 
present, of the Ultrasound Imaging and Therapeutics Research Laboratory.  Research 
contributions of specific individuals are highlighted following each chapter.  
I would like to acknowledge the support of my thesis committee members, Drs. 
Eleanor Donnelly, Ross Ethier, Andrés García, Francisco Robles, and Krishnendu Roy.  I 
appreciate their advice throughout this process, and their insights have greatly improved 
this research.   
I have had the privilege of working with many excellent collaborators.  I 
specifically would like to thank Dr. Ross Ethier, who has been substantially involved in 
my research from the start.  I specifically would also like to thank Eric Snider, a previous 
graduate student in the Ethier Lab, who I greatly enjoyed working with.  
 v 
Outside of my research, I have had many wonderful experiences working with the 
Georgia Tech Capstone Program.  I specifically would like to thank Profs. James Rains 
and James Stubbs for giving me opportunities to pursue other professional outlets during 
my time at Georgia Tech.   
Lastly, I would like to thank my friends and family for their unconditional support.  
Specifically, I would like to thank my mom and dad.  There are not enough words to 
express my gratitude for their encouragement, and I am eternally grateful to always have 













TABLE OF CONTENTS 
ACKNOWLEDGEMENTS iv 
LIST OF TABLES ix 
LIST OF FIGURES x 
LIST OF ABBREVIATIONS xxi 
SUMMARY xxiv 
CHAPTER 1. Introduction 1 
1.1 Overview of ultrasound and photoacoustic imaging 2 
1.2 Monitoring stem cell therapies 6 
1.2.1 Monitoring stem cells in ophthalmic applications 7 
1.2.2 Stem cell monitoring in the spinal cord 9 
1.3 Monitoring Particles 11 
CHAPTER 2. Photoacoustic properties of anterior ocular tissues 13 
2.1 Abstract 13 
2.2 Introduction 14 
2.3 Materials and Methods 16 
2.3.1 Eye preparation 16 
2.3.2 Imaging protocol 17 
2.3.3 Calculating and analyzing PA spectra 18 
2.3.4 PA analysis in phantom experiments of pigment and scattering 18 
2.3.5 Analysis of local tissue composition using spectroscopic PA processing 19 
2.4 Results 22 
2.5 Discussion 35 
2.6 Conclusions 37 
CHAPTER 3. A stem cell tracking platform for ophthalmic applications using 
US/PA imaging  38 
3.1 Abstract 38 
3.2 Introduction 39 
3.3 Materials and Methods 42 
3.3.1 Cell culture 42 
3.3.2 Synthesis of gold nanospheres 42 
3.3.3 Labeling cells with gold nanospheres 43 
3.3.4 Assessing stem cell multipotency after gold nanosphere labeling 44 
3.3.5 Overview of Vevo LAZR imaging system 46 
3.3.6 Analyzing PA signals of labeled cells in a tissue-mimicking phantom 46 
3.3.7 Comparing PA imaging and fluorescent microscopy in agarose gels 47 
3.3.8 Ex vivo studies in whole porcine eyes 47 
3.3.9 Trabecular meshwork dissection studies 50 
 vii 
3.3.10 Spectroscopic analysis of multi-wavelength PA datasets 51 
3.3.11 Locating stem cells in photoacoustic images 52 
3.3.12 Locating stem cells in fluorescent images 53 
3.3.13 Evaluating laser safety in vivo 53 
3.3.14 Synthesis of Prussian blue nanocubes 54 
3.3.15 Image-guided magnetic delivery of stem cells in vivo 55 
3.4 Results 57 
3.4.1 Characterization of gold nanospheres and stem cell labelling 57 
3.4.2 Stem cell detection in perfused porcine eyes 63 
3.5 Discussion 68 
3.6 Conclusions 72 
3.7 Future Work 72 
3.8 Contributions from collaborators 83 
CHAPTER 4. Trimodal imaging to guide stem cell therapy of the spinal cord 
using prussian blue nanocubes 84 
4.1 Abstract 84 
4.2 Introduction 85 
4.3 Materials and methods 87 
4.3.1 Materials 87 
4.3.2 Synthesis of small SPION precursors and PBNCs 88 
4.3.3 Characterization of nanoparticles 89 
4.3.4 Imaging Equipment 90 
4.3.5 In vitro studies of PBNC-labeled stem cells 91 
4.3.6 Ex vivo spinal cord access and stem cell injection protocol 92 
4.3.7 Ex vivo intraoperative US/PA image-guidance 92 
4.3.8 Ex vivo trimodal US/PA/MR imaging 93 
4.3.9 In vivo surgical procedure and imaging protocols 95 
4.3.10 Histological analysis of PBNC-labeled stem cells 98 
4.3.11 Ex vivo porcine studies 99 
4.3.12 Stem cell viability probe 99 
4.4 Results 100 
4.4.1 Characterization of PBNCs 100 
4.4.2 Characterization of PBNC-labeled stem cells in vitro 105 
4.4.3 Intraoperative studies, ex vivo and in vivo 107 
4.4.4 In vivo longitudinal monitoring 115 
4.5 Discussion 121 
4.6 Conclusions 125 
4.7 Future work 126 
4.8 Contributions from collaborators 134 
CHAPTER 5. Tracking particles to inform vaccine design 135 
5.1 Abstract 135 
5.2 Introduction 136 
5.3 Materials and methods 139 
5.3.1 Particle synthesis and characterization 139 
5.3.2 PA assessment of PLPs in a tissue-mimicking phantom 141 
 viii 
5.3.3 In vivo studies 142 
5.4 Results 143 
5.4.1 Particle synthesis and characterization 143 
5.4.2 In vivo studies using uncoated nPLPs 148 
5.4.3 In vivo studies using adjuvant-coated particles 154 
5.5 Discussion 164 
5.6 Conclusions 167 
5.7 Future work 168 
5.8 Contributions from collaborators 169 
CHAPTER 6. Conclusions 170 
References  174 
 
 ix 
LIST OF TABLES 
Table 1. Comparison of laser parameters used in relevant ophthalmic applications. ....... 75 
Table 2. Relaxometry measurements of PBNCs and SPIONs ........................................ 103 
Table 3.  Description of PLP formulations.  The size column indicates target diameter of 
~1 µm (micro) or ~300 nm (nano).  The absorber column indicates type of dye 
encapsulated.  The coating column indicates whether the PLP has no coating or an 
adjuvant (CpG) coating.  The modality column indicates PA or fluorescent contrast. .. 144 
Table 4. Average diameter of different types of nPLPs.  PDI = polydispersity index. .. 147 





LIST OF FIGURES 
Figure 1. PA spectrum of blood (blue line), melanin (yellow line), and gold nanorods 
(orange line).  The PA spectrum of each absorber corresponds to the absorbance 
spectrum. ............................................................................................................................. 5 
Figure 2. Visualization of anatomy and PA signals in the anterior segment.  (A, B) 
Grayscale ultrasound images showing anatomy of the ex vivo porcine eye. S= sclera, AC 
= anterior chamber, C = cornea, L= lens, TM = trabecular meshwork, AI = anterior iris, 
PI =posterior iris, SCS = suprachoroidal space, and CPE = ciliary pigmented epithelium. 
(C) Corresponding histologic image of the porcine anterior segment stained with 
hematoxylin and eosin. (D-G) Overlay of ultrasound and PA (color scale) images at 
different locations (scans at 0°, 45°, 90°, and 135°) at λ = 700 nm.  PA signals appeared 
at melanin-rich regions, such as the TM and throughout the iris, and consistently 
appeared at the same anatomical landmark in all frames.  Scale bar = 3 mm. ................. 24 
Figure 3. Photoacoustic spectra in fixed and fresh brown porcine eyes. (A) Representative 
PA spectra for the scleral region (S), TM, anterior iris (AI), and posterior iris (PI) for 
fixed brown porcine eyes.  Average PA spectra and standard deviations were also 
calculated for the anterior iris (B) and posterior iris (C) in multiple fresh brown porcine 
eyes.  PA spectra appeared similar in fixed and fresh eyes.  The measured PA spectrum 
(solid blue line) of the anterior iris was compared to the reported absorption spectrum of 
melanin (dashed blue line).  (C) The measured PA spectrum (solid orange line) of the 
posterior iris was compared to the reported absorption spectrum (dashed orange line) of 
HbO2 to highlight a potential source of PA imaging artifacts following spectroscopic 
analysis. ............................................................................................................................. 26 
Figure 4. Photoacoustic spectrum of fresh pigment as a function of depth.  A silicone tube 
was filled with purified pigment and cross-sectional US/PA images were acquired.  The 
PA spectrum was analyzed within different regions of interest.  “Top” and “Bottom” 
indicate locations closest to, and further from, the transducer with the least and most light 
attenuation, respectively.  (A) The PA spectrum of melanin was modified by depth due to 
light absorption of melanin, causing a significant change in the PA spectrum.  (B) The 
experiment was repeated with the addition of a scattering layer (sclera), resulting in 
further modification of the measured PA spectrum of melanin. ....................................... 28 
Figure 5. Spectroscopic photoacoustic analysis using LLS regression in brown porcine 
eyes. (A) Absorption spectra from literature used for sPA analysis, and resulting 
computed distributions of melanin (B), HbO2 (C), and Hb (D).  (E-H) as in (A-D), but 
using measured PA spectra. Overlay of ultrasound (grayscale) and spectroscopic PA 
 xi 
images showed localization of melanin (blue color scale), HbO2 (orange color scale), and 
Hb (pink color scale).  Melanin was localized as expected. Absorption spectra from the 
literature and measured by photoacoustic imaging produced similar results.  Some 
artifacts remained in the HbO2 images (C and G).   Scale bar = 3 mm. ........................... 30 
Figure 6. Comparison of measured PA spectra in blue and brown eyes.  (A) Overlay of 
ultrasound (grayscale) and photoacoustic (color scale) images in a blue porcine eye.  PA 
signal was localized to the posterior iris.  (B-D) Spectra were separated based on results 
from brown porcine eyes.  (B) A modified melanin spectrum, resembling that of 
oxygenated hemoglobin, was isolated to the posterior iris in both eye colors and was the 
dominant spectrum observed in blue eyes.  (C and D) Other types of spectra were 
observed in blue eyes, but were not localized to a consistent location. (D) The PA 
spectrum resembling melanin was most prevalent in brown eyes. Scale bar = 3 mm. ..... 32 
Figure 7. Spectroscopic PA analysis using LLS regression in blue porcine eyes. (A) 
Literature absorption spectra used for sPA analysis. (B-D) sPA analysis using the 
literature absorption spectra.  (E) Measured PA spectra used for sPA analysis, which 
were compiled from brown eye datasets, except for the spectrum of Hb.  (F-H) sPA 
analysis using the measured PA spectra.  Overlay of ultrasound (grayscale) and 
spectroscopic PA images showed localization of melanin (blue color scale), HbO2 
(orange color scale), and Hb (pink color scale). Absorbers were localized as expected 
according to known anatomy.  Literature absorption spectra or measured photoacoustic 
spectra produced similar results, and either can be applied for sPA analysis. These results 
show that the PA spectra can be used for sPA analysis in both brown and blue eyes. Scale 
bar = 3 mm. ....................................................................................................................... 34 
Figure 8.  Perfusion set up. Ex vivo porcine eyes were hydrostatically clamped using an 
elevated reservoir to mimic the in vivo situation, specifically by maintaining 
physiological IOP and fluid flow rates within the anterior segment and through the 
aqueous outflow pathway.  AuNS-labeled MSCs were injected using a separate syringe.  
The elevated reservoir remained in place during the injection and 5 hour incubation 
period.  Stem cells circulated in the anterior chamber because inflowing media from the 
elevated reservoir drained through the TM, which is part of the eye’s natural fluid 
outflow pathway................................................................................................................ 49 
Figure 9. Diagram of the method of image-guided magnetic delivery of PBNC-labeled 
stem cells to the TM.  Cartoon depicts PBNC-labeled stem cells being pulled to the TM 
using a ring magnet (A).  Schematic of the in vivo procedure in rats (B).  The eye was 
proptosed, and a ring magnet was placed over the eye while 25 μl of PBNC-labeled stem 
cells (1000k cells/μl) were injected into the eye.  The magnet was in place for 3 hours 
post-injection followed by US/PA imaging. ..................................................................... 57 
 xii 
Figure 10. Characterization of gold nanospheres.  (A) TEM confirmed uniform particle 
morphology and particle diameter of approximately 20 nm.  (B) UV-Vis 
spectrophotometry of AuNSs with a peak absorbance at 520 nm. ................................... 58 
Figure 11. MSC labeling with gold nanospheres.  Brightfield micrographs of eosin-
stained naïve (unlabeled) MSCs (A, B) and AuNS-labeled MSCs (C–E).  (E) Enlarged 
image of the region of interest defined by the red box in (D). Yellow arrows identify 
AuNSs (black spots). (F)  UV-Vis spectrophotometry comparing the spectral signature of 
naïve (black, dashed line) and AuNS-labeled MSCs (red, solid line). ............................. 59 
Figure 12. AuNS-labeled MSCs maintain multipotency.  MSCs were labeled with AuNSs 
followed by adipogenic (A – C) or osteogenic (D – F) differentiation and compared to 
AuNS-labeled MSCs that were fed maintenance media on the same schedule (G – I).  
Columns left to right: no (A, D, G), Von Kossa (B, E, H), and Oil Red O staining (C, F, 
I). ....................................................................................................................................... 60 
Figure 13. Photoacoustic properties of AuNS-labeled MSCs. Ultrasound (grayscale), 
photoacoustic (color scale), and overlay images at 700 nm wavelength for (A) unlabeled 
MSCs and (B) AuNS-labeled MSCs. Scale bar = 2 mm. (C) Representative PA spectrum 
of melanin at the iris and AuNS-labeled MSCs.  The distinct spectra, notably differences 
in slope, make AuNSs a promising contrast agent choice for stem cell tracking in the 
anterior segment, where melanin is the major PA signal source. ..................................... 61 
Figure 14. PA and fluorescent imaging signals vs. cell number loaded into agarose gel 
phantoms. Double-labeled MSCs (labeled with AuNSs and CFSE) were suspended at 
known concentrations in agarose gels formed in 48 well plates.  Triplicates were prepared 
for each cell concentration.  Total fluorescent and total PA signal were compared to cell 
nuclei count (DAPI staining) over a depth of 0.5 mm.  Each point represents total signal 
for one gel. PA and fluorescent microscopy produced similar results, which further 
motivates use of minimally invasive PA imaging to track stem cells in the anterior 
segment. ............................................................................................................................ 63 
Figure 15. Ultrasound and photoacoustic imaging of AuNS-labeled MSCs delivered into 
the anterior chamber of perfused porcine eyes ex vivo.  (A) Anatomical landmarks were 
identified, including the TM.  PA datasets were analyzed before injection, and 
immediately, nine, and fifteen minutes post-injection (columns left to right).  (A - D) PA 
imaging at 680 nm wavelength.   (E - L) Spectroscopic analysis of multi-wavelength PA 
datasets distinguished signals from endogenous absorbers and AuNS-labeled MSCs. 
Pixels identified as melanin (E – H) and AuNS-labeled MSCs (I - L).  Scale bar = 3 mm.
........................................................................................................................................... 65 
 xiii 
Figure 16. Ultrasound and PA imaging detects AuNS-labeled MSC location five hours 
post-injection in perfused porcine eyes ex vivo.  Multi-wavelength PA datasets were 
processed with spectroscopic analysis.  The left and right columns show PA signals 
separated according to contribution of melanin (A – G) and AuNS-labeled MSCs (B – 
H).  Each row corresponds to different numbers of cells injected: (A, B) control (perfused 
with media for 5 hours, no cells injected), (C, D) 250,000 cells, (E, F) 500,000 cells, and 
(G, H) 1,000,000 cells.  Most AuNS-labeled MSCs were detected on the anterior lens, but 
some reached the angle for the 500k (F) and 1000k (H) cell injections.  Scale bar = 3 mm.
........................................................................................................................................... 66 
Figure 17. Three-dimensional US/PA imaging to detect location of AuNS-labeled MSCs 
at five hours post-injection.  (A, B) Overlays of ultrasound (grayscale) and spectroscopic 
PA (color scale) images.  Spectroscopic PA analysis distinguished melanin (cool color 
map) and AuNS-labeled MSCs (hot color map). (A) Control, (perfused with media, no 
cells injected). (B) 1000k cells injected.  AuNS-labeled MSCs accumulated on the 
anterior lens and iris.  (C) Spectroscopic datasets were further processed to identify 
AuNS-labeled MSCs at the iris and the TM region. Non-uniform stem cell delivery 
around the circumference of the iris and TM was observed. A = anterior; L = lateral; E = 
elevational; P = posterior. ................................................................................................. 67 
Figure 18. Comparison of the distribution of MSCs as visualized by confocal fluorescent 
microscopy (A) and spectroscopic PA imaging (B) in dissected porcine anterior 
segments.  MSCs were double-labeled with a fluorescent marker (CFSE) and AuNSs. 
Images show stem cell distribution around the circumference of the TM. ....................... 68 
Figure 19. Assessing laser safety in vivo.  Rats (n = 2) were anesthetized for combined 
US/PA imaging using the Vevo LAZR.  The entire right eye was irradiated (A – C) 
according to the parameters in Table 1 from wavelengths of 700 – 950 nm in 25 nm 
increments.  The contralateral eye was not irradiated (D – F).  Photos were taken of both 
eyes before laser light irradiation (A, D), 24 hours (B, E), and 1 week after laser light 
irradiation (C, F).  No gross changes indicative of ocular damage were observed in either 
eye. .................................................................................................................................... 76 
Figure 20. Ultrasound and photoacoustic images of rat eyes in vivo.  Representative two- 
(A) and three-dimensional (B) ultrasound (grayscale) and PA (color scale) overlay 
images acquired with the Vevo LAZR and 50 MHz transducer.  In 2D cross-sectional 
views, ultrasound depicted anatomy, including the cornea, eye lid, and iris, and PA 
signals were observed at the iris (A).  Three-dimensional US/PA volumetric images 
depicted inconsistent PA signal at the iris and a potential source of imaging artifacts 
resulting from PA signals from black hair, which can inaccurately extend onto the eye 
 xiv 
(B). US/PA images may be improved by developing focused light-delivery systems.  
Scale bar = 3 mm. ............................................................................................................. 77 
Figure 21. Demonstration of focused light delivery in a porcine eye ex vivo.  Photograph 
of the imaging set up (A).  An enucleated porcine eye was secured in a holder and 
submerged in PBS.  A 20 MHz ultrasound only transducer was positioned above the 
cornea on-axis.  Light was focused by positioning an external optical fiber for transscleral 
light delivery to the angle.  Combined ultrasound (grayscale) and PA (color scale) images 
were acquired using the focused light delivery system (B) or the Vevo LAZR (C), which 
irradiates the entire anterior segment.  Focused light delivery only produced PA signals at 
the region of interest - the angle and TM (B).  Scale bar = 3 mm. ................................... 78 
Figure 22. Characterization of photomagnetic PBNCs and labeled stem cells.  (A, B) 
TEM of PBNCs with an edge length of ~200 nm.  (C)  Absorption spectrum of PBNCs, 
measured by UV-Vis spectrophotometry, with a peak at 734 nm wavelength.  Histology 
of eosin-stained adipose-derived MSCs confirmed successful cell labeling with PBNCs 
(D-H).  Naïve MSCs at 20x (D) and 40x (E) magnification.  MSCs incubated with 
PBNCs at 1 OD at 20x (F) and 40x (G) magnification.  MSCs incubated with PBNCs at 2 
OD at 40x magnification (H). PBNCs are blue in color, indicated by black arrows. 
Proceeding studies were conducted with PBNCs at a concentration of 2 OD. ................. 79 
Figure 23.  Photoacoustic imaging and magnetic delivery of PBNC-labeled stem cells in 
perfused porcine eyes ex vivo.  Two-dimensional ultrasound (grayscale) and PA (color 
scale) overlay images of PBNC-labeled stem cells in the anterior chamber immediately 
post-injection (A).  After 24 hours of magnet exposure, PBNC-labeled stem cells were 
pulled to the cornea at the location of the disc magnet (B).  (C)  Three-dimensional 
US/PA images confirmed 2D results, indicating initial feasibility of using PBNCs for 
magnetic guidance and imaging of MSCs.  Scale bar = 3 mm. ........................................ 80 
Figure 24.  Image-guided magnetic delivery of PBNC-labeled MSCs to the TM in vivo.  
in nude rats.  Two- (A, C, E) and three-dimensional (B, D, F) combined ultrasound 
(grayscale) and PA (color scale) datasets were acquired for eyes that received no 
injection (A, B); PBNC-labeled MSCs only (C, D); and PBNC-labeled MSCs and a ring 
magnet (E, F).  Minimal background PA signals were observed in control eyes due to 
lack of melanin (A, B).  PA signal from PBNC-labeled MSCs was visible in injected eyes 
(C - F), and more PBNC-labeled MSCs appeared near the angle after magnet exposure 
for 3 hours (E, F). .............................................................................................................. 82 
Figure 25.  Photographs of eyes after image-guided magnetic delivery of PBNC-labeled 
MSCs in vivo.  Top row (A – C): images from the rat that received PBNC-labeled MSCs 
and a magnet.  Bottom row (D - F): images from the rat that received PBNC-labeled 
MSCs only.  In both cases, the contralateral eye received no injection.  Contralateral eye 
 xv 
before (A, D) and after (B, E) imaging. (C, F) Injected eye after imaging.  No gross 
changes in ocular morphology were observed in eyes that received injections and were 
imaged. .............................................................................................................................. 83 
Figure 26. Surgical and imaging set up for in vivo intraoperative studies.  The combined 
US/PA imaging transducer was positioned on top of the exposed cord while the needle 
was brought into position (A, B).  US/PA images were acquired as the needle was 
inserted, during, and immediately post-injection after needle removal.  Zoomed in 
photograph depicting the position of the transducer and syringe (B). .............................. 97 
Figure 27 Chemical structure photoacoustic imaging probe for sensing apoptosis.  The 
probe consisted of an aggregating/quenching unit (AgQ; red circle), IR800 dye (purple 
circles), and peptide sequence (green circle).  Cleavage of the DEVD peptide by caspase-
3 upon apoptosis induces aggregation of the probe through a condensation reaction that 
takes place between CABT (red circle) and the thiol and amino groups of cysteine (blue 
circle).  As a result of aggregation, fluorescent signal is quenched and PA signal is 
enhanced.  Thus, enhanced PA signal corresponds to cell death. ................................... 100 
Figure 28. Characterization of size-controlled PBNCs synthesized from SPION 
precursors.  TEM images of PBNCs. PBNCs with an edge length of (A) ~20 nm, (B) 
~40 nm, and (C) ~200 nm synthesized from 3 nm, 5 nm, and 10 nm diameter SPIONs, 
respectively.  (D – F) Images at increased magnification for 20 nm, 40 nm, and 200 nm 
PBNCs, respectively. (G) Scatter plot showing relationship between SPION diameter and 
resulting PBNC size. ....................................................................................................... 101 
Figure 29. Magnetic and optical properties of PBNCs. (A) UV-Vis spectrophotometry 
shows the peak absorption for the 20 nm, 40 nm, and 200 nm PBNCs, with a peak at 685 
nm, 720 nm, and 740 nm respectively.  (B) Magnetic moment curves show a 5-fold 
increase in magnetization for 20 nm PBNCs compared to the 3 nm SPIONs based on 
nanoparticle mass.  Results confirmed photomagnetic properties of PBNCs. ............... 102 
Figure 30. Trimodal US/PA/MRI of PBNCs in a tissue-mimicking phantom.  All PBNCs 
were suspended at the same concentration based on optical density (OD = 2).  The 
phantom contained four dome-shaped inclusions.  One contained gelatin only, and the 
other three contained different types of PBNCs.  The same inclusion was imaged with all 
modalities: top row (A – D) T2-weighted MR images; middle row (E – H) US images; 
bottom row (I – L) PA images at 740 nm wavelength. Columns (left to right): gelatin 
control, 20 nm, 40 nm, or 200 nm PBNCs.  All PBNCs produced MR (B – D) and PA (J 
– K) contrast.  Plot of PA spectra for all PBNC types (M). ............................................ 104 
Figure 31. PA signal of PBNC-labeled MSCs in vitro.  (A) Brightfield microscopy of 
eosin-stained cells verified successful labeling based on blue pigment, indicative of 
 xvi 
PBNCs, colocalized with pink cytoplasm.  (B) Representative PA spectrum of PBNC-
labeled MSCs at 5k cells/μl. (C) Images of all dome inclusions.  Top row: ultrasound 
(grayscale) only.  Bottom row: US/PA (color scale) overlays.  (D) Bar graph of 
comparing PA signal with cell concentration.  Scale bar = 2 mm. ................................. 106 
Figure 32. MRI of stem cells labeled with PBNCs in vitro. MRI studies were conducted 
with the same phantom used in the PA studies. Coronal images were acquired using a 
MSME sequence to determine average T2 relaxation times (A).  T2 relaxation time 
increased with decreasing cell concentration.  Representative T2-weighted MR images 
(B; top row) and parametric fit images depicting relaxation time (B; bottom row). ...... 107 
Figure 33. US/PA image guidance of real-time needle insertion in a rat spinal cord ex 
vivo.   Top row: ultrasound (grayscale) only.  Bottom row: combined ultrasound 
(grayscale) and photoacoustic (color scale) images at 740 nm wavelength. Red arrows 
indicate the 33G needle tip. Scale bar = 2 mm. .............................................................. 108 
Figure 34. Injection of PBNC-labeled MSCs in a rat spinal cord ex vivo. Throughout the 
injection, combined ultrasound (grayscale) and photoacoustic (color scale) images were 
acquired using a 20 MHz transducer and a laser operating at 740 nm wavelength.  (A – 
D) US/PA images at 0, 1, 2, and 4 μl injected, respectively, at a concentration of 10k 
cells/μl.  (E) Plot comparing PA signal with injection volume.  Scale bar = 2 mm. ...... 109 
Figure 35. Multi-modal detection of PBNC-labeled stem cells.  PBNC-labeled MSCs 
were suspended at 10k cells/μl. Top row: control, no cells injected.  Middle row: 2 μl 
injection of PBNC-labeled stem cells.  Bottom row: 5 μl injection of PBNC-labeled stem 
cells.  PA images (A - C) were acquired at 740 nm wavelength. Muscle was placed over 
the cord prior to MR imaging to mimic the clinical procedure and the post-operative 
imaging scenario. MR images were acquired using T2 (D - F) and T2* (G - I) pulse 
sequences. Red arrows indicate location of stem cells.  Scale bar = 2 mm. ................... 110 
Figure 36. Multi-modal detection of PBNC-labeled MSCs with overlying muscle.  
PBNC-labeled MSCs (red arrows) at 10k cells/μl were injected twice along the spinal 
cord.  Sagittal US/PA (A, B) and T2* MR images (C) depicted the ~ 2 μl (left) and 5 μl 
(right) injections of PBNC-labeled MSCs before (A) and after (B, C) a layer of muscle 
was placed over the spinal cord.  Brightfield microscopy of eosin-stained tissue at 10x 
(D, E) and 40x (F) magnification further verified injection locations (D – F). .............. 111 
Figure 37. In vivo US/PA image-guidance of needle insertion in the rat spinal cord.   
Combined ultrasound (grayscale) and PA (color scale) images were acquired with a 20 
MHz transducer at 740 nm wavelength in real-time.  Red arrows indicate the needle tip.  
Images from t = 0 seconds, 5 seconds, and 30 seconds (A – C), respectively.  Scale bar = 
3 mm. .............................................................................................................................. 112 
 xvii 
Figure 38. In vivo US/PA imaging during PBNC-labeled MSC injection into the rat spinal 
cord.   Combined ultrasound (grayscale) and PA (color scale) images acquired with a 20 
MHz transducer at 740 nm wavelength during injection of PBNC-labeled MSCs at 10k 
cells/μl.  Images at t = 0, 2, and 4 μl injected (A – C), respectively.  Scale bar = 3 mm.113 
Figure 39. In vivo intraoperative US/PA and post-operative MRI.  (A) Combined 
ultrasound (grayscale) and PA (color scale) images were acquired intraoperatively with a 
20 MHz transducer at 740 nm wavelength after a 5 μl injection of PBNC-labeled MSCs 
at 10k cells/μl.  Post-operative MR images were acquired 24 hours later (B).  Photograph 
of the excised spinal cord depicting PBNC-labeled MSCs (C).  Scale bar = 3 mm. ...... 114 
Figure 40. Histology of PBNC-labeled MSCs at 24 hours.  Stem cells were double-
labeled with PBNCs and a fluorescent dye (CellTracker Green) in culture prior to 
injection into the spinal cord.  (A) Brightfield microscopy of eosin-stained spinal cord 
and blue PBNCs.  (B) Confocal microscopy of DAPI-stained spinal cord and green 
PBNC-labeled MSCs. ..................................................................................................... 115 
Figure 41. Longitudinal monitoring of PBNC-labeled MSCs in vivo – axial views. Post-
operative combined ultrasound (grayscale) and PA (color scale) images were acquired 
using at 20 MHz transducer at 740 nm wavelength at 3, 5, 7, 10, and 14 days, 
respectively (A – E).  PBNC-labeled MSCs were still visible at day 14 with PA imaging 
(E).  T2-weighted MR images confirmed presence of PBNC-labeled MSCs (F).  Scale bar 
= 3 mm. ........................................................................................................................... 117 
Figure 42. Longitudinal monitoring of PBNC-labeled MSCs MRI in vivo – sagittal and 
coronal views.  PBNC-labeled MSCs (5 μl at 10k cells/μl) were injected into the spinal 
cord at three separate locations. Sagittal (top row; A – D) and coronal (bottom row; E – 
H) Post-operative T2-weighted MR images at 5 (A, E), 7 (B, F), 10 (C, G), and 14 days 
(D, H).  Blue arrows indicate injections of PBNC-labeled MSCs. ................................. 118 
Figure 43. Longitudinal monitoring of PBNC-labeled MSCs with US/PA imaging in vivo 
– coronal views.  Three-dimensional PA datasets were integrated with depth (y-
dimension) to create a maximum intensity projection and produce coronal maps of 
PBNC-labeled MSCs at day 5, 7, 10, and 14 post-operatively (A – D), respectively.  Red 
box indicates approximate location of the spinal cord.  Scale bar = 3 mm. ................... 120 
Figure 44. Confirming presence of PBNC-labeled MSCs after 14 days post-injection.  
Stem cells were double-labeled with PBNCs and a fluorescent dye, CellTracker Green.  
(A, B) Brightfield microscopy of eosin-stained spinal cords and blue PBNCs.  (C) 
Confocal microscopy of DAPI-stained spinal cord and green fluorescent stem cells. ... 121 
 xviii 
Figure 45.  US/PA imaging of PBNCs in a porcine spine ex vivo.  A 25 μl volume of 
PBNCs (blue arrows) was injected directly into the spinal cord at two locations.  Two-
dimensional US (grayscale) and PA (color scale) sagittal views before (A) and after (B) 
injection.  Three-dimensional US/PA volumetric image visualized the injection bolus (C).  
The spinal cord was excised and both injections were observed (D).  Scale bar = 3 mm.
......................................................................................................................................... 128 
Figure 46. Detection scheme of the stem cell apoptosis probe.  The probe consists of the 
DEVD peptide sequence (green oval), dye (purple polygon), and an 
aggregating/quenching unit (AgQ; red triangle).  Upon cell apoptosis, caspase-3 cleaves 
the DEVD motif, allowing the probe to aggregate and enhance PA signal corresponding 
to cell apoptosis............................................................................................................... 130 
Figure 47. Assessing stem cell apoptosis detection in vitro in a tissue-mimicking 
phantom.  Combined ultrasound (grayscale) and PA (color scale) images of live, 
unlabeled MSCs (A) and dead MSCs incubated with the probe (B).  (C) PA spectra of 
dead cells (red line), live cells (green line), and the probe alone (black line). ............... 132 
Figure 48.  Apoptosis probe delivery using light-activated nanodroplets.  Laser light-
activated nanodroplets may be able to temporarily permeabilize the cell membrane 
through acoustic stimulation to improve delivery efficiency (A). Combined ultrasound 
(grayscale) and PA (color scale) images of live (B, D) and dead stem cells treated with 
doxorubicin (C, E).  Top row (B, C):  stem cells incubated with the probe and 
nanodroplets.  Bottom row (D, E): stem cells incubated with nanodroplets only.  All 
groups were irradiated with 300 laser pulses for duration of 10 ns at a frequency of 10 
Hz. ................................................................................................................................... 134 
Figure 49. Characterization of PLPs with UV-Vis spectrophotometry.  (A) Absorbance 
spectra of free Dye750 (green), free Dye950 (pink), and relevant endogenous absorbers 
for lymph node imaging in BALB/c mice, Hb (blue) and HbO2 (red).  Extinction spectra 
of mPLPs (B) and nPLPs (C) loaded with Dye750 or Dye950.  Similar spectral signatures 
were observed for the free dye and dye encapsulated in the PLPs; however, some 
differences were observed.  Noise in the spectra of mPLPs resulted from scattering of the 
larger particle.  Differences in the ratios between extinction peaks can result from 
differences in concentration of dye encapsulated in each particle type. ......................... 145 
Figure 50. In vivo US/PA imaging of Dye950-nPLP trafficking to the lymph node.  
Ultrasound (grayscale) and PA (color scale) overlay images after spectroscopic analysis 
to distinguish Hb, HbO2, and Dye950-nPLPs (columns left to right).  Maps of absorber 
distribution before injection (A – C), 30 minutes (D – F), 1.5 hours (G – I), 2 hours (J – 
L), and 24 hours (M – O) after injection.  PLPs were detected near the lymph node by 2 
 xix 
hours post-injection (L) and more substantial accumulation was observed by 24 hours 
post-injection (O).  Pink arrows point to particles.  Scale bar = 3 mm. .......................... 150 
Figure 51. In vivo and ex vivo fluorescent imaging of DiI-nPLPs.  BALB/c mice received 
subcutaneous injections of DiI-nPLPs and were imaged 24 hours later with IVIS.  DiI-
nPLP accumulation was not apparent at the left inguinal lymph node in vivo while the 
skin was intact (A).  Increased fluorescent signal was present at the left inguinal lymph 
node ex vivo (B). ............................................................................................................. 152 
Figure 52. Histology of Dye950-nPLPs and DiI-nPLPs at 24 hours.  Brighfield and 
confocal microscopy from the left inguinal lymph node from the mouse injected with 
Dye950-nPLPs (A, B) or DiI-nPLPs (C, D), respectively.  Dye950-nPLPs may be 
indicated by dark green/brown speckles throughout the eosin-stained lymph node (A, B; 
black arrows).  (C, D) DiI-nPLPs (red) were visible at the DAPI-stained lymph node 
periphery ......................................................................................................................... 154 
Figure 53. In vivo US/PA imaging of CpG-Dye950-nPLP trafficking to the lymph node.  
PA datasets were post-processed using spectroscopic analysis to distinguish absorbers: 
CpG-Dye950-nPLPs (A – E; left column) and blood (F – J; right column).  Absorber 
distribution maps immediately (A, F), 4 hours (B, G), 8 hours (C, H), 24 hours (D, I), and 
48 hours (E, J) after injection.  (K) Photographs of excised lymph nodes.  Scale bar = 3 
mm. ................................................................................................................................. 157 
Figure 54. Topographic maps of absorbers from the injection site to the lymph node. 
Spectroscopic PA analysis of 3D volumetric datasets distinguished CpG-Dye950-nPLPs 
(A – E; left column) and blood (F – J; right column).  Images were integrated over depth 
(y-dimension).  Over time the size of the injection footprint decreased, and particles were 
distributed in a branched pattern extending from the injection site (B – E).  Scale bar = 3 
mm. ................................................................................................................................. 159 
Figure 55. Three-dimensional volumetric images of CpG-Dye950-nPLP trafficking from 
the injection site.  Ultrasound (grayscale) depicts anatomy and spectroscopic PA analysis 
(color scale) distinguished CpG-Dye950-nPLPs at 4 hours (A, B) and 48 hours (C, D) 
post-injection.  The size of the injection site decreased by 48 hours post-injection and 
PLPs appeared to be in superficial vessels (C, D). ......................................................... 160 
Figure 56. In vivo and ex vivo fluorescent imaging of CpG-DiI-nPLPs at 24 hours.  
Particle accumulation was not apparent at the left inguinal lymph node in vivo while the 
skin was intact (A).  Increased fluorescent signal was present at the left inguinal lymph 
node ex vivo (B). ............................................................................................................. 162 
 xx 
Figure 57. Histology of CpG-Dye950-nPLPs and CpG-DiI-nPLPs at 24 hours.  Brighfield 
and confocal microscopy from the left inguinal lymph node from the mouse injected with 
CpG-Dye950-nPLPs (A, B) or CpG-DiI-nPLPs (C, D), respectively.  CpG-Dye950-
nPLPs may be indicated by dark green/brown speckles throughout the eosin-stained 
lymph node (A, B).  (C, D) Some CpG-DiI-nPLPs (red) were visible at the periphery of 




LIST OF ABBREVIATIONS 
2D Two-dimensional 
3D Three-dimensional 
a.u. Arbitrary units 
AgQ Aggregating/quenching 
AI Anterior iris 
AuNR Gold nanorod 
AuNS Gold nanosphere 
bPEI Branched polyethyleneimine 
CFSE Carboxyfluorescein succinimidyl ester 
CPE Ciliary pigmented epithelium 
CT Computed tomography 
DEVD Aspartate-glutamate-valine-aspartate 
DIUF Deionized ultra-filtered 
DMEM Dulbecco’s modified eagle medium 
FBS Fetal bovine serum 
Hb Deoxygenated hemoglobin 
HbO2 Oxygenated hemoglobin 
IACUC Institutional animal care and use committee 
IOP Intraocular pressure 
iPSC Induced pluripotent stem cell 
IVIS In vivo imaging system 
 xxii 
LLS Linear least squares 
MCOCT Molecular contrast optical coherence tomography 
mPLP micro-sized pathogen-like particle 
MRI Magnetic resonance imaging 
MSC Mesenchymal stem cell 
MSME Multi-slice multi-echo 
nPLP Nano-sized pathogen-like particle 
OCT Optical coherence tomography 
OD Optical density 
OPO Optical parametric oscillator 
OR Operating room 
PA Photoacoustic 
PBNC Prussian blue nanocube 
PBS Phosphate buffered saline 
PDI Polydispersity index 
PET Positron emission tomography 
PI Posterior iris 
PLGA Poly(lactide-co-glycolic acid) 
PLP Pathogen-like particle 
PVA Poly-vinyl alcohol 
RPE Retinal pigmented epithelium 
SCS Suprachoroidal space 
sPA Spectroscopic photoacoustic 
 xxiii 
SPION Superparamagnetic iron oxide nanoparticle 
SQUID Superconducting quantum interference device 
TE Echo time 
TM Trabecular meshwork 




Development of novel therapies relies heavily on histology to evaluate outcomes.  
While histology provides detailed information at the molecular level, drawbacks include 
highly invasive, destructive sample preparation. Clinical translation of novel therapies 
would be expedited by further developing minimally invasive, longitudinal imaging 
methods. 
Combined ultrasound (US) and photoacoustic (PA) imaging augmented with 
contrast agents is an excellent option to address this need.  Complimentary information 
provided by US/PA imaging allows morphological, functional, and cellular/molecular 
assessment of tissue.  US signals are produced by backscattering of acoustic waves.  
Generation of PA signals relies on the photoacoustic effect, where acoustic waves are 
produced upon absorption of light. Based on this unique contrast mechanism, a variety of 
endogenous and exogenous absorbers exist for PA imaging to suppress background signals 
and facilitate molecular, cellular, or tissue-level imaging.  
This thesis describes development of a US/PA imaging toolbox, consisting of 
contrast agents, imaging hardware, imaging protocols, and detection algorithms, that can 
be customized for variety of applications where longitudinal, in vivo imaging of specific 
cells or particles is beneficial.  To demonstrate versatility, these US/PA imaging tools were 
developed and combined in different ways to facilitate implementation in three distinct 
applications: 1) stem cell monitoring in ophthalmology to aid development of glaucoma 
therapies; 2) intra- and post-operative monitoring to guide stem cell therapies of the spinal 
cord; and 3) monitoring particle trafficking to inform vaccine design.  Although the 
 xxv 
applications investigated were extremely different, common themes were identified 
throughout, highlighting versatility of the US/PA imaging toolbox and similar research 
needs for later development.  Overall, the tools developed here lay the foundation for 






CHAPTER 1. INTRODUCTION 
Development of novel therapies relies heavily on histology to evaluate outcomes.  
While histology provides detailed information at the molecular level, drawbacks include 
highly invasive, destructive sample preparation.1–3  As a result longitudinal monitoring is 
challenging, making it difficult to fully understand therapeutic outcomes.  Clinical 
translation of novel therapies would be expedited by further developing minimally 
invasive, longitudinal imaging methods for tracking.   
Currently many imaging technologies exist at the preclinical or clinical stage to 
address this need, including magnetic resonance imaging (MRI), x-ray/computed 
tomography (CT), optical imaging, positron emission tomography (PET), and ultrasound 
(US) imaging.  MRI has been widely used for longitudinal, in vivo monitoring of stem cells 
for a variety of neural and vascular applications, including stroke,4 spinal cord injury,5 and 
myocardial infarction.6  Bioluminescence is an excellent optical method for small animal 
cellular-level imaging.7,8  CT is best-suited for monitoring structural and anatomical 
changes, but gold nanoparticles have been used to label stem cells and T-cells for 
tracking.9,10  PET is often employed to monitor cell function, where uptake of 
fluorodeoxyglucose, a glucose analog that generates PET contrast, is an indicator of cell 
metabolism.2,11 
In the above examples, each modality was employed based on individual 
advantages and drawbacks.  Compromises are always made between resolution, sensitivity, 
acquisition speed, penetration depth, contrast, safety, and cost.  MRI allows high spatial 
resolution, non-ionizing, whole body imaging, but it suffers from high cost and slow image 
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acquisition.  CT also allows high spatial resolution, whole body imaging, but use of 
ionizing radiation raises safety concerns.   PET is an excellent option for highly sensitive 
molecular imaging; however, spatial resolution is extremely poor.  Thus, PET cannot 
provide detailed information on localization for tracking applications.  Optical methods 
allow high sensitivity, high resolution, high contrast molecular imaging, but in vivo 
monitoring is hindered by limited penetration depth.2,12   
The ideal qualities of a longitudinal, in vivo tracking platform include high spatial 
resolution, high contrast, high sensitivity, safe, deep, real-time imaging to facilitate 
tracking of cells and particles in a variety of scenarios.  Another desirable feature is the 
ability to monitor functional outcomes at the molecular, cellular, or tissue-level.  Overall, 
no single modality is perfect for addressing all of these requirements.  Instead, multiple 
modalities can be combined to provide complimentary information and create a synergistic 
approach to develop cell and particle trafficking platforms.  Combining optical and acoustic 
methods is an excellent option based on the desired features listed above.  One specific 
example is ultrasound-guided photoacoustic (PA) imaging.13–15  In previous work, US/PA 
imaging has been successfully implemented in a few examples of tracking cells and 
particles in vivo.16–18  This thesis expands on this work by describing development of a 
versatile US/PA imaging toolbox that can be applied to wider range of applications where 
tracking cells and particles is desired to aid development and translation of novel therapies.    
1.1 Overview of ultrasound and photoacoustic imaging 
Ultrasound is widely used in clinic to assess anatomy and tissue function.  
Advantages include portability, low cost, adaptable resolution, deep imaging, and safety.  
Real-time imaging also makes ultrasound appealing for longitudinal monitoring 
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applications.  Ultrasound signals are generated by backscattering of acoustic waves due to 
differences in acoustic impedance, a tissue property that describes resistance to acoustic 
wave propagation.19  However, all soft tissues are primarily water- and fat-based with 
similar acoustic properties.  As a result different tissues have similar acoustic impedance.  
Thus, ultrasound suffers from inherently poor contrast, which hinders exclusive use of 
ultrasound for tracking cells and particles.  However, photoacoustic imaging, an analog of 
ultrasound, can address this shortcoming.   
PA imaging combines the best qualities of acoustics and optics to provide high 
contrast, high resolution functional information at imaging depths of several centimeters, 
and absorption-based contrast of PA imaging compliments scattering-based contrast of 
ultrasound.  PA imaging relies on the photoacoustic effect, where acoustic waves are 
produced upon absorption of light.  When an optical absorber is irradiated by a nanosecond 
pulsed laser, heat deposition causes rapid thermoelastic expansion of the surrounding tissue 
to produce an acoustic wave.  The resulting wave can be detected using a traditional 
ultrasound imaging transducer, which simplifies integration of this multi-modal 
approach.12,13,20 Together with ultrasound, the multi-modal approach provides combined 
anatomical and functional information for longitudinal tracking of cells and particles.  
The use of an optical absorber is a key requirement for photoacoustic imaging.  A 
wide variety of endogenous and exogenous optical absorbers exist and serve as PA contrast 
agents.15  Endogenous absorbers include melanin, oxygenated hemoglobin, and 
deoxygenated hemoglobin.  Exogenous absorbers can be broadly classified as dyes, 
nanoparticles, or composites.  There are countless available combinations within these 
groups.  For example, nanoparticle size, shape, and material can be customized.  
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Nanoparticle size can range from several nanometers to micrometers.  Nanoparticle shapes 
include shells, rods, cubes, cages, spheres, plates, stars, etc.  Nanoparticle materials include 
silver, carbon, gold, and copper.  Different combinations of these properties result in a 
unique optical absorbance spectrum, and in turn, produce a distinct PA spectrum, which 
can ultimately be distinguished from background absorbers with multi-wavelength PA 
imaging techniques and spectroscopic analysis.21–26   
Multi-wavelength PA imaging and spectroscopic analysis can distinguish multiple 
optical absorbers in heterogeneous tissue, where the PA signal at each pixel is a 
superposition of individual PA signals from endogenous and exogenous absorbers. 27  The 
foundation of spectroscopic PA imaging is illustrated in Figure 1.  The PA spectrum of 
melanin, blood, and gold nanorods all have distinct optical signatures.  However if a PA 
image was acquired with a single wavelength, for example 800 nm, it would be impossible 
to distinguish all species since each absorber simultaneously contributes to the PA signal.  
This problem is mathematically equivalent to having multiple unknowns and one equation.  
By using many wavelengths and spectroscopic analysis, it becomes possible to distinguish 




Figure 1. PA spectrum of blood (blue line), melanin (yellow line), and gold nanorods 
(orange line).  The PA spectrum of each absorber corresponds to the absorbance spectrum.    
Determining multi-wavelength PA imaging protocols, tailoring detection 
algorithms and spectroscopic analysis techniques, and development/synthesis of 
exogenous contrast agents, are critical aspects of developing longitudinal US/PA imaging 
platforms.  These individual US/PA imaging tools can be developed to create a universal 
toolbox for tracking cells and particles, and individual tools can be combined in different 
ways to create custom imaging platforms that are relevant to many applications.   
This thesis describes development of a US/PA imaging toolbox and demonstrates 
use in three unique applications: 1) stem cell monitoring in ophthalmology to aid 
development of glaucoma therapies; 2) intra- and post-operative monitoring to guide stem 
cell therapies of the spinal cord; and 3) monitoring particle trafficking to inform vaccine 
design.  In spite of the clear differences in these application, the same basic approach was 
used throughout and similar tools were required: 
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 Spectroscopic properties of imaged tissues were evaluated to determine the 
optical properties of an appropriate exogenous contrast agent. 
 The contrast agent was synthesized. 
 An approach was determined to label the cell or particle with the contrast agent. 
 A US/PA imaging protocol was developed to detect the PA signal of interest. 
  Images were post-processed using spectroscopic analysis and other algorithms.  
The thesis is organized as follows.  The remainder of Chapter 1 describes the 
motivation for addressing the above applications.  Chapters 2 and 3 describe the ophthalmic 
research.  Chapter 4 describes the spinal cord research.  Chapter 5 describes the vaccine 
particle research.  Each chapter concludes with a section on future work specific to each 
application.  Chapter 6 describes common conclusions and future needs identified 
throughout to highlight overarching themes for continued research.  Overall results 
demonstrate versatility of the platform and lay the groundwork for further development of 
the US/PA imaging toolbox. 
1.2 Monitoring stem cell therapies 
Stem cell therapy for regenerative medicine holds great promise for many 
applications, especially those with few treatment options.  In spite of significant research 
efforts, few stem cell therapies have reached clinical translation.  While there are many 
challenges to address, one major limitation is lack of knowledge of stem cell behavior in 
vivo.2,28  At the research stage, histology is the primary tool for evaluating therapy 
progression, but assessment at multiple time points is challenging.  Thus, development is 
inherently inefficient as histology provides an incomplete view of experimental success or 
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failure.  At the clinical stage, longitudinal monitoring is critical for translation by providing 
clinicians with feedback on therapy progression to inform modifications and increase the 
likelihood of a positive outcome.  For these reasons, there is a critical need for in vivo 
longitudinal monitoring of stem cell therapies, which can be addressed by US/PA imaging 
tools.  Previous researchers have demonstrated US/PA imaging to monitor stem cell 
therapies and macrophage interactions in muscle using gold nanospheres (AuNSs) and  
gold nanorods (AuNRs).16,17,28,29 The current work seeks to extend these techniques to new 
applications in ophthalmology and the spinal cord.  Both applications have a new set of 
requirements to address, and results can extend beyond these applications and even beyond 
stem cell tracking.   
1.2.1 Monitoring stem cells in ophthalmic applications 
Glaucoma is the second leading cause of blindness in the world, estimated to impact 
more than 70 million people.30 Disease progression is associated with cell death at the 
trabecular meshwork (TM), a fluid drainage tissue in the anterior eye.31–33  TM dysfunction 
can result in increased intraocular pressure (IOP), a frequently observed characteristic of 
the disease.  However, there is no cure for glaucoma, and existing treatment methods focus 
on symptom management.   
A promising therapy is to deliver stem cells to the TM to regenerate the tissue and 
restore normal function.  Both induced pluripotent stem cells (iPSCs) and mesenchymal 
stem cells (MSCs) have been investigated in several different models of glaucoma.34–37  
Results showed stem cells decreased IOP and restored TM function.  However conclusions 
on how stem cells interacted with the environment to induce a therapeutic response were 
contradictory.36,37  One study found MSCs reduced IOP over 20 days, but histology showed 
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no MSCs were present in the TM by 96 hours post-delivery. 36  In another study, IOP was 
reduced immediately following MSC delivery, but increased again after 15 days.  However, 
in this case, histology detected MSCs in the TM and other anterior tissues for 23 days post-
delivery.37  It is difficult to explain these conflicting results with information from a single 
time point.  Many questions could be answered if a longitudinal monitoring technique was 
available to monitor the stem cells.   
A variety of longitudinal imaging technologies exist for ophthalmic applications.  
In particular, optical coherence tomography (OCT) is widely used in clinic.  OCT is 
analogous to ultrasound, except contrast is based on optical scattering. 38,39  Thus, OCT has 
similar disadvantages to ultrasound, and poor contrast limits the use of OCT to monitor 
stem cell therapies.  Beyond stem cell monitoring, there is a broader need for anterior 
segment and specifically TM imaging technologies, which are currently lacking.31  In 
general, purely optical methods prove challenging for TM imaging due to light attenuation 
from melanin absorption and scleral scattering.   
As a combined optical and acoustic method, PA imaging addresses both needs: 1) 
it is a favorable option for anterior segment imaging because it will be less affected by light 
attenuation compared to purely optical methods; and 2) high contrast from optical 
absorption allows stem cell detection.  PA imaging has been demonstrated in the anterior 
and posterior segments, but current research is limited.40,41  In addition, ultrasound imaging 
is already used in clinic for ophthalmic applications and therapeutic use of lasers is 
common, which simplifies the addition of PA imaging.42  For these reasons, combined 
US/PA imaging is an excellent option to monitor stem cells in the anterior segment to aid 
development of novel glaucoma therapies.   
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1.2.2 Stem cell monitoring in the spinal cord  
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of the brain and 
spinal cord, characterized by degeneration of motor neurons.  Stem cell therapies are of 
interest for treating ALS due to their ability to directly and indirectly regenerate tissue 
through differentiation into motor neurons or inducing a pro-regenerative response by 
secreted factors.43  Significant research efforts have shown some success in preclinical and 
clinical studies, but major hurdles remain.44–46  Similar to issues described in using stem 
cells for glaucoma treatment, there is a limited understanding of the therapeutic 
mechanism, including stem cell migration patterns and interactions with the 
microenvironment.  On a more basic level, it is difficult to know if stem cell delivery was 
successful.   
The most promising delivery method is direct injection of the MSCs into the gray 
matter of the ventral horn, where cell bodies of motor neurons are localized.  Direct 
injection is risky, but increases likelihood of a successful outcome.45–47  Great care needs 
to be taken during the injection, as a small misstep could have dire consequences.  Pre- or 
intraoperative MRI can help guide the injection.  Pre-operative MRI can be used to 
determine injection coordinates, but this has minimal benefit because surgeons may need 
to adapt coordinates during the procedure.  Intraoperative MRI is expensive, challenging 
to implement, and many research and clinical facilities will not have this system.   
For these reasons, alternative imaging methods are needed to intraoperatively guide 
the MSC injection in real-time.  To allow direct injection into the spinal cord, a lumbar 
laminectomy is performed. 44,45,47  A convenient acoustic and optical window is created by 
removing the overlying bone (laminae) to allow US/PA imaging. Spectroscopic PA 
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imaging can provide additional guidance by helping to navigate vasculature and distinguish 
white vs. grey matter.48,49  Lastly, immediate feedback on injection success can be provided 
by labeling stem cells with optical absorbers to allow PA imaging.    
Post-operatively, longitudinal monitoring is needed to monitor MSCs as therapy 
progresses.  Longitudinal information can provide researchers with a better understanding 
of stem cell behavior to assist with therapy development or can provide physicians with 
feedback on therapy progression.  MRI has been used for tracking stem cells tagged with 
superparamagnetic iron oxide nanoparticles (SPIONs) in the spinal cord and brain.50–52  
Significant stem cell migration was observed and varied according to injection site and 
type of injury.  MRI has been able to detect stem cells for several months post-injection.50,51  
One study found a detection limit of 1000 cells in vitro.50   
Though MRI is the gold standard for central nervous system (CNS) imaging, 
lengthy image acquisition time makes real-time assessment of three-dimensional volumes 
difficult.  US/PA imaging can be a valuable research tool for monitoring stem cell therapies 
in the spinal cord.  US/PA imaging allows real-time imaging and acquisition of three-
dimensional volumetric images.  Furthermore in vitro studies of AuNS-tagged-MSCs also 
showed 200 cells could be detected with PA, meaning more sensitive detection may be 
possible.53  Overall, longitudinal stem cell tracking in the spinal cord using US/PA imaging 
address shortcomings of existing methods.  US/PA imaging may assist in therapy 
development and translation by providing a tool for intraoperative and post-operative 
guidance of stem cell therapies.   
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1.3 Monitoring Particles 
US/PA imaging platforms can similarly be developed for longitudinal monitoring 
of particles using the same research approach and tools.  By labeling a particle of interest 
with an optical absorber for PA imaging, particles can be tracked using multi-wavelength 
PA imaging and spectroscopic analysis.  Longitudinal monitoring of particles is of interest 
for vaccine development.  
Recent research in designing next-generation vaccines investigates the best strategy 
to present immunomodulatory molecules to stimulate a robust immune response.54  
Development of particulate vaccines which mimic pathogens, termed pathogen-like 
particles (PLPs), are of great interest to control delivery of vaccine components.54–57.  One 
type of PLP, composed of poly(lactide-co-glycolic acid) (PLGA), can be synthesized to 
have a diameter of 1 µm (mPLPs) or 300 nm (nPLPs).  Physical qualities of PLPs induce 
different immune responses.54–58 
Subsets of dendritic cells, a particular type of antigen-presenting cell, preferentially 
interact with m- or nPLPs.54,58,59  To assess these interactions, in previous work PLPs were 
labeled with fluorescent markers, injected subcutaneously, and allowed to traffic to the 
lymph node in vivo.  After 24 hours lymph nodes were harvested for histology.  Fluorescent 
microscopy showed both types of PLPs were localized to the T cell zones, indicating 
cellular transport.  mPLPs were also localized along the periphery of lymph nodes, 
indicating passive transport.54  However, having longitudinal information would more 
holistically explain trafficking to the lymph node, thus facilitating more efficient design of 
vaccines to induce a particular response.  
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Two-photon intravital imaging, where the skin is removed and replaced with a 
transparent viewing window, has been widely used for in vivo longitudinal imaging of the 
lymph node.  This modality has high resolution, can monitor complex cellular interactions 
in and around the lymph node, and has drastically advanced in vivo understanding of 
immunology.60,61   However, the imaging procedure requires a specialized surgery, is 
highly invasive, and may cause an unwanted immune response.  
PA imaging offers a minimally invasive alternative for lymph node imaging and 
has been implemented with a wide variety optical absorbers, including nanodroplets, 
metallic nanoparticles, endogenous absorbers, and dyes.12,62–65  However, PA imaging has 
not been used for longitudinal monitoring of vaccine particles.  By tagging different 
formulations of PLPs with optical absorbers, multi-wavelength PA imaging and 
spectroscopic analysis can be used to detect PLP trafficking to the lymph node, including 
localization, particle kinetics, and changes in blood flow.  Ultrasound provides additional 
information by visualizing changes in lymph node morphology.  Overall longitudinal 
monitoring of PA-tagged PLPs will aid vaccine development by providing a better 
understanding of potential mechanisms of action.  In this thesis, the US/PA imaging 
platform was demonstrated using two formulations of nPLPs.  However, the tools 
developed here are relevant to monitoring countless vaccine formulations, including 
various particle sizes, materials, surface coatings and molecule density.58   
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CHAPTER 2. PHOTOACOUSTIC PROPERTIES OF ANTERIOR 
OCULAR TISSUES   
The chapter is adapted from an article published in the Journal of Biomedical Optics: 
Kubelick, K. P., Snider, E. J., Ethier, C. R., & Emelianov, S. (2019). Photoacoustic 




 Clinical imaging techniques for the anterior segment of the eye provide excellent 
anatomical information, but molecular imaging techniques are lacking.  Molecular 
photoacoustic imaging is one option to address this need, but implementation requires use 
of contrast agents to distinguish molecular targets from background photoacoustic signals.  
Contrast agents are typically selected based on a priori knowledge of photoacoustic 
properties of tissues; however, photoacoustic properties of anterior ocular tissues have not 
been studied yet.  Herein, anterior segment anatomy and corresponding photoacoustic 
signals were analyzed in brown and blue porcine eyes ex vivo.  Measured photoacoustic 
spectra were compared to known optical absorption spectra of endogenous chromophores.  
In general, experimentally measured photoacoustic spectra matched expectations based on 
absorption spectra of endogenous chromophores reported in the literature, and similar 
photoacoustic spectra were observed in blue and brown porcine eyes.  However, unique 
light-tissue interactions at the iris modified photoacoustic signals from melanin. The 
measured PA spectra established herein can be used for a variety of applications in 
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molecular PA imaging, such as detecting photoacoustically labeled stem cells in the 
anterior segment for glaucoma treatment.   
2.2 Introduction 
 The most-investigated approaches for noninvasive assessment of internal ocular 
structures have been ultrasound (US) and optical imaging techniques.66–74 Clinical use of 
ultrasound biomicroscopy and optical coherence tomography (OCT) are well-established 
in ophthalmology.66,67,75  OCT provides excellent anatomical information by measuring 
changes in backscattered light.71 Advances in OCT now allow real-time imaging, wide-
field imaging, higher resolution detection, and assessment of other tissue optical properties, 
such as birefringence.75–79 Overall OCT research has drastically improved the quality of 
anatomical imaging in ophthalmology.  However, molecular imaging techniques are 
lacking.  Accordingly, development of molecular contrast OCT (MCOCT) seeks to address 
this need by manipulating backscattering properties to distinguish molecular targets.80–82  
One approach is to introduce exogenous contrast agents that increase backscattering.  
However, high background signals from surrounding tissue still make it difficult to 
distinguish molecular targets.  As a result, researchers have invented other clever solutions, 
including magnetomotive OCT and US, spectroscopic-OCT, pump-probe OCT, and 
photothermal OCT.82–84   
 Significant effort has recently been dedicated to development of photothermal OCT 
for the retina.85–88  In photothermal OCT, an optical absorber is irradiated with light.  Heat 
deposition causes thermoelastic expansion of the surrounding tissue and ultimately changes 
the optical path length measured by OCT.85  Thus, photothermal OCT obtains molecular 
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information by indirectly measuring changes in backscattering resulting from an absorption 
event.  A more straightforward approach may be to use an imaging modality that directly 
measures optical absorption, such as photoacoustic (PA) imaging.   
 PA imaging is similar to photothermal OCT in that irradiation of an optical absorber 
results in heat deposition and thermoelastic expansion of surrounding tissues.  However, 
conditions used in PA imaging produce transient acoustic waves detected by a traditional 
ultrasound transducer.13,89,90  Thus PA imaging combines advantages of optical and 
acoustic modalities to allow high resolution, high contrast, real-time, molecular imaging.  
A variety of endogenous and exogenous optical absorbers produce PA signals.91  These 
optical absorbers serve as PA contrast agents and are detected using multi-wavelength 
spectroscopic PA imaging.  Because PA contrast is based on absorption, molecular 
information compliments anatomical information provided by scattering-based modalities 
such as OCT or ultrasound.  Thus, ultrasound and photoacoustic (US/PA) imaging systems 
are frequently combined, which is advantageous due to the established use of ultrasound 
in clinical ophthalmology.70,74,92  Similarly, a multi-modal PA/OCT system has also been 
demonstrated for molecular imaging at the posterior segment to assess the retina.93,94   
 Our work focuses on extending molecular PA imaging to the anterior segment of 
the eye, i.e. tissues anterior to the vitreous humor. Anterior segment imaging techniques, 
such as OCT, slit-lamp microscopy, and ultrasound biomicroscopy, primarily provide 
anatomical information.75  There is a need for molecular imaging techniques that could aid 
diagnosis, guide therapies, and improve understanding of anterior ocular diseases, 
including glaucoma, uveitis, and iridial pathologies.82  Implementation of molecular PA 
imaging requires endogenous or exogenous contrast agents that must be carefully selected 
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based on a priori knowledge of PA properties of anterior segment tissues to ensure the 
contrast agent or interventional devices can be distinguished from background PA 
signals.95–97  Although PA imaging has been demonstrated at a select few wavelengths in 
the anterior segment,98–100 exploration of PA properties over a broad range of wavelengths 
is required to inform contrast agent selection for molecular PA imaging.   
 Thus, the goal of the work presented here was to establish PA spectral properties 
for the anterior segment over a range of wavelengths corresponding to the ideal tissue 
optical window.91  In some cases, PA spectra in biological tissues directly correspond to 
optical absorption spectra of endogenous chromophores, i.e. melanin, oxygenated, and 
deoxygenated hemoglobin.  Alternatively, PA spectra can be modified by light-tissue 
interactions.101  We hypothesized the latter scenario may occur in the anterior segment due 
to the role of anterior tissues to control light propagation.  Differences in eye color, 
resulting from unique combinations of scattering and melanin absorption at the iris, may 
also modify PA spectra.102,103  For these reasons, we systematically measured the PA 
spectral properties of anterior segment structures in blue and brown porcine eyes, which 
are a relevant model of human anatomy and pigmentation.  Results can aid development 
of molecular PA imaging strategies in the anterior eye, specifically by informing contrast 
agent selection to detect stem cells for glaucoma treatment.36,104,105   
2.3 Materials and Methods 
2.3.1 Eye preparation 
 All experiments used enucleated porcine eyes (Holifield Farms, Covington, GA).  
Blue and brown porcine eyes were studied to represent the two extremes in the range of 
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eye color from light to dark.  Blue or brown eye color was determined by visual inspection, 
and no other colors were observed in samples from the slaughterhouse.  Fresh and fixed 
eye globes were imaged.  Eye globes were fixed by submersion in 10% neutral buffered 
formalin overnight before imaging, then maintained in phosphate buffed saline (PBS) prior 
to use.  In total, 10 brown (3 fresh and 7 fixed) and six blue porcine eyes (2 fresh and 4 
fixed) were imaged.  Minimal differences between PA spectra of fresh and fixed samples 
were observed (data not shown).      
2.3.2 Imaging protocol 
 The Vevo LAZR imaging system (FUJIFILM VisualSonics, Inc.) imaging system, 
incorporating ultrasound and photoacoustic (US/PA) imaging modes, was used for all 
imaging experiments.  US/PA images were acquired using a 256-element transducer array 
operating at 20 MHz (LZ250) or 40 MHz (LZ550) center frequencies.  The laser source 
was a Q-switched Nd:YAG laser pumped optical parametric oscillator (OPO) system 
(PRF = 20 Hz, 7 ns pulse duration).  PA images were acquired within the 680 - 970 nm 
wavelength range at a frame rate of 5 Hz.  Variations in laser pulse energy were corrected 
at the time of data acquisition using built in features of the Vevo LAZR.     
 In the first set of brown eye data, US/PA images were acquired at 1 degree 
increments as the eye was rotated 360.  Data was collected using both the 20 MHz and 40 
MHz transducers, and the wavelength was varied from 680 nm to 970 nm in increments of 
10 nm.  The transducer was oriented either on-axis or perpendicular to the trabecular 
meshwork for translimbal light delivery for a total of 4 datasets. Preliminary analysis 
confirmed ultrasound-determined anatomy and PA spectra were similar in all views.  Thus, 
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data acquisition at every degree was unnecessary.  Adjustments were made to permit 
acquisition of more wavelengths and compile more thorough spectroscopic information.  
Specifically, US/PA images were acquired every 45 degrees at wavelengths from 680 nm 
to 970 nm in 5 nm increments.  US/PA images were post-processed in MATLAB 
(MathWorks, Inc.) to determine the PA spectrum at anatomical landmarks.  
2.3.3 Calculating and analyzing PA spectra 
 The average PA spectra for the anterior and posterior iris, trabecular meshwork, 
and sclera were determined to establish PA spectral properties specific to anatomy of the 
anterior segment.  Each spectrum was determined by calculating the average PA signal 
over each region of interest.  Each region of interest was isolated using spatial masks 
determined by manual segmentation based on anatomical information depicted in US/PA 
images.  Variations in mask size and shape had minimal impact on PA spectra; specifically, 
the magnitude of the variation in the PA spectra between masks was comparable to the 
variations in the PA spectra between eyes and was thus not considered significant.  The 
spectrum for each region of interest was then low-pass filtered using a 10-point moving 
average.  The resulting spectra are henceforth referred to as “measured PA spectra”.  
Measured PA spectra were compared to established optical absorption spectra for 
deoxygenated hemoglobin (Hb), oxygenated hemoglobin (HbO2), and melanin.
106–112 
2.3.4 PA analysis in phantom experiments of pigment and scattering 
 The measured PA spectrum for the posterior iris required further analysis to 
evaluate effects of optical scattering.  Following methods described elsewhere, melanin 
was isolated from dissected irises of fresh brown porcine eyes by collecting tissue in 10 ml 
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of water and mechanically disrupting to release pigment.113,114  Pigment samples were size 
separated via centrifugation and isolated particles were resuspended in 2 ml of PBS for 
US/PA imaging.  
 A 10 x 10 cm plastic container held isolated pigment samples for US/PA imaging.  
Two small holes were drilled on opposite sides of the container and a silicone tube (Helix 
Medical) with an inner diameter of 0.062” and an outer diameter of 0.095” was fed through 
each hole and secured.  The thickness of the iris was approximately 1 mm based on 
anatomical ultrasound images, slightly smaller than the inner diameter of the silicone tube. 
The tube was loaded with the following samples for US/PA imaging: PBS, iris pigment 
alone, and the same iris pigment with a piece of sclera wrapped around the tube.  In the PA 
images of the circular cross-section of the tube, three regions of interest (top, middle, and 
bottom of the tube) were identified.  The average PA signal was determined for each region 
of interest to assess changes in the PA spectrum of pigment due to light attenuation as a 
function of depth.  
2.3.5 Analysis of local tissue composition using spectroscopic PA processing 
 The PA signal at each pixel, i.e., pressure 𝑃(𝑥, 𝑦, 𝜆), is expressed as described 
elsewhere48,90,115–117 and is reproduced in Equation 1: 
 





where 𝜆 is the wavelength, 𝜇𝑎(𝜆) is the optical absorption coefficient, 𝐹(𝑥, 𝑦, 𝜆) is the 
fluence, and Γ is the Grüneisen parameter.  For heterogeneous tissue the total PA signal at 
each pixel is a superposition of each PA signal from 𝑛 optical absorbers.   
 Spectroscopic PA datasets were pre-processed to correct for wavelength-dependent 
fluence attenuation in the iris.  Fluence, 𝐹(𝑧, 𝜆), is expressed as101,118: 
 𝐹(𝑧, 𝜆) = 𝐹𝑜(𝜆)𝑒
−𝜇𝑒𝑓𝑓(𝜆)∙𝑧 (2) 
where 𝑧 is the imaging depth and 𝐹0 is the fluence at the iris surface. Effective attenuation, 
𝜇𝑒𝑓𝑓(𝜆) =  √3𝜇𝑎(𝜆) (𝜇𝑎(𝜆) +  𝜇𝑠(𝜆)(1 − 𝑔(𝜆)), was calculated based on: (i) the 
coefficient of anisotropy, 𝑔(𝜆) = 2.25 ∙ 𝜆−0.155,119 and (ii) the optical scattering 
coefficient, 𝜇𝑠(𝜆), of 10% intralipid,
120 and (iii) 𝜇𝑎(𝜆) of melanin at the retinal pigmented 
epithelium (RPE).107,108   
 Unfortunately published iris-specific absorption and scattering values were not 
available for our wavelength range.  The best alternatives to estimate 𝜇𝑒𝑓𝑓  at the iris were 
to use generic scattering (intralipid) and melanin absorption in the RPE.  For brown eyes, 
𝜇𝑎(𝜆 [𝑛𝑚]) = 8 ∙ 10
10 𝜆−3.48 [𝑐𝑚−1], and for blue eyes, 𝜇𝑎(𝜆 [𝑛𝑚]) = 6.5 ∙
1010 𝜆−3.48 [𝑐𝑚−1].107,108  The exponent of λ from the expression for μa(𝜆) is the critical 
parameter to describe the melanin absorption spectrum and was taken directly from 
published data for the RPE.107  However, concentrations of melanin vary by orders of 
magnitude in ocular tissues, and the values of the leading coefficient in the expression for 
𝜇𝑎(𝜆) were reduced to accommodate different melanin concentrations and distributions at 
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the iris compared to the RPE.107  The leading coefficients were incrementally adjusted until 
artifacts at the posterior iris were minimized.  However, processing was conservative, and 
some artifacts were deliberately kept.  Fluence correction is a complex technical issue and 
further work is required in the future.101,118  Using Eq. 2, 𝐹(𝑧, 𝜆) was calculated to produce 
a spatial distribution map of fluences in the iris.  The PA signal, 𝑃, in Eq. 1 was multiplied 
by 1/𝐹(𝑧, 𝜆) to correct for wavelength and depth-dependent fluence attenuation.101,118   
 After fluence correction, spectroscopic PA datasets were filtered using a 3 x 3 pixel 
(41 µm x 45 µm) median filter to remove large noise spikes.  Images were then low pass 
filtered using a 6 x 9 x 3 pixel (depth x width x wavelength) moving average filter, 
approximately corresponding to 252 µm x 405 µm and a wavelength range of 15 nm.  
Photoacoustic signals below the noise floor, defined by 𝑚𝑖𝑛(𝑃) + 0.025(𝑚𝑎𝑥(𝑃) −
𝑚𝑖𝑛(𝑃)), were eliminated.  
 After filtering, spectroscopic PA datasets were analyzed using the linear least 
squares (LLS) regression method.  LLS regression creates a spatial distribution map of 
each optical absorber in tissue.  Concentration, 𝐶, of each absorber was estimated by 
separating contributions of each absorber to the total PA signal at each pixel.  According 
to LLS regression methods described elsewhere,90,121,122 the optical absorption coefficient, 
𝜇𝑎(𝜆), in Eq. 1 can be expressed as the product of the concentration of the 
absorber, 𝐶𝑖(𝑥, 𝑦) , and the optical cross-section of the absorber, 𝜎𝑎.  Eq. 1 is rewritten as:  
 
𝑃(𝑥, 𝑦, 𝜆) = Γ 𝐹(𝑥, 𝑦, 𝜆) ∑ 𝐶𝑖(𝑥, 𝑦)
𝑛
𝑖=1
𝜎𝑎𝑖(𝜆)  (3) 
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 The optical cross-section describes the likelihood an absorption event will occur, 
and 𝜎𝑎𝑖 is a matrix whose rows and columns correspond to wavelength and the normalized 
absorption spectrum of each pre-selected optical absorber, respectively. For our studies, 
two matrices of optical cross-sections were determined a priori for LLS regression.  The 
first matrix of optical cross-sections was obtained from the normalized absorption spectra 
of melanin, HbO2, and Hb,  which are reported in the literature and represent optical 
properties of generic tissue.106–112  The second matrix of optical cross-sections was obtained 
from our normalized measured PA spectra, which were specific to anterior ocular tissues.  
Thus, the same images were processed with LLS regression to produce two sets of 
concentration maps based on absorption spectra from the literature or based on our 
measured PA spectra.         
 Other research has established that it is theoretically ideal to use the maximum 
number of wavelengths for LLS regression of spectroscopic PA datasets.123,124  In practice, 
such an approach may introduce inaccuracies due to laser energy stability, noise, and 
overlap of optical spectra.123,124 Thus a subset of acquired wavelengths, 𝜆 = 720 −
970 𝑛𝑚, was used for LLS regression of spectroscopic PA datasets.  This range captured 
a majority of wavelengths acquired, eliminated wavelengths with energy instability, and 
preserved distinct features of all spectra.   
2.4 Results 
 Brown porcine eyes were imaged ex vivo to evaluate PA response from constituent 
tissues.  Ultrasound images resolved anatomical features in the anterior segment, such as 
the sclera, cornea, lens, and iris (Figure 2A and 2B).  Histology aided proper identification 
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of structures (Figure 2C).  Heavy pigmentation was also noted at the posterior iris (Figure 
2C).  By ultrasound, the cornea appeared slightly darker compared to other tissues, 
consistent with its relative transparency, and the interface between the cornea and sclera 
was distinct, reflecting differences in composition and microstructural organization of the 
cornea relative to other tissues.  As expected, other tissues, such as the TM, could not be 
unequivocally identified due to similar scattering and ultrasound speckle patterns, 
confirming low ultrasound contrast between most tissue types.  
 PA images were acquired at 700 nm wavelength and consecutive 45 cross-
sections.  PA signals were observed in melanin-rich tissues, namely the anterior and 
posterior iris and TM (Figure 2D-G).  Although the ciliary pigmented epithelium (CPE) is 
melanin-rich, no PA signal was present in this tissue due to strong attenuation of light by 
the overlying iris and sclera, resulting in low fluence at the CPE.  PA signal was observed 
in some views in the scleral region, possibly corresponding to the suprachoroidal space 
(SCS) (Figure 2E and G).  Although the sclera and SCS are not pigmented, the PA signal 
at these locations may result from sub-surface fluence.    
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Figure 2. Visualization of anatomy and PA signals in the anterior segment.  (A, B) 
Grayscale ultrasound images showing anatomy of the ex vivo porcine eye. S= sclera, AC = 
anterior chamber, C = cornea, L= lens, TM = trabecular meshwork, AI = anterior iris, PI 
=posterior iris, SCS = suprachoroidal space, and CPE = ciliary pigmented epithelium. (C) 
Corresponding histologic image of the porcine anterior segment stained with hematoxylin 
and eosin. (D-G) Overlay of ultrasound and PA (color scale) images at different locations 
(scans at 0°, 45°, 90°, and 135°) at λ = 700 nm.  PA signals appeared at melanin-rich 
regions, such as the TM and throughout the iris, and consistently appeared at the same 
anatomical landmark in all frames.  Scale bar = 3 mm. 
 Spectroscopic PA datasets were acquired in brown eyes at the anterior iris and 
posterior iris, scleral region, and TM from λ = 680 - 970 nm.  Representative PA spectra 
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were plotted for fixed brown porcine eyes and distinct PA spectra were observed for each 
region (Figure 3A).  To assess impact of fixation on the PA spectra, average PA spectra 
and standard deviations were calculated for multiple fresh brown porcine eyes (Figure 3B 
and 2C).  PA spectra were similar between fresh and fixed eyes.  The measured PA 
spectrum at the anterior iris closely followed the absorption spectrum of melanin reported 
in the literature (Figure 3B). Unexpectedly, the measured PA spectrum at the posterior iris 
did not follow the spectrum of melanin (Figure 3C) and showed more similarities to the 
literature absorption spectrum of oxygenated hemoglobin (HbO2).  Although HbO2 was not 
expected in ex vivo tissue, comparison with the measured PA spectrum at the posterior iris 
was important.  Similarities between the absorption spectrum of HbO2 and the PA spectrum 
at the posterior iris (Figure 3C) highlight a potential source of PA imaging artifacts, and in 
turn impact use of these PA spectra to identify endogenous absorbers, select contrast 
agents, and facilitate molecular PA imaging, such as stem cell tracking.      
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Figure 3. Photoacoustic spectra in fixed and fresh brown porcine eyes. (A) Representative 
PA spectra for the scleral region (S), TM, anterior iris (AI), and posterior iris (PI) for fixed 
brown porcine eyes.  Average PA spectra and standard deviations were also calculated for 
the anterior iris (B) and posterior iris (C) in multiple fresh brown porcine eyes.  PA spectra 
appeared similar in fixed and fresh eyes.  The measured PA spectrum (solid blue line) of 
the anterior iris was compared to the reported absorption spectrum of melanin (dashed blue 
line).  (C) The measured PA spectrum (solid orange line) of the posterior iris was compared 
to the reported absorption spectrum (dashed orange line) of HbO2 to highlight a potential 
source of PA imaging artifacts following spectroscopic analysis.   
 We suspected the measured PA spectrum at the posterior iris actually represented 
a PA signal from melanin modified by wavelength-dependent fluence reaching the 
posterior iris.  Therefore, fluence attenuation due to tissue absorption and scattering was 
studied in a silicone tube phantom.  Cross-sectional US/PA images of the tube filled with 
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purified pigment were acquired and divided into three regions of interest to study fluence 
attenuation and the effect on the PA spectrum of melanin at increasing depths (Figure 4A).  
At the top of the tube, the PA spectrum matched the literature absorption spectrum of 
melanin.  As light was attenuated by overlying pigment, the spectrum of melanin shifted 
and a peak appeared at 850 nm at the bottom of the tube (Figure 4A). Additional scattering 
from scleral tissue further modified the PA spectrum of melanin (Figure 4B).  Specifically, 
compared to attenuation primarily by optical absorption (Figure 4A), the spectrum shifted 
at shallower depths, and a peak was observed in the middle of the tube (Figure 4B).  The 
spectrum in the bottom region of interest further shifted with a peak closer to 900 nm.  We 
suspected similar fluence attenuation occurred for light propagating from the anterior to 
posterior iris in situ.  In other words, even though the measured PA spectrum at the 
posterior iris should match the literature absorption spectrum of melanin, the observed PA 
spectrum at the posterior iris (Figure 3C), resulted from wavelength-dependent light-tissue 
interactions.   
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Figure 4. Photoacoustic spectrum of fresh pigment as a function of depth.  A silicone tube 
was filled with purified pigment and cross-sectional US/PA images were acquired.  The 
PA spectrum was analyzed within different regions of interest.  “Top” and “Bottom” 
indicate locations closest to, and further from, the transducer with the least and most light 
attenuation, respectively.  (A) The PA spectrum of melanin was modified by depth due to 
light absorption of melanin, causing a significant change in the PA spectrum.  (B) The 
experiment was repeated with the addition of a scattering layer (sclera), resulting in further 
modification of the measured PA spectrum of melanin. 
 The literature absorption spectra of melanin, HbO2, and Hb (Figure 5A) were 
compared to the measured PA spectra (Figure 5E) by processing spectroscopic PA datasets 
from brown eyes using the LLS regression method.  The set of literature absorption spectra 
and measured PA spectra were used to obtain two different matrices of optical cross-
sections.  A spectrum for Hb could not be measured in brown eyes due to high melanin 
content; thus, the absorption spectrum of Hb from the literature was used instead (Figure 
5E).  The goal of this study was to compare each set of concentration maps, generated using 
the literature absorption spectra, serving as the “ground truth”, or our experimentally 
obtained measured PA spectra.   
 Using either set of spectra, melanin was localized as expected at the anterior iris, 
posterior iris, and TM (Figure 5B and 5F).  Because HbO2 was not expected in post-mortem 
 29 
tissue, pixels indicating presence of HbO2 were determined to be image artifacts (Figure 
5C).  Agreement between the concentration maps for HbO2 (Figure 5C) and the posterior 
iris (Figure 5G) indicated the artifact occurred due to the measured spectrum at the 
posterior iris being most similar to that of HbO2 among the species we considered (melanin, 
Hb, HbO2) although clearly the match is only very approximate (Figure 3C).  Although the 
posterior iris is a melanin rich-tissue, the PA spectrum was modified by fluence attenuation.  
Without fluence correction, LLS regression predicted a prominent HbO2 distribution at the 
posterior iris (data not shown).  By implementing fluence correction, melanin was 
accurately localized to the anterior iris (Figure 5B and 5F) and the presence of HbO2 was 
minimized at the posterior iris (Figure 5C and 5G).  Hb was primarily localized to the 
posterior iris, but some discrepancies were observed between distribution maps (Figure 5D 
and 5H).  LLS regression of sPA datasets from multiple brown eyes produced similar 
results, indicating PA properties were similar across various colorations of brown eyes 
from light to dark. Agreement between both sets of concentration maps (Figure 5B–D and 
5F–H) impacts future use of measured PA spectra for molecular PA imaging.  Similar 
concentration maps across multiple brown eyes indicated our measured PA spectra can be 
used to inform contrast agent selection for a particular application according to endogenous 
absorber distribution.  
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Figure 5. Spectroscopic photoacoustic analysis using LLS regression in brown porcine 
eyes. (A) Absorption spectra from literature used for sPA analysis, and resulting computed 
distributions of melanin (B), HbO2 (C), and Hb (D).  (E-H) as in (A-D), but using measured 
PA spectra. Overlay of ultrasound (grayscale) and spectroscopic PA images showed 
localization of melanin (blue color scale), HbO2 (orange color scale), and Hb (pink color 
scale).  Melanin was localized as expected. Absorption spectra from the literature and 
measured by photoacoustic imaging produced similar results.  Some artifacts remained in 
the HbO2 images (C and G).   Scale bar = 3 mm. 
 Characterization and analysis of PA properties was repeated in blue porcine eyes 
(Figure 6). Each spectrum in brown and blue eyes was normalized according to its peak 
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absorption to better visualize the photoacoustic properties in different eye colors.  Results 
do not depict differences in magnitude of PA signals.  The posterior iris was the only 
structure to consistently show a PA signal in the blue eye at the 700 nm wavelength (Figure 
6A).  Due to less melanin than in brown eyes, PA signals were not evident in other tissues.  
The PA signal from melanin at the posterior iris was modified by fluence attenuation, and 
thus a similar artifact was observed in the blue eye (Figure 6B) as in brown eyes. Other 
types of PA spectra were also occasionally observed in blue eyes (Figure 6C and 6D), but 
were not localized to a consistent location, i.e., the spectrum shown in Figure 6B was most 
prevalent in blue eyes.   
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Figure 6. Comparison of measured PA spectra in blue and brown eyes.  (A) Overlay of 
ultrasound (grayscale) and photoacoustic (color scale) images in a blue porcine eye.  PA 
signal was localized to the posterior iris.  (B-D) Spectra were separated based on results 
from brown porcine eyes.  (B) A modified melanin spectrum, resembling that of 
oxygenated hemoglobin, was isolated to the posterior iris in both eye colors and was the 
dominant spectrum observed in blue eyes.  (C and D) Other types of spectra were observed 
in blue eyes, but were not localized to a consistent location. (D) The PA spectrum 
resembling melanin was most prevalent in brown eyes. Scale bar = 3 mm. 
 Spectroscopic PA analysis using the LLS regression method was repeated for blue 
eyes (Figure 7).  In the case of blue eyes, sPA analysis was conducted using the measured 
PA spectra from brown eye datasets, except for the spectrum of Hb, which was possible to 
isolate in a blue eye.  Spectroscopic PA datasets from the blue porcine eyes were similarly 
processed using either the literature absorption spectra (Figure 7A) or the measured PA 
spectra (Figure 7E) to identify absorbers.  After correcting for wavelength-dependent 
fluence attenuation, melanin was accurately localized at the iris (Figure 7B and 7F).  Some 
effects of fluence attenuation remained (Figure 7C and 7G).  However, fluence correction 
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increased melanin localization at the posterior iris (Figure 7B and 7F) and minimized the 
presence of HbO2 (Figure 7C) and the modified melanin spectrum at the posterior iris 
(Figure 7G).  Hb was also identified (Figure 7D and 7H).  sPA analysis in blue eyes 
accurately localized absorbers, and agreement between concentration maps (Figure 7B–D 
and 7F–H) indicated conservation of PA properties across drastically different eye colors.   
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Figure 7. Spectroscopic PA analysis using LLS regression in blue porcine eyes. (A) 
Literature absorption spectra used for sPA analysis. (B-D) sPA analysis using the literature 
absorption spectra.  (E) Measured PA spectra used for sPA analysis, which were compiled 
from brown eye datasets, except for the spectrum of Hb.  (F-H) sPA analysis using the 
measured PA spectra.  Overlay of ultrasound (grayscale) and spectroscopic PA images 
showed localization of melanin (blue color scale), HbO2 (orange color scale), and Hb (pink 
color scale). Absorbers were localized as expected according to known anatomy.  
Literature absorption spectra or measured photoacoustic spectra produced similar results, 
and either can be applied for sPA analysis. These results show that the PA spectra can be 




 Clinically available ophthalmic imaging modalities such as OCT and ultrasound 
provide excellent anatomical information for ocular tissues.74,75,125  However molecular 
imaging techniques have not developed as rapidly for the anterior segment.81,82  PA 
imaging is one option to address the need for molecular imaging in the anterior eye.  
Implementation of molecular PA imaging requires use of endogenous or exogenous 
contrast agents.13,91  Contrast agents must be carefully selected based on the application of 
interest and PA properties of the surrounding tissues.  Without prior knowledge of PA 
properties of anterior segment tissues, it is impossible to ensure a contrast agent can be 
distinguished from background PA signals.  Thus, the first step to extend molecular PA 
imaging to the anterior eye is to establish PA spectral properties.   
 We here systematically analyzed PA properties of anterior segment tissues to 
produce a set of measured PA spectra in the first optical window between 680 – 970 nm to 
facilitate molecular PA imaging.  Distinct PA spectra were observed at the TM, anterior 
iris, posterior iris, and scleral region in brown porcine eyes.  Similar PA spectra were 
observed at the posterior iris in blue porcine eyes.  These measured PA spectra were 
compared to literature absorption spectra by analyzing sPA datasets of blue and brown 
porcine eyes using LLS regression to produce concentration maps of each absorber.  Good 
agreement was observed between absorber maps, which validates future use of our PA 
spectra to facilitate molecular PA imaging in vivo.     
 Each measured PA spectrum was expected to match a known absorption spectrum 
of an endogenous absorber, specifically melanin.  However, this was only true for the 
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anterior iris in brown eyes.  In other tissues, the PA spectrum was modified by wavelength- 
and depth-dependent fluence attenuation.  These effects were most prominent at the 
posterior iris, especially in blue eyes.  The impact of fluence attenuation on the PA 
spectrum at the iris was consistent with results from a simplified phantom experiment.  
Without fluence correction, sPA analysis using LLS regression contained many artifacts 
and mistakenly attributed PA signals to light absorption by HbO2, which coincidentally has 
a spectrum similar to the fluence-modified melanin spectrum.  Wavelength- and depth-
dependent fluence correction allowed better PA identification of melanin in the anterior 
segment and minimized artifacts.   
 Further improvement to the fluence correction method is possible.  Specifically, we 
assumed a uniform concentration of melanin, but concentration varies spatially throughout 
the iris.  In addition, at the wavelengths of interest (680 - 970 nm), information on melanin 
absorption and scattering at the iris were unknown.  Thus, optical properties of the iris were 
estimated based on available data for the RPE and a general model of scattering (intralipid) 
as substitutes.106–108,119,120  This motivates further study so that parameters specific to the 
iris can be determined.  We anticipate the effects of fluence attenuation observed here will 
impact molecular PA imaging strategies in the future.   
 Comparison between blue and brown porcine eyes indicated that the set of 
measured PA spectra were independent of eye color, at least in the near infrared region.  
This result was fortuitous but not obvious a priori.  Although blue and brown eyes have 
the same type of pigment, in the visible spectrum differences in melanin concentration and 
scattering produce variations in eye color.  In spite of distinct optical properties in the 
visible regime, PA properties in the near-infrared regime were similar across eye colors. 
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This result was important to confirm our measured PA spectra were applicable to both 
extremes in eye color (blue and brown).  Thus, a single set of measured PA spectra can 
possibly inform molecular PA imaging strategies across the full spectrum of eye colors.  
Each eye color does not appear to require a unique set of spectra to predict endogenous 
absorber distribution and background PA signals to inform contrast agent selection.  If this 
were the case, implementing molecular PA imaging in the anterior eye would likely be 
impractical.     
2.6 Conclusions 
 Photoacoustic tissue properties were analyzed throughout the anterior segment.  
Measured PA spectra were compiled based on distinct PA spectra observed in the anterior 
and posterior iris, TM, and sclera.  These spectra were compared to existing published 
absorption spectra.  sPA analysis using both the measured PA spectra and published 
absorption spectra accurately localized absorbers throughout the anterior segment.  In 
addition, the measured PA spectra from the brown eye were used for sPA analysis of 
datasets from the blue eyes.  Although there are many eye colors in the visible range, our 
comparison of blue and brown porcine eyes indicated anterior segments are 
photoacoustically similar in the near infrared wavelength range.  Results have important 
implications for development of molecular PA imaging strategies and other light-based 
imaging techniques and therapies in the anterior segment, including our particular 
application of interest, stem cell tracking for glaucoma treatment. 
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CHAPTER 3. A STEM CELL TRACKING PLATFORM FOR 
OPHTHALMIC APPLICATIONS USING US/PA IMAGING  
The chapter is adapted from an article published in Theranostics: 
Kubelick, K. P.,* Snider, E. J.,* Ethier, C. R., & Emelianov, S. (2019). Development of a 
stem cell tracking platform for ophthalmic applications using ultrasound and photoacoustic 
imaging. Theranostics, 9(13), 3812.  *Equal contribution 
 
3.1 Abstract 
 Glaucoma is the second leading cause of blindness in the world. Disease 
progression is associated with reduced cellularity in the trabecular meshwork (TM), a fluid 
drainage tissue in the anterior eye. A promising therapy seeks to deliver stem cells to the 
TM to regenerate the tissue and restore its function.  However, like many stem cell-based 
regenerative therapies, pre-clinical development relies heavily on histology to evaluate 
outcomes. To expedite clinical translation, we are developing an ultrasound/photoacoustic 
(US/PA) imaging platform for longitudinal tracking of stem cells in the anterior eye.  
Mesenchymal stem cells (MSCs) were pre-labeled with gold nanospheres in vitro and 
injected through the cornea of ex vivo porcine eyes.  Physiological pressure was imposed to 
mimic in vivo conditions.  AuNS-labeled MSCs were injected through the cornea while 
single-wavelength US/PA images were acquired.  At 5 hours post-injection, three-
dimensional multi-wavelength US/PA datasets were acquired and spectroscopic analysis 
was used to detect AuNS-labeled MSCs.  US/PA results were compared to fluorescent 
microscopy.  The US/PA imaging platform was able to provide real-time monitoring of the 
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stem cell injection and distinguish AuNS-labeled MSCs from highly absorbing background 
tissues in the anterior segment.  Our US/PA imaging approach can inform preclinical 
studies of stem cell therapies for glaucoma treatment, motivating further development of 
this theranostic imaging tool for ophthalmic applications.  Several future research 
directions were also identified from these studies and were explored: 1) assessing laser 
safety in vivo; 2) custom focused-light delivery systems; and 3) use of photomagnetic 
nanocubes to improve delivery efficiency.   
3.2 Introduction 
 Glaucoma is the second leading cause of blindness in the world, estimated to affect 
more than 70 million people.30 Disease progression is frequently associated with elevated 
intraocular pressure (IOP), which in turn is associated with reduced cellularity in the 
trabecular meshwork (TM), a fluid drainage tissue in the anterior eye.31–33  There is no cure 
for glaucoma, and existing treatments focus on slowing disease progression.   
 A promising therapeutic approach is to deliver stem cells to the TM to regenerate 
this tissue and restore its function, so as to lower IOP.  To this end, induced pluripotent 
stem cells and mesenchymal stem cells (MSCs) have been investigated as therapeutics to 
renormalize IOP in glaucoma.34–37  Although stem cell delivery decreased IOP and restored 
TM function, conclusions on how stem cells caused a positive therapeutic outcome were 
inconsistent and contradictory.36,37 
 In this case, like many other regenerative therapies using stem cells, preclinical 
development relies heavily on histology to evaluate outcomes.2,3  Although histology 
provides detailed information at the cellular and molecular level, drawbacks include highly 
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invasive, destructive sample preparation.1–3 A related approach is fluorescent imaging of 
pre-labeled cells in whole tissue using confocal microscopy 2,126, which is somewhat less 
time-consuming than traditional histology but is also destructive and typically suffers from 
poor imaging resolution at depths beyond the sub-millimeter scale due to strong optical 
scattering by the overlying tissues.2  As a result, longitudinal monitoring is challenging, 
making it more difficult to interpret results and inform future therapy design.  Development 
and clinical translation of this novel stem cell therapy would thus be expedited by 
developing a minimally invasive, longitudinal stem cell tracking platform for the anterior 
eye.   
 A variety of imaging technologies exist at the preclinical or clinical stage to address 
this need, including magnetic resonance imaging (MRI), X-ray/computed tomography 
(CT), optical imaging, positron emission tomography (PET), and ultrasound.  Each has its 
own advantages, and compromises are always made between resolution, sensitivity, image 
acquisition speed, penetration depth, contrast, safety, and cost. Specific to ophthalmology, 
optical coherence tomography (OCT) and ultrasound are widely used clinically 39,42,73,127–
129, with contrast based on backscattering of optical and acoustic waves, respectively.38,41,71  
Both modalities provide excellent anatomical information, but their contrast is inherently 
poor. OCT faces an additional challenge for anterior segment imaging due to light 
penetration through highly scattering ocular tissues, such as the sclera.130–132   
 One preclinical imaging modality, photoacoustic (PA) imaging, has been explored 
for anterior and posterior segment imaging in ophthalmology, but current research is 
limited.100,133–135  Unlike OCT and ultrasound, PA imaging is advantageous because 
contrast is based on optical absorption that significantly varies between different tissue 
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types.  In PA imaging, a pulsed laser irradiates an optical absorber, such as an exogenous 
contrast agent.  Heat deposition upon absorption causes thermoelastic expansion of the 
surrounding tissue to create transient acoustic waves, which can be detected with a 
traditional ultrasound transducer.12,13,15,20  PA imaging combines advantages of acoustic 
and optical modalities to provide cellular- or molecular-level information with high 
resolution and contrast at increased imaging depths.2,3  Furthermore, combined ultrasound 
and photoacoustic (US/PA) imaging simultaneously provides anatomical and functional 
information.12,13  This multi-modal imaging approach is even more appealing due to 
existing clinical use of ultrasound in ophthalmic applications.128   
 In this work, we describe development of a combined US/PA imaging platform to 
track stem cells in the anterior eye.  We first compare the detection capabilities of a 
traditional optical modality (confocal microscopy of fluorescently labeled cells) with 
photoacoustic imaging in a simplified phantom system where the number of cells was 
known a priori. We then proceed to image cells in whole, intact tissue using US/PA 
imaging. Although PA imaging has been used to successfully monitor stem cells in other 
applications, translation of US/PA imaging of stem cells in the anterior segment of the eye 
has to satisfy several unique requirements involving the optical properties of anterior ocular 
tissues, selection of a contrast agent to label stem cells, light-tissue interactions, and laser 
safety.18,53,136–139 We show proof-of-principle of the US/PA imaging platform to monitor 
stem cell location in real-time and to distinguish stem cells from highly absorbing 
background tissues in the anterior segment of the eye. This work will inform future 
development of stem cell therapies for glaucoma treatment and lays the groundwork for a 
novel theranostic imaging tool in ophthalmology.    
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3.3 Materials and Methods 
3.3.1 Cell culture 
 Human adipose-derived MSCs (Lonza) were grown in α-minimum essential 
medium supplemented with 20% fetal bovine serum (FBS), penicillin, streptomycin, and 
L-glutamine. At 80-90% confluency, MSCs were detached using 0.05% Trypsin/EDTA 
and seeded in fresh T75 cell culture flasks at a density of 5,000 cells/cm2.  In all 
experiments, MSCs were used at passage numbers five or six. Each MSC donor strain was 
validated by Lonza for expression of MSC surface markers (CD13, CD29, CD44, CD73, 
CD90, CD105, and CD166) and minimal expression of negative MSC markers (CD14, 
CD131, CD45). Each MSC donor strain was also previously characterized in our lab for 
adipogenic, chondrogenic, and osteogenic differentiation potential, as well as CD90 
expression following expansion.140 
3.3.2 Synthesis of gold nanospheres 
 Gold nanospheres (AuNSs) were synthesized following the citrate reduction 
method, as detailed in previous reports.141  Briefly, hydrogen tetrachloroaurate (III) hydrate 
(Alfa Aesar) and sodium citrate tribasic dihydrate (Sigma-Aldrich), were used as received.  
AuNSs, 20 nm diameter, were synthesized via the citrate reduction method as described 
elsewhere.142 Briefly, 0.5 ml of a 1% w/v solution of hydrogen tetrachloroaurate was added 
to 47 ml of deionized ultrafiltered (DIUF) water. The solution was brought to a boil while 
stirring, then 2.5 ml of a 1% w/v solution of sodium citrate was added.  After approximately 
15 minutes, the solution appeared red and was cooled to room temperature.  UV-Vis 
spectrophotometry (Synergy HT microplate reader, BioTek Instruments) between 400 nm 
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to 995 nm was used to validate the absorbance spectrum.  Transmission electron 
microscopy (TEM; Hitachi HT7700 TEM, IEN/IMAT Materials Characterization Facility, 
Georgia Institute of Technology) was used to validate particle size and morphology.   
Carbon formvar TEM grids (Electron Microscopy Sciences) were prepared by drop casting 
3 l of particle solution and drying overnight at room temperature. Images were acquired 
at an accelerating voltage of 100 – 120 kV.  The hydrodynamic diameter and zeta-potential 
of AuNSs were assessed (Malvern Zetasizer Nano ZS).   Dynamic light scattering (DLS) 
measurements to determine hydrodynamic diameter were performed at 25˚C using a 
disposable cuvette.  Six recordings were obtained, each consisting of 13 measurements.  
Zeta-potential measurements were performed using a Folded Capillary Zeta Cell (Malvern) 
to determine the surface charge of AuNSs.  Six recordings were obtained, each consisting 
of at least 12 measurements.    
3.3.3 Labeling cells with gold nanospheres 
 AuNSs were sterilized under UV light for at least 12 hours prior to stem cell 
labeling experiments. Adipose-derived MSCs (Lonza) were incubated for 24 hours with 
AuNSs at an optical density of 2, a measure of concentration according to light absorbance, 
which corresponds to approximately 200 μg/ml of gold/ml of media, in α-minimum 
essential medium (Mediatech) supplemented with 20% FBS, 2mM L-glutamine, and 1x 
penicillin/streptomycin. AuNSs were previously determined to have minimal cytotoxic 
effects on stem cell viability and multipotency.142  We also carried out Alamar blue tests 
and confirmed that, for the AuNS concentration used in this study, stem cell metabolic 
activity was not impacted.  Following uptake, gold nanosphere-labeled stem cells 
(hereinafter referred to as AuNS-labeled MSCs) were collected and used for cell tracking 
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experiments.  AuNS-labeled MSCs were washed with phosphate buffered saline (PBS) to 
remove excess nanoparticles, detached with Trypsin-EDTA, and centrifuged (300 x g, 10 
minutes) to separate free AuNSs from AuNS-labeled MSCs.  Successful labeling was 
confirmed by measuring cellular side scatter by flow cytometry (Attune NxT flow 
cytometer, Thermo Fisher) as previously described 126,143, brightfield microscopy (Zeiss 
Axio Observer) of naïve (unlabeled) and AuNS-labeled MSCs stained with eosin in vitro, 
and UV-Vis spectrophotometry measurements (Evolution 220 Spectrophotometer, Thermo 
Scientific) of AuNS-labeled MSCs and naïve MSCs.  For fluorescent cell detection, in 
addition to AuNSs, MSCs were also labeled with 5 µM carboxyfluorescein succinimidyl 
ester (CFSE, Affymetrix) for fifteen minutes at 37oC, followed by washing with cell culture 
media to remove excess CFSE (hereinafter referred to as double-labeled MSCs). 
3.3.4 Assessing stem cell multipotency after gold nanosphere labeling 
 MSCs were seeded in a 6-well plate with maintenance media and allowed to adhere 
to the plate overnight.  Maintenance media was changed the following day, and MSCs were 
incubated with fresh media containing AuNSs as described above (see Section 3.3.3).  
After 24 hours, the AuNS-containing media was removed and AuNS-labeled MSCs were 
rinsed three times with PBS to remove residual nanoparticles.  Then, two of the wells 
underwent osteogenic differentiation, two of the wells underwent adipogenic 
differentiation, and two of the wells were fed maintenance media.   
 Osteogenic induction media consisted of Dulbecco’s Modified Eagle Medium 
(DMEM; Corning), 10% FBS, 1% penicillin/streptomycin, 100 nM dexamethasone 
(Sigma-Aldrich), 10 nM beta-glycerophosphate (Calbiochem), and 50 μg ascorbic acid 
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(Sigma-Aldrich). AuNS-labeled MSCs were fed osteogenic induction media every three 
days for two weeks.  A Von Kossa staining kit (Millipore Sigma) was used to evaluate 
presence of calcium deposits indicative of osteogenesis.  AuNS-labeled MSCs were stained 
per the manufacturer’s protocol.  Briefly, media was aspirated, and the AuNS-labeled 
MSCs were washed with PBS (w/o Ca2+ or Mg2+) followed by fixation in 10% neutral 
buffered formalin for 10 minutes.  The formalin was aspirated, and cells were washed with 
PBS again.  Cells were covered with 5% silver nitrate for 40 minutes under UV light.  The 
silver nitrate solution was aspirated, and cells were rinsed with distilled water.  Cells were 
covered with 5% sodium thiosulfate for 2 minutes, followed by rinsing in running tap 
water.  Cells were covered with nuclear fast red stain for 5 minutes, followed by rinsing in 
running tap water.  Staining was assessed with brightfield microscopy (Leica).    
 For adipogenic differentiation, AuNS-labeled MSCs were grown in maintenance 
media until reaching 100% confluence.  At this point, AuNS-labeled MSCs were then fed 
adipogenic induction and adipogenic maintenance media.  Adipogenic maintenance media 
consisted of DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, and 10 
μg/ml insulin (Sigma-Aldrich).  Adipogenic induction media consisted of DMEM 
supplemented with 10% FBS, 1% penicillin/streptomycin, 1 μM dexamethasone (Sigma-
Aldrich), 10 μg/ml insulin (Sigma-Aldrich), 100 μM indomethacin (Sigma-Aldrich), and 
10 μg/ml 3-isobutyl-1-methylxanthine (IBMX; Sigma-Aldrich).  AuNS-labeled MSCs 
were cultured in adipogenic induction media for 3 days followed by two days in adipogenic 
maintenance media.  This cycle was repeated three times followed by 7 additional days in 
the adipogenic maintenance media.  Oil Red O staining (Sigma-Aldrich) was used to 
evaluate presence of lipid deposits indicative of adipogenesis.  A stock solution of Oil Red 
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O was prepared by adding 300 mg of Oil Red O to 100 mL of 99% isopropanol.  The 
working solution consisted of 3 parts stock solution and 2 parts DIUF.  The working 
solution sat at room temperature for 10 minutes, followed by filtration.   To stain the AuNS-
labeled MSCs, the media was aspirated, and cells were rinsed with PBS.  AuNS-labeled 
MSCs were then fixed with 10% neutral buffered formalin for 10 minutes.  The formalin 
was aspirated, and cells were washed again with PBS.  Each well was then covered with 
60% isopropanol.  After 4 minutes, the isopropanol was poured off, and the cells were 
covered with the Oil Red O working solution.  After 5 minutes, cells were rinsed with 
running tap.  Staining was assessed with brightfield microscopy (Leica).  
3.3.5 Overview of Vevo LAZR imaging system 
 A Vevo LAZR (FUJIFILM VisualSonics, Inc.) imaging system, incorporating 
ultrasound and photoacoustic (US/PA) imaging modes, was used for all imaging 
experiments. US/PA images were acquired using a 256 element transducer array operating 
at 20 MHz (LZ250) center frequency. The laser source was a Q-switched Nd:YAG pumped 
optical parametric oscillator (OPO) laser (pulse repetition frequency = 20 Hz, 7 ns pulse 
duration).  PA images were acquired within the 680 - 970 nm wavelength range at a frame 
rate of 5 Hz. Variations in laser pulse energy were corrected at the time of data acquisition 
using built-in features of the Vevo LAZR.  All three-dimensional (3D) US/PA images were 
produced using a translational motor stage.   
3.3.6 Analyzing PA signals of labeled cells in a tissue-mimicking phantom 
 To verify successful cell labeling, AuNS-labeled MSCs were imaged in a tissue-
mimicking gelatin phantom 144.  The base of the phantom consisted of 8% (w/v) gelatin 
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and 0.2% (w/v) silica (Sigma-Aldrich). Inclusions were made by adding 16% (w/v) gelatin 
to an equal volume of AuNS-labeled MSCs.  Each inclusion was imaged over a range of 
wavelengths (λ = 680 nm to 970 nm at 5 nm increments).  Data was exported and post-
processed in MATLAB (MathWorks, Inc.).   
3.3.7 Comparing PA imaging and fluorescent microscopy in agarose gels 
 Double-labeled MSCs (AuNSs and CFSE) were collected, fixed in 10% neutral 
buffered formalin for 10 minutes, and suspended at concentrations of 0, 1k, 5k, 10k, 25k, 
50k, 100k, 250k and 500k cells/ml in 1% (w/v) agarose gels (Sigma Aldrich).  Triplicates 
of each gel were formed in 48 well plates. Once solidified, the gels were removed from the 
well plate and stained using DAPI (Thermo Fisher; see section 4.3.10 for detailed 
protocol).  Each gel was imaged using confocal microscopy (LSM 700, Zeiss) followed by 
US/PA imaging at a wavelength of 700 nm to produce three-dimensional images for both 
modalities.  Total fluorescent signal, total PA signal, and cell counts from DAPI labeling 
were determined.  Although the cylindrical gels had a depth of approximately 17 mm, 
analysis could only be performed for a smaller region of interest with a depth of 0.5 mm 
due to limited light penetration of confocal microscopy.  The region of interest was selected 
according to the optimum light focal depth for each modality, and cells were evenly 
distributed throughout the gel.   
3.3.8 Ex vivo studies in whole porcine eyes 
 For ocular delivery experiments, porcine eyes from a slaughterhouse (Holifield 
Farms, Covington, GA) were used within 3 to 4 hours after enucleation.  Eyes were secured 
on top of a tissue-mimicking phantom base composed of 1% (w/v) agarose.  To maintain 
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physiological pressures during cell injection, a reservoir containing serum-free, phenol red-
free DMEM (supplemented with 1x penicillin, 1x streptomycin, 1x amphotericin, and 2 
mM L-glutamine) was connected to each eye by cannulating the anterior chamber using a 
23-gauge needle passing through the cornea. The elevated reservoir was placed 10 to 16 
cm above the limbus (cornea-sclera transition region) to clamp IOP at 8 to 12 mmHg.  A 
250 µL suspension of double-labeled MSCs at concentrations of 1000, 2000, or 4000 
cells/l were injected into the anterior chamber through the cornea using a 27-gauge 
needle.  After injection, eyes remained pressure clamped at a physiological pressure of 8 
to 12 mmHg and were stored in a cell culture incubator for 5 hours.  During this time, 
media from the elevated reservoir flowed into the anterior chamber and then out through 
the trabecular meshwork, which naturally drains fluid from the anterior chamber; thus 
allowing for continuous stem cell circulation in the anterior chamber and complete 
exchange of the anterior chamber fluid.  The schematic of the perfusion set up is presented 
in Figure 8.  Eyes were then fixed by submersion in a 10% neutral buffered formalin 
solution for 24 hours.   
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Figure 8.  Perfusion set up. Ex vivo porcine eyes were hydrostatically clamped using an 
elevated reservoir to mimic the in vivo situation, specifically by maintaining physiological 
IOP and fluid flow rates within the anterior segment and through the aqueous outflow 
pathway.  AuNS-labeled MSCs were injected using a separate syringe.  The elevated 
reservoir remained in place during the injection and 5 hour incubation period.  Stem cells 
circulated in the anterior chamber because inflowing media from the elevated reservoir 
drained through the TM, which is part of the eye’s natural fluid outflow pathway.   
 Eyes were fully submerged in PBS for US/PA imaging.  In a subset of eyes, two-
dimensional (2D) US/PA images were continuously acquired during cell injections at 680 
nm wavelength. Spectroscopic US/PA images were also acquired within the 680 – 970 nm 
wavelength range in 5 nm increments for the first 15 minutes post-injection.  After 5 hours 
post-injection, eyes were fixed, and then 3D spectroscopic US/PA datasets were acquired 
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in all eyes (n=4 for each cell concentration).  Due to hardware limitations, 3D US/PA 
images were acquired at a subset of wavelengths (680 – 710 nm wavelength range, 5 – 10 
nm increments).  All datasets were exported to MATLAB for post-processing.  Three-
dimensional volumetric US/PA images were produced using AMIRA (Thermo Fisher).       
3.3.9 Trabecular meshwork dissection studies 
 Five-hours after cell injection, fixed eyes were dissected to isolate the anterior 
segment, similar to previously reported methods 145,146, to specifically assess double-
labeled MSC localization at the TM. Briefly, orbital connective tissue was removed, and 
eyes were hemisected with a razor blade to isolate the front half of the eye. The vitreous 
humor and lens were removed, the iris was cut radially back to the iris root and pectinate 
ligaments until the TM was revealed, and the ciliary processes were carefully removed 
while preserving the TM. Any remaining vascularized or pigmented tissue was removed. 
Dissected anterior segments (n=4 for each cell concentration) were marked with stickers 
of black printed letters and two small pieces of dowel rod to act as fiducial markers for 
both fluorescent microscopy and US/PA imaging.  
 For US/PA imaging, dissected anterior segments were secured with the cornea 
facing down on top of a tissue-mimicking phantom base composed of 1% (w/v) agarose 
and were fully submerged in PBS.  This orientation was required to maintain light delivery 
consistent with that of the inverted confocal microscope.  Three-dimensional spectroscopic 
US/PA datasets were acquired in all dissected eyes (n=4 for each cell concentration) and 
exported to MATLAB for post-processing.      
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 For fluorescent microscopy, anterior segments were placed in PBS on a 50 mm 
glass-bottomed dish (Ted Pella).  Additional scleral tissue posterior to the TM was removed 
as needed to bring the TM in contact with the glass bottomed dish. Micrographs of the 
entire TM circumference were captured by confocal microscopy (LSM 700, Zeiss) as z-
stacks of tile scans at 50x. Brightfield overlays were also captured.  Maximum intensity 
projections were created for each en face image for further processing.  
3.3.10 Spectroscopic analysis of multi-wavelength PA datasets 
 All PA datasets were post-processed using MATLAB.  Initially, all PA datasets 
were spatially filtered using a 41 µm x 45 µm (3 x 3 pixel) median filter to suppress large 
noise fluctuations.  Then, for two-dimensional spectroscopic PA datasets, a moving 
average filter with a spatial kernel of 252 µm x 405 µm, roughly three times the axial and 
lateral resolution, and a wavelength kernel of 15 nm was used.  For three-dimensional 
spectroscopic PA datasets, the spatial kernel was extended in the elevational dimension 
(267 µm or 3 imaging slices), and no wavelength filtering was performed.  Finally, PA 
signals below the noise threshold, defined as 𝑃𝑚𝑖𝑛 +  0.025 (𝑃𝑚𝑎𝑥 −  𝑃min) were 
eliminated from the dataset, where 𝑃min and 𝑃𝑚𝑎𝑥 are the lowest and the largest values of 
the PA signals, respectively. 
 Following filtering, PA datasets were analyzed with spectroscopic analysis using 
Equation 3 above (see Section 2.3.5).  In this case, the resulting PA signal at each pixel, 
𝑃(𝑥, 𝑦, 𝜆), was assumed to be a superposition of individual PA signals from melanin, the 
primary endogenous absorber in the anterior eye, and AuNS-labeled MSCs.  Therefore 
𝜎𝑎𝑖(𝜆) is a matrix of optical cross-sections for i absorbers, melanin and AuNS-labeled 
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MSCs.  Optical cross-sections were determined a priori 147, and linear least squares 
regression was used to produce separate concentration maps {𝐶𝑖; 𝑖 = 1,2} depicting 
melanin or AuNS-labeled MSC localization in the anterior eye. The concentration maps, 
𝐶𝑖, were restricted to positive values.  
3.3.11 Locating stem cells in photoacoustic images 
 For whole, ex vivo porcine eyes, PA datasets were further processed to eliminate 
signals from stem cells that had accumulated on the lens, thus highlighting stem cells 
localized to the iris and the TM region, as follows.  The 3D concentration maps of melanin 
and stem cells, obtained from spectroscopic analysis, were integrated with respect to 
anterior-posterior depth, thus projecting the PA signals onto a 2D plane showing absorber 
distribution (melanin or cells) around the circumference of the eye.  To eliminate PA 
signals from the anterior lens, the map of melanin distribution was used to define an annular 
ring mask, as follows: the mask’s inner border was taken to be .5 mm exterior to the inner 
edge of the melanin map, representing the pupillary margin, and the mask’s outer border 
was taken as 3 mm exterior to the inner border of the mask.  The map of cell distribution 
was then multiplied by this annular ring mask to isolate cells at the iris and in the angle.  
 For dissected anterior segments, the 3D concentration maps were also integrated 
with respect to depth to produce 2D maps of absorber distribution, and the map of melanin 
distribution was used to create an annular ring mask defining the TM region.  Unlike the 
situation in whole eyes, the iris had been removed from the dissected anterior segments; 
thus, the melanin distribution essentially coincided with the TM, as the only remaining 
melanin-rich tissue.  The inner border of the mask was defined to be the inner edge of the 
 53 
melanin map, i.e. the anterior margin of the TM (nearest to the cornea).  The outer border 
of the mask was defined as 1 mm exterior to the inner border to match the fluorescent 
image processing technique (see Section 3.3.12 below).  The map of cell distribution was 
multiplied by this annular ring mask to isolate cells in the TM region.  The signals resulting 
from the stickers and dowel rods, which were adhered to the cornea as fiducial markers, 
were removed during image processing.    
3.3.12 Locating stem cells in fluorescent images 
 Due to inherent differences between visualization of anatomical landmarks in PA 
imaging vs.  fluorescent microscopy, different masking methods were required to visualize 
stem cell distribution in the TM region by fluorescent microscopy.  In dissected anterior 
segments an annular ring mask was created with the inner border defined to be the corneal 
margin, as observed in brightfield images.  The outer border of the mask was defined to be 
1 mm exterior to the inner border of the mask, to match the mask created for PA images.  
Fluorescent images were masked and exported to MATLAB for further processing.  Images 
were filtered with the same approach used for PA image processing.  Specifically, a 3 x 3 
pixel median filter was used to remove noise spikes, followed by filtering using a moving 
average with a kernel size of 400 µm x 400 µm. The signals resulting from the stickers and 
dowel rods, which were adhered to the cornea as fiducial markers, were removed.    
3.3.13 Evaluating laser safety in vivo 
 All experiments involving animals were performed under the guidelines of the 
Institutional Animal Care and Use Committee (IACUC) of the Georgia Institute of 
Technology.  Female nude rats (RNU; n=2; Charles River Laboratories) with pigmented 
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eyes were used in these studies.  Anesthesia was induced with 5% isoflurane at 
approximately 500 mL/min and maintained at approximately 2% isoflurane.  The right eye 
was imaged with the Vevo LAZR system and combined US/PA images were acquired 
using a 50 MHz transducer.  The entire eye was scanned using a three-dimensional 
translation motor and multi-wavelength sweeps from 700 nm – 950 nm in increments of 
25 nm.  The left eye was not irradiated with the laser and served as a control.  After laser 
irradiation, rats were monitored for gross changes in ocular morphology, indicative of laser 
damage, and any behavioral changes.  Photographs were taken of both eyes before imaging, 
24 hours after laser light irradiation, and 1 week after laser light irradiation.  US/PA 
datasets were exported to MATLAB for post-processing.  Three-dimensional volumetric 
images were created using AMIRA.   
3.3.14 Synthesis of Prussian blue nanocubes 
 Prussian blue nanocubes (PBNCs) were produced using previously reported 
methods.148  All reaction components were used as received.  Briefly, PBNCs were 
synthesized via a seed-mediated method using superparamagnetic iron oxide nanoparticle 
(SPION) precursors (Ocean NanoTech).  SPIONs with a 10 nm diameter served as a source 
of iron to form cubic nanoparticles.  The reactant, 5% by potassium hexacyanoferrate (II) 
trihydrate (Sigma-Aldrich) by mass in DIUF water, and catalyst, 5% by volume of 37% 
HCl (Sigma-Aldrich) in DIUF water, were prepared.  While stirring, 60 mg of SPIONs 
were added to 150 ml of DIUF water, followed by 7.5 ml of the reactant and 2.5 ml of the 
catalyst. The reaction was stirred for at least 1 hour. PBNCs were dextran coated by adding 
10 mg of dextran/mg of Fe.  TEM (Hitachi HT7700 TEM, IEN/IMAT Materials 
Characterization Facility, Georgia Institute of Technology) was used to characterize PBNC 
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morphology.  The optical absorption spectrum was measured using UV-Vis 
spectrophotometry (Evolution 220 Spectrophotometer, Thermo Scientific).  MSCs were 
labeled with PBNCs at an optical density of 2 following the same protocol used for labeling 
stem cells with gold nanospheres (see Section 3.3.3 above).   
3.3.15 Image-guided magnetic delivery of stem cells in vivo  
 All experiments involving animals were performed under IACUC guidelines of the 
Georgia Institute of Technology.  Albino, female nude rats (NIH; n = 2; Taconic) were 
used in these studies.  Thus, eyes were not pigmented.  To prepare for the procedure, ring 
magnets (H125D; Amazing Magnets) were submerged in a vial containing 70% ethanol 
overnight.  In addition, a nitrile glove was cut into small squares (approximately 1 cm x 1 
cm).  Each square had a small slit cut in the middle, which was approximately the size of 
a rat eye, and were submerged into a second vial containing 70% ethanol to clean.  
Anesthesia was induced with an injection of ketamine (75 mg/kg) and dexdomitor (.5 
mg/kg).  Only half of the recommended dose was administered, and then the rat was 
prepared for the procedure.  The rat was placed on its side on a heating pad covered with a 
sterile drape under a dissecting microscope.  A tetracaine drop was delivered to the surgical 
eye (the right eye).  Once the rat reached the surgical plane, the right eye was injected with 
PBNC-labeled MSCs.  One rat received PBNC-labeled MSCs only.  The second rat 
received PBNC-labeled MSCs and a ring magnet placed around the TM for three hours.  
The contralateral eye (left eye) of both animals was untreated.  Injections were delivered 
as follows.    
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 A 31G insulin syringe (BD) was filled with a 25 μl volume of PBNC-labeled MSCs 
at 1000 cells/μl.  One of the pre-cut squares was removed from the ethanol and dried on 
the sterile drape.  The right eye was proptosed by pushing the eye through the slit in the 
middle of the square.  Next, the needle was carefully inserted through the cornea from the 
nasal side of the eye with the bevel facing up.  The syringe plunger was quickly depressed.  
After the injection, the needle remained in the eye for 1 minute to avoid reflux.  The needle 
was then removed, and the square was pulled off of the eye.  For the rat that received a ring 
magnet, prior to the injection the magnet was removed from the ethanol vial, briefly dried, 
and placed around the proptosed right eye.  Thus, the eye was injected while the magnet 
was in place.  After the injection, the ring magnet was briefly removed to pull off the 
square, but was immediately returned to the eye.  Sterile saline drops were administered to 
both eyes to moisturize.  After 3 hours post-injection in both animals, 3D volumetric 
US/PA datasets were acquired with the Vevo LAZR system using the 50 MHz transducer 
from 700 – 950 nm wavelengths in 25 nm increments.  The diagram in Figure 9 depicts the 
method used in the aforementioned in vivo studies.   
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Figure 9. Diagram of the method of image-guided magnetic delivery of PBNC-labeled stem 
cells to the TM.  Cartoon depicts PBNC-labeled stem cells being pulled to the TM using a 
ring magnet (A).  Schematic of the in vivo procedure in rats (B).  The eye was proptosed, 
and a ring magnet was placed over the eye while 25 μl of PBNC-labeled stem cells (1000k 
cells/μl) were injected into the eye.  The magnet was in place for 3 hours post-injection 
followed by US/PA imaging. 
 Photographs were taken before and after injections and US/PA imaging.  After 
imaging, rats were sacrificed, and eyes were enucleated.  US/PA datasets were exported 
for post-processing using MATLAB, and 3D volumetric images were created in AMIRA.  
3.4 Results 
3.4.1 Characterization of gold nanospheres and stem cell labelling 
 Gold nanospheres to label stem cells for photoacoustic imaging were successfully 
synthesized, as verified by TEM (Figure 10A) and UV-Vis spectrophotometry (Figure 
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10B).  The average hydrodynamic diameter and surface charge of AuNSs were determined 
using DLS and zeta-potential, respectively.  The AuNSs had an average hydrodynamic 
diameter of 17.89 nm +/- 6.4 nm with an average poly-dispersity index of 0.106 +/- 0.020.  
The average surface charge of AuNSs was -29.7 mV +/- 11 mV.  Both results agreed with 
previous reports 142. 
 
Figure 10. Characterization of gold nanospheres.  (A) TEM confirmed uniform particle 
morphology and particle diameter of approximately 20 nm.  (B) UV-Vis 
spectrophotometry of AuNSs with a peak absorbance at 520 nm.   
 Brightfield microscopy confirmed successful labeling of stem cells with AuNSs 
after incubation with nanoparticles for 24 hours in vitro (Figure 11C–E) compared to naïve 
(unlabeled) stem cells (Figure 11A–B).  UV-Vis spectrophotometry further confirmed 
successful stem cell labeling based on changes in optical properties (Figure 11F).  AuNS-
labeled MSCs showed a peak at ~700 nm.  Although AuNSs typically absorb at ~520 nm 
wavelength, surface plasmon resonance coupling upon particle endocytosis caused a red-
shift in the peak absorption 149. 
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Figure 11. MSC labeling with gold nanospheres.  Brightfield micrographs of eosin-stained 
naïve (unlabeled) MSCs (A, B) and AuNS-labeled MSCs (C–E).  (E) Enlarged image of 
the region of interest defined by the red box in (D). Yellow arrows identify AuNSs (black 
spots). (F)  UV-Vis spectrophotometry comparing the spectral signature of naïve (black, 
dashed line) and AuNS-labeled MSCs (red, solid line).   
 Prior to proceeding with imaging experiments, AuNS-labeled MSCs were further 
characterized by assessing differentiation to assure the nanoparticles did not impact 
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multipotency (Figure 12).  Adipogenic or osteogenic differentiation were induced in 
AuNS-labeled MSCs.  Brightfield microscopy showed changes in cell morphology upon 
differentiation (Figure 12A and 12D) compared to naive MSCs (Figure 12G).  Oil Red O 
staining confirmed adipogenesis (Figure 12C), indicated by red stained lipid vesicles 
(Figure 12C).  Von Kossa staining confirmed osteogenesis, indicated by black staining of 
calcium deposits (Figure 12E).  Overall, gold nanospheres did not appear to impact stem 
cell multipotency, which agrees with previous results.150,151 
 
Figure 12. AuNS-labeled MSCs maintain multipotency.  MSCs were labeled with AuNSs 
followed by adipogenic (A – C) or osteogenic (D – F) differentiation and compared to 
AuNS-labeled MSCs that were fed maintenance media on the same schedule (G – I).  
Columns left to right: no (A, D, G), Von Kossa (B, E, H), and Oil Red O staining (C, F, I).   
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 After characterizing nanoparticles and labeled stem cells, photoacoustic properties 
of AuNS-labeled MSCs were assessed.  Tissue-mimicking phantom experiments showed 
that AuNS-labeled MSCs had an increased PA signal at 700 nm wavelength compared to 
naïve MSCs (Figure 13A and 13B).  A representative PA spectrum of AuNS-labeled MSCs 
was compared to melanin, the primary endogenous absorber in the anterior segment (Figure 
13C).147  Surface plasmon resonance coupling, initially observed from UV-Vis 
spectrophotometry, was also observed with photoacoustic imaging, indicated by absorption 
of AuNS-labeled MSCs well-beyond 700 nm wavelength (Figure 13C).  Most importantly, 
the PA spectra were distinct, e.g., having different slopes.  This supported the feasibility of 
AuNS labeling to identify and track stem cells within the anterior segment without 
interference from melanin signal.   
 
Figure 13. Photoacoustic properties of AuNS-labeled MSCs. Ultrasound (grayscale), 
photoacoustic (color scale), and overlay images at 700 nm wavelength for (A) unlabeled 
MSCs and (B) AuNS-labeled MSCs. Scale bar = 2 mm. (C) Representative PA spectrum 
of melanin at the iris and AuNS-labeled MSCs.  The distinct spectra, notably differences 
in slope, make AuNSs a promising contrast agent choice for stem cell tracking in the 
anterior segment, where melanin is the major PA signal source. 
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 Further in vitro analysis was conducted with stem cells in agarose phantoms, a 
simplified system that allowed us to evaluate the ability of US/PA imaging to detect cells 
under well-controlled conditions and compare to fluorescent microscopy (Figure 14).  Cells 
were labeled with both CFSE, a fluorescent dye, and AuNSs (termed “double-labeled 
MSCs”).  Known numbers of double-labeled MSCs were suspended in agarose gel 
phantoms at several different concentrations.  Triplicates were prepared for each cell 
concentration.  All agarose gels were imaged by confocal microscopy and PA imaging to 
produce 3D datasets. Although our PA imaging system has a light penetration depth of 
more than 20 mm, a region of interest with a depth of 0.5 mm was used to enable a fair 
comparison to confocal fluorescent microscopy, which has more limited light penetration.  
When comparing total PA signal to cell number loaded into the phantom, a linear 
relationship was observed (R2 = 0.94), as was the case when comparing fluorescent signal 
to cell number (R2 = 0.98).  The lower detection limits were approximately 10k cells/ml 
and 5k cells/ml for PA and fluorescence, respectively.  Therefore, PA imaging is a viable 
option for minimally invasive, longitudinal monitoring, and information provided is 
comparable to that of existing fluorescent cell tracking techniques, with the added benefit 
of increased light penetration.  
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Figure 14. PA and fluorescent imaging signals vs. cell number loaded into agarose gel 
phantoms. Double-labeled MSCs (labeled with AuNSs and CFSE) were suspended at 
known concentrations in agarose gels formed in 48 well plates.  Triplicates were prepared 
for each cell concentration.  Total fluorescent and total PA signal were compared to cell 
nuclei count (DAPI staining) over a depth of 0.5 mm.  Each point represents total signal 
for one gel. PA and fluorescent microscopy produced similar results, which further 
motivates use of minimally invasive PA imaging to track stem cells in the anterior segment.   
3.4.2 Stem cell detection in perfused porcine eyes 
We next carried out studies in perfused whole porcine eyes, which are an excellent 
model system due to similar pigmentation and anatomy to the human eye 152,153.  A 
physiological pressure was imposed using an elevated reservoir to mimic the in vivo 
secretion and flow of aqueous humor throughout the anterior chamber (Figure 8).  Thus, 
after injection, stem cells were allowed to circulate in the anterior chamber because 
inflowing media from the elevated reservoir continuously flowed out through the trabecular 
meshwork, which is part of the eye’s natural fluid drainage pathway. 
   AuNS-labeled MSCs were injected through the cornea into the anterior chamber.  
Real-time, single wavelength PA imaging visualized the stem cell injection and circulation 
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through the chamber for the first 15 minutes post-injection (Figure 15A – D), showing 
potential for image-guided delivery.  However, single-wavelength PA imaging did not 
distinguish the AuNS-labeled stem cells from background signals from melanin-rich 
tissues, such as the iris and TM (Figure 15A).  Thus, multi-wavelength PA imaging and 
spectroscopic analysis were required. 
We distinguished AuNS-labeled MSCs from background (melanin) signal using 
multi-wavelength PA imaging and spectroscopic analysis.  Prior to injection of AuNS-
labeled MSCs, melanin was accurately localized to the iris and TM (Figure 15E), and no 
cells were identified (Figure 15I), indicating minimal cross-talk between the spectra of 
melanin and AuNS-labeled MSCs. Immediately post-injection, AuNS-labeled MSCs and 
melanin could also be distinguished (Figure 15F–H and 15J–L).  Some PA artifacts were 
also observed.  For example, because the imaging plane was positioned to visualize the 
syringe needle, it was not necessarily centered over the pupil and was closer to the pupillary 
margin, where out-of-plane light absorption from the iris can occur. This created a PA 
signal artifact that appeared at the surface of the lens (Figure 15A), which can be removed 
by 3D imaging of the eye.  In addition, the syringe needle produced a PA signal at the 
center of the anterior chamber (Figure 15E–H) 154.   
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Figure 15. Ultrasound and photoacoustic imaging of AuNS-labeled MSCs delivered into 
the anterior chamber of perfused porcine eyes ex vivo.  (A) Anatomical landmarks were 
identified, including the TM.  PA datasets were analyzed before injection, and 
immediately, nine, and fifteen minutes post-injection (columns left to right).  (A - D) PA 
imaging at 680 nm wavelength.   (E - L) Spectroscopic analysis of multi-wavelength PA 
datasets distinguished signals from endogenous absorbers and AuNS-labeled MSCs. Pixels 
identified as melanin (E – H) and AuNS-labeled MSCs (I - L).  Scale bar = 3 mm. 
Stem cells were similarly injected into the anterior chamber of perfused porcine 
eyes and allowed to circulate for 5 hours, which is sufficient time for complete exchange 
of all fluid in the anterior chamber due to flow resulting from fluid drainage through the 
trabecular meshwork.   To assess differences in delivery efficiency, injections were carried 
out with low, medium, and high cell numbers (250k, 500k and 1000k cells, respectively). 
Multi-wavelength US/PA imaging and spectroscopic analysis was able to distinguish 
melanin and stem cells at 5 hours post-injection (Figure 16).  When 250k stem cells were 
injected, few cells were visible at 5 hours, and those that could be seen were primarily 
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localized to the anterior lens (Figure 16C and 16D).  As cell numbers increased, stem cells 
began to coat the iris and reach the angle (Figure 16F and 16H).  In general, poor delivery 
efficiency was observed.     
 
Figure 16. Ultrasound and PA imaging detects AuNS-labeled MSC location five hours 
post-injection in perfused porcine eyes ex vivo.  Multi-wavelength PA datasets were 
processed with spectroscopic analysis.  The left and right columns show PA signals 
separated according to contribution of melanin (A – G) and AuNS-labeled MSCs (B – H).  
Each row corresponds to different numbers of cells injected: (A, B) control (perfused with 
media for 5 hours, no cells injected), (C, D) 250,000 cells, (E, F) 500,000 cells, and (G, H) 
1,000,000 cells.  Most AuNS-labeled MSCs were detected on the anterior lens, but some 
reached the angle for the 500k (F) and 1000k (H) cell injections.  Scale bar = 3 mm. 
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Although the 2D US/PA imaging results above provided useful information, 3D 
imaging was required to more accurately localize stem cells, due to spatially non-uniform 
flow in the anterior chamber and through the TM. Three-dimensional multi-wavelength 
US/PA imaging at 5 hours post-injection and spectroscopic analysis confirmed 2D results 
(Figure 17A and 17B).  Specifically, stem cells primarily accumulated on the anterior lens 
(Figure 17B).  Three-dimensional volumes were then segmented via geometric masking to 
eliminate stem cell signals at the lens (Figure 17C), with the inner and outer margins of the 
ring mask corresponding to .5 mm external to the pupillary margin and the irideo-corneal 
angle, respectively.  Strong stem cell signals at the lens suppressed weaker PA signals from 
stem cells at other anterior tissues, where fewer cells accumulated.  Masking allowed better 
visualization of stem cell localization near the irideo-corneal angle, permitting 
circumferentially non-uniform stem cell distribution to be observed.  
 
Figure 17. Three-dimensional US/PA imaging to detect location of AuNS-labeled MSCs 
at five hours post-injection.  (A, B) Overlays of ultrasound (grayscale) and spectroscopic 
PA (color scale) images.  Spectroscopic PA analysis distinguished melanin (cool color 
map) and AuNS-labeled MSCs (hot color map). (A) Control, (perfused with media, no cells 
injected). (B) 1000k cells injected.  AuNS-labeled MSCs accumulated on the anterior lens 
and iris.  (C) Spectroscopic datasets were further processed to identify AuNS-labeled 
MSCs at the iris and the TM region. Non-uniform stem cell delivery around the 
circumference of the iris and TM was observed. A = anterior; L = lateral; E = elevational; 
P = posterior. 
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At five hours post-injection, intact porcine eyes were hemisected, and extraneous 
tissues were removed to leave a shell containing only the TM, cornea, and anterior sclera.  
Dissected anterior segments were used to evaluate capabilities of existing fluorescent 
microscopy techniques and photoacoustic imaging to track double-labeled stem cells. 
Image post-processing and electronic masking specifically showed stem cells in the TM 
region (Figure 18).  Four dissected anterior segments for each cell concentration were 
imaged using both modalities.  Non-uniform stem cell distributions around the 
circumference of the TM were observed with both modalities, with some degree of, but 
less than perfect, overlap (see representative images in Figure 18).    
 
Figure 18. Comparison of the distribution of MSCs as visualized by confocal fluorescent 
microscopy (A) and spectroscopic PA imaging (B) in dissected porcine anterior segments.  
MSCs were double-labeled with a fluorescent marker (CFSE) and AuNSs. Images show 
stem cell distribution around the circumference of the TM. 
3.5 Discussion 
This study shows proof-of-concept for the ability of a US/PA tracking platform to 
longitudinally monitor stem cell delivery in the anterior eye. We labeled stem cells with 
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AuNSs for PA imaging and injected them into the anterior chamber of perfused porcine 
eyes ex vivo. We were able to detect stem cell delivery and circulation in the anterior 
chamber in real-time using single-wavelength PA imaging.  The more powerful multi-
wavelength PA imaging and spectroscopic analysis were able to distinguish AuNS-labeled 
MSCs from background signals, laying the groundwork for future in vivo studies.  Results 
support further development of our US/PA platform as a tool to supplement information 
from existing tracking methods, with the significant advantage of allowing minimally 
invasive longitudinal imaging.   
Gold nanospheres were used to label stem cells for several reasons.  The first 
important aspect is cytocompatibility; AuNSs have previously been shown to have minimal 
effects on stem cell differentiation and viability 142.  Second, this is an efficient way to 
detect labeled cells due to surface plasmon resonance coupling of gold nanospheres upon 
endocytosis 149.  Without particle aggregation within cellular vesicles, free AuNSs absorb 
at ~ 520 nm and would not be detected within the 680 – 970 nm wavelength range.  Third, 
the PA spectrum of AuNS-labeled stem cells was also distinct from background PA spectra 
of tissues in the anterior eye 147, further supporting the use of AuNSs to detect stem cells.  
Previous work showed AuNS-labeled MSCs injected in muscle could be detected at up to 
10 days post-injection 53, indicating potential for longitudinal in vivo imaging in ophthalmic 
applications.   
Although our initial studies were successful with AuNSs, many other contrast agents 
exist for labeling and tracking cells with PA imaging, including organic nanomaterials 
155,156, dyes 157, other metallic nanoparticles 18,21,158, and photomagnetic nanoparticles 
126,138.  The use of dyes is appealing because the small molecules can be cleared; however, 
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dyes are prone to photobleaching, which may limit longitudinal imaging 15.  Beyond gold 
nanospheres, nanoparticle material, shape, and size can be varied to produce a more distinct 
PA spectrum to better detect stem cells in the presence of background signal from adjacent 
tissues 15.  For ophthalmic applications, gold nanorods are also of interest; however, 
potential instability and cytotoxicity are disadvantages compared to gold nanospheres 
159,160.  Beyond detection, the use of photomagnetic nanoparticles has appealing qualities 
for other purposes, such as multi-modal imaging or magnetic steering 126. 
In agarose gel phantom experiments, fluorescent microscopy and PA imaging were 
equally effective at detecting double-labeled stem cells (AuNS and CFSE).    These 
experimental conditions favored fluorescent microscopy, since no additional optical 
scatterers were introduced into the gel (unlike the situation in the eye) and a region of 
interest with a depth of only 0.5 mm was selected to accommodate the limited light 
penetration of fluorescent microscopy.  In the anterior eye, the presence of highly scattering 
tissues, such as the sclera, and strong melanin absorption, will further reduce light 
penetration.  Thus, implementing purely optical imaging methods to monitor stem cells in 
the anterior segment may be challenging.  Although our current PA imaging system cannot 
detect single stem cells, clinically relevant cell concentrations could be detected in agarose 
gels and ex vivo porcine eyes with highly scattering tissues intact.  The ability to image 
intact ocular tissues was a key advantage of PA imaging compared to confocal fluorescent 
microscopy, which required dissection of porcine eyes to image the TM and visualize stem 
cells.  As a result, PA imaging can potentially facilitate minimally invasive, longitudinal 
stem cell tracking in vivo in the future.       
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In dissected samples from whole eyes, agreement between confocal fluorescent 
microscopy and PA imaging results was reasonable but not perfect, which we believe can 
be explained by several reasons.  First, different masking methods were required for each 
modality because visualization of anatomical landmarks differed, and it was impossible to 
precisely align the masks despite our best efforts. Second, fluorescent microscopy could 
potentially detect single cells, while US/PA imaging detected groups of cells.  Third, due 
to sensitivity of confocal imaging to light attenuation, which limits imaging depth, we had 
to dissect away tissue to visualize the TM because of the presence of highly scattering and 
pigmented tissues in the eye’s anterior segment. This dissection may have also slightly 
disturbed the remaining tissues and the labeled cell distributions. For these reasons, we 
concluded that confocal fluorescent microscopy was unfortunately an imperfect 
comparison for our PA stem cell tracking platform in whole eyes.  However, because 
fluorescent microscopy is currently used as an assessment tool for monitoring stem cell 
delivery and is also an absorption-based modality like PA imaging, we believe it was the 
most reasonable modality to attempt comparison.   
Multi-wavelength PA imaging and spectroscopic analysis distinguished AuNS-
labeled stem cells from background signals (primarily melanin) in 2D cross-sections and 
in 3D volumetric images.  Although studies were conducted in ex vivo porcine eyes, we 
implemented flow in the eye to mimic the in vivo environment where there is a continuous 
circulation of fluid in the anterior eye.  By 5 hours post-injection, AuNS-labeled MSCs 
accumulated primarily on the anterior lens.  At higher cell numbers (500k and 1000k), 
some stem cells reached the angle, where the TM is located, but challenges with delivery 
efficiency were apparent.  The US/PA tracking platform clearly highlighted poor delivery 
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efficiency to the TM target tissue.  Thus, US/PA tracking provided valuable information 
regarding stem cell localization.  As the platform is translated to longitudinal in vivo 
studies, correlating stem cell localization and migratory patterns with changes in 
intraocular pressure, one indicator of glaucoma risk, can provide valuable information to 
better design stem cell therapies.   
3.6 Conclusions 
We demonstrate a US/PA imaging platform that can provide longitudinal feedback 
to assess MSC delivery in the anterior eye.  Compared to existing stem cell detection 
techniques in the anterior eye, namely histology and/or confocal microscopy, which 
requires time-consuming, destructive sample preparation, US/PA tracking was minimally 
invasive and could be implemented in intact porcine eyes.  Thus, US/PA tracking can 
provide additional, more holistic information on therapy progression to researchers and 
clinicians.  Initial results also showed poor stem cell delivery efficiency, highlighting 
opportunities for future development of a theranostic US/PA platform to expedite therapy 
development and clinical translation.   
3.7 Future Work  
The key next steps for advancing the US/PA imaging platform for monitoring stem 
cell therapies for the anterior eye are assessing laser safety, improving poor delivery 
efficiency, and executing in vivo studies in small animal models.  Feasibility of all aspects 
have been assessed in preliminary experiments detailed herein.   
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Development of custom ophthalmic US/PA imaging hardware, specifically high 
frequency transducers and focused light delivery systems, will be critical for small animal 
imaging, clinical translation, and safety of anterior ocular US/PA imaging systems 161,162.  
Our current imaging set up using the Vevo LAZR US/PA imaging system is not ideal for 
ophthalmic applications.  One issue is the resolution of the transducer.  The highest 
available transducer frequency for this system is 50 MHz, which leads to a resolution of 
approximately 100 μm.  In clinical studies in humans, others report using 35 - 80 MHz 
transducers to visualize detailed anterior segment anatomy, such as the trabecular 
meshwork.163  This highlights clear hardware inadequacies for small animal studies in rats 
and mice, where the diameter of the eye is only several millimeters compared to ~ 2 cm in 
large animal models and humans.  Thus, compatibility of the US/PA imaging system with 
high frequency transducers is desired.   
Another issue is light delivery.  The current US/PA imaging system irradiated the 
entire anterior segment.  For initial studies, this was beneficial by allowing assessment of 
off-target stem cell localization due to rapid acquisition of 3D datasets to create volumetric 
US/PA images.  On the other hand, technical challenges were also introduced by irradiating 
the entire anterior segment.  From an image processing perspective, stem cell detection was 
more challenging due to background PA signals outside the region of interest, the TM.  
More imaging artifacts were also introduced by irradiating extraneous tissues.  Most 
importantly, irradiating the entire anterior segment raised safety concerns due to the 
potential for unintentional, unnecessary laser light irradiation of the retina. 
To inform design of a custom light delivery and US/PA imaging system in the 
future, laser parameters of our existing system were compared to other laser-based 
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technologies specifically designed for ophthalmic applications.  Table 1 summarizes 
parameters of a pulsed laser system designed for retinal imaging 164 and a clinical system 
165–167 used for laser trabeculoplasty procedures.  The retinal imaging system from the 
literature (referred to as the “literature system”) evaluated ocular damage caused by a 
pulsed, femtosecond laser at 730 nm wavelength, and light was focused to a 3.5 μm 
diameter spot size directly onto the retina.164  Our current system has a 2 cm2 spot size that 
is focused at the anterior segment, which is inherently less risky.  Results for the literature 
system indicated that average powers below 68 mW at the retina caused no damage to 
photoreceptors.164  Although our system has an incident average power of 260 mW, the 
retina would be exposed to lower power due to light absorption from melanin and scattering 
at the sclera.  Exact values for our system can be determined by modeling.  However, it is 
important to note that PA signals were not observed at ocular structures posterior to the iris 
in our ex vivo porcine studies (Figure 2 and Figure 15), which indicated limited light 
delivery to the retina.   
From a safety perspective, using the lowest possible laser power is ideal.  However, 
from an imaging perspective, using the highest possible laser power is ideal to increase 
imaging sensitivity and detect low concentrations of stem cells.  Developing a US/PA 
imaging system that focuses light at the angle to irradiate the TM can balance imaging and 
safety requirements.  A relevant system to inform design is currently used in clinic for laser 
trabeculoplasty (Table 1).165–167  In laser trabeculoplasty, a goniolens focuses light at the 
angle, where the TM is located.  By focusing light at the TM, higher average power is 
allowed because risk of off-target irradiation at the retina is minimized.  Compared to the 
Vevo LAZR and femtosecond retina system, laser trabeculoplasty has approximately a 5-
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fold and 15-fold higher average power, respectively.  Note that the goal of laser 
trabeculoplasty is to induce slight damage of the TM to stimulate healing.  However, even 
at the high power used in laser trabeculoplasty, off target damage at the retina is avoided 
with focused light delivery, and higher laser powers are allowed with laser trabeculoplasty.  
Ultimately lower laser power would be needed for US/PA imaging purposes, but focused 
light delivery allows more flexibility in determining parameters.  Overall, parameters for 
retinal imaging and laser trabeculoplasty provide an excellent starting point for design of 
our custom light delivery system in the future. 
Table 1. Comparison of laser parameters used in relevant ophthalmic applications. 
 
Prior to developing any custom hardware, initial assessments were conducted in 
vivo using the Vevo LAZR system to assess safety of the current system in practice.  Three-
dimensional multi-wavelength US/PA datasets were acquired of the right eye in nude rats 
(n = 2) using the 50 MHz transducer at the highest laser power possible, 13 mJ, with the 
Vevo LAZR.  The contralateral eye was not irradiated.  Rats were observed for behavioral 
changes, and photographs were taken of both eyes before, 24 hours, and 1 week after laser 
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light irradiation to evaluate any gross changes in ocular morphology, especially opacity 
(Figure 19).   No differences in behavior, morphological changes, or ocular clouding 
indicative of ocular damage were observed.  The white line across the eye in Figure 19B is 
the rat’s whisker.  To fully characterize damage, histology is required to assess retinal 
changes and an optomotor response test can determine visual function.  However, initial 
studies provided encouraging results as no obvious, extreme damage was observed.   
 
Figure 19. Assessing laser safety in vivo.  Rats (n = 2) were anesthetized for combined 
US/PA imaging using the Vevo LAZR.  The entire right eye was irradiated (A – C) 
according to the parameters in Table 1 from wavelengths of 700 – 950 nm in 25 nm 
increments.  The contralateral eye was not irradiated (D – F).  Photos were taken of both 
eyes before laser light irradiation (A, D), 24 hours (B, E), and 1 week after laser light 
irradiation (C, F).  No gross changes indicative of ocular damage were observed in either 
eye.    
In vivo US/PA datasets from the safety study were post-processed to assess image 
quality using the 50 MHz transducer and laser light irradiation of the entire anterior 
segment (Figure 20).  Anatomical features, such as the cornea, iris, eye lid, and angle were 
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identifiable in two-dimensional US/PA images, and PA signals from melanin were also 
observed at the iris (Figure 20A).  However, three-dimensional US/PA images were 
difficult to decipher (Figure 20).  High background signals from black fur surrounding the 
eye created imaging artifacts and suppressed PA signals from relevant anterior segment 
structures.  This can be noted by the fact that PA signals were not observed throughout the 
iris (Figure 20B).  Overall, to strike a balance between safety, development of a clinical 
system, and improved image quality, focused light delivery is needed.   
 
Figure 20. Ultrasound and photoacoustic images of rat eyes in vivo.  Representative two- 
(A) and three-dimensional (B) ultrasound (grayscale) and PA (color scale) overlay images 
acquired with the Vevo LAZR and 50 MHz transducer.  In 2D cross-sectional views, 
ultrasound depicted anatomy, including the cornea, eye lid, and iris, and PA signals were 
observed at the iris (A).  Three-dimensional US/PA volumetric images depicted 
inconsistent PA signal at the iris and a potential source of imaging artifacts resulting from 
PA signals from black hair, which can inaccurately extend onto the eye (B). US/PA images 
may be improved by developing focused light-delivery systems.  Scale bar = 3 mm.   
In a proof-of-concept study using ex vivo porcine eyes, an early-stage focused light 
delivery system was implemented. An external 300 μm diameter optical fiber was coupled 
to a traditional ultrasound transducer, i.e. the transducer had no built-in optical fibers for 
PA imaging (Figure 21).  The external optical fiber was positioned for transscleral light 
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delivery, and PA signals were isolated to the angle (Figure 21B), unlike images acquired 
with the Vevo LAZR (Figure 21C).  Furthermore, the ability to easily implement 
transscleral light delivery, which is challenging with purely optical techniques like OCT, 
highlighted another benefit of PA imaging.  Transscleral light delivery eliminates concerns 
of unintentional retinal irradiation and simplifies light delivery as sophisticated optical 
components are not required to direct light at the angle.     
 
Figure 21. Demonstration of focused light delivery in a porcine eye ex vivo.  Photograph 
of the imaging set up (A).  An enucleated porcine eye was secured in a holder and 
submerged in PBS.  A 20 MHz ultrasound only transducer was positioned above the cornea 
on-axis.  Light was focused by positioning an external optical fiber for transscleral light 
delivery to the angle.  Combined ultrasound (grayscale) and PA (color scale) images were 
acquired using the focused light delivery system (B) or the Vevo LAZR (C), which 
irradiates the entire anterior segment.  Focused light delivery only produced PA signals at 
the region of interest - the angle and TM (B).  Scale bar = 3 mm.    
To address the issue of poor delivery efficiency, we are currently developing 
PBNCs with combined magnetic and optical properties 168.  Magnetic properties allow 
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PBNC-labeled stem cells to be pulled to a tissue target, such as the TM 126.  Optical 
properties allow detection of PBNC-labeled stem cells with PA imaging.  Thus, PBNC-
labeled stem cells may allow image-guided magnetic delivery in the future.  Figure 22 
shows initial characterization of PBNCs and verifies stem cell labeling.  Further details on 
PBNC characterization are described in Chapter 4.  
 
Figure 22. Characterization of photomagnetic PBNCs and labeled stem cells.  (A, B) TEM 
of PBNCs with an edge length of ~200 nm.  (C)  Absorption spectrum of PBNCs, measured 
by UV-Vis spectrophotometry, with a peak at 734 nm wavelength.  Histology of eosin-
stained adipose-derived MSCs confirmed successful cell labeling with PBNCs (D-H).  
Naïve MSCs at 20x (D) and 40x (E) magnification.  MSCs incubated with PBNCs at 1 OD 
at 20x (F) and 40x (G) magnification.  MSCs incubated with PBNCs at 2 OD at 40x 
magnification (H). PBNCs are blue in color, indicated by black arrows. Proceeding studies 
were conducted with PBNCs at a concentration of 2 OD.   
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 The first set of studies to assess image-guided magnetic delivery of PBNC-labeled 
stem cells were conducted using the ex vivo perfusion set up in porcine eyes.  Since results 
with AuNS-labeled MSCs showed cells primarily fell to the lens, a disc magnet was placed 
on the cornea to essentially attempt to reverse the problem with PBNC-labeled MSCs 
(Figure 23).   A 250 μl volume of PBNC-labeled stem cells at 1000k cells/μl was injected 
in the anterior chamber of perfused porcine eyes.  The disc magnet was placed on the 
cornea for 24 hours while fluid in the anterior chamber continually circulated due to natural 
outflow through the TM.  Minimal PA signal was observed at the lens after 24 hours, and 
PBNC-labeled stem cells were localized to the cornea at the location of the disc magnet.   
 
Figure 23.  Photoacoustic imaging and magnetic delivery of PBNC-labeled stem cells in 
perfused porcine eyes ex vivo.  Two-dimensional ultrasound (grayscale) and PA (color 
scale) overlay images of PBNC-labeled stem cells in the anterior chamber immediately 
post-injection (A).  After 24 hours of magnet exposure, PBNC-labeled stem cells were 
pulled to the cornea at the location of the disc magnet (B).  (C)  Three-dimensional US/PA 
images confirmed 2D results, indicating initial feasibility of using PBNCs for magnetic 
guidance and imaging of MSCs.  Scale bar = 3 mm. 
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 Next, preliminary in vivo studies were conducted in nude rats (n = 2) to assess 
PBNC-labeled MSC guidance with a ring magnet.   Note that these rats had an albino 
phenotype to focus attention on magnetic delivery and minimize challenges associated with 
in vivo detection and image processing, more specifically due to high background signals, 
modification of PA spectra from melanin (see Chapter 2), and high sensitivity required to 
detect a smaller amount of PBNC-labeled stem cells in vivo in small animals.  Due to lack 
of melanin, minimal PA signals were observed in 2D and 3D images prior to delivery of 
PBNC-labeled MSCs (Figure 24A and 24B).    A 25 μl volume of PBNC-labeled stem cells 
at 1000 cells/μl was injected into the anterior chamber of the right rat eye.  One rat received 
no magnet (Figure 24C and 24D).  The second rat received a ring magnet placed around 
the TM (Figure 24 E and 24F).  The ring magnet had a power of 9.19 lbs, with a 0.281” 
thru hole diameter, and was axially polarized.    Both animals were imaged after 3 hours.   
Without the magnet, PBNC-labeled stem cells were primarily localized at the center of the 
anterior segment and appeared to coat the lens and cornea (Figure 24 C and 24D).  With 
the magnet, PBNC-labeled stem cells were detected closer to the angle, and less PA signal 
was observed at the center of the eye (Figure 24 E and 24F).  Based on anatomy from 
ultrasound, PA signals located outside of the eye were disregarded (Figure 24C and 24E), 
i.e it is extremely unlikely that stem cells can accumulate on the surrounding eye lid.  These 
PA signals were inconsistently observed across images and may come from changes in 





Figure 24.  Image-guided magnetic delivery of PBNC-labeled MSCs to the TM in vivo.  in 
nude rats.  Two- (A, C, E) and three-dimensional (B, D, F) combined ultrasound (grayscale) 
and PA (color scale) datasets were acquired for eyes that received no injection (A, B); 
PBNC-labeled MSCs only (C, D); and PBNC-labeled MSCs and a ring magnet (E, F).  
Minimal background PA signals were observed in control eyes due to lack of melanin (A, 
B).  PA signal from PBNC-labeled MSCs was visible in injected eyes (C - F), and more 
PBNC-labeled MSCs appeared near the angle after magnet exposure for 3 hours (E, F).   
Initial results from in vivo magnetic delivery studies appeared promising.  In 
addition, rats that received PBNC-labeled MSCs were observed for changes in ocular 
morphology indicative of laser damage (Figure 25).  Although further assessment is 
required, no gross changes were observed, which was a positive result considering lack of 
melanin in albino rats, and thus less ocular protection from light.  Together, optical and 
magnetic properties of PBNCs may facilitate image-guided magnetic stem cell delivery to 
the TM to improve therapeutic outcomes and clinical utility, adding to the theranostic 
potential of the US/PA platform in the future.   
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Figure 25.  Photographs of eyes after image-guided magnetic delivery of PBNC-labeled 
MSCs in vivo.  Top row (A – C): images from the rat that received PBNC-labeled MSCs 
and a magnet.  Bottom row (D - F): images from the rat that received PBNC-labeled MSCs 
only.  In both cases, the contralateral eye received no injection.  Contralateral eye before 
(A, D) and after (B, E) imaging. (C, F) Injected eye after imaging.  No gross changes in 
ocular morphology were observed in eyes that received injections and were imaged.  
3.8 Contributions from collaborators 
 In this chapter, specific contributions were made by Eric Snider, Bailey Hannon, 
Heechul Yoon, and Andrei Karpiouk  For the ex vivo porcine experiments using gold 
nanospheres, Eric Snider maintained and prepared cells, injected cells into porcine eyes, 
dissected porcine tissue, prepared agarose gels, and imaged with fluorescent microscopy.  
Bailey Hannon shared her expertise and provided training to execute in vivo ocular 
injections.  Heechul Yoon shared gave advice on improving image-processing techniques.  
Andrei Karpiouk assisted in designing and building the focused-light delivery set up. 
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CHAPTER 4. TRIMODAL IMAGING TO GUIDE STEM CELL 
THERAPY OF THE SPINAL CORD USING PRUSSIAN BLUE 
NANOCUBES 
This chapter is adapted from several articles which have been published or accepted for 
publication, are currently under review, or are in preparation: 
Donnelly, E. M.,* Kubelick, K. P.,* Dumani, D. S., & Emelianov, S. Y. (2018). 
Photoacoustic Image-Guided Delivery of Plasmonic-Nanoparticle-Labeled Mesenchymal 
Stem Cells to the Spinal Cord. Nano Letters, 18(10), 6625-6632. *Equal Contribution 
Laffey, M.,* Kubelick, K. P.,* Donnelly, E. M., & Emelianov S. (2019). Effects of freezing 
on mesenchymal stem cells labeled with gold nanoparticles.  Tissue Engineering Part C: 
Methods.  Accepted. *Equal Contribution 
Dumani, D. S.,* Cook, J. R.,* Kubelick, K. P.,* Luci, J. J., & Emelianov, S. Y.  (2019).  
Photomagnetic Prussian blue nanocubes: synthesis, characterization, and biomedical 
applications.  Nanomedicine. Accepted.  *Equal Contribution  
Kubelick, K.P. & Emelianov, S.Y.  (2019). Trimodal imaging to guide stem cell therapy 
of the spinal cord using Prussian blue nanocubes.  Under review.   
Kubelick, K.P. & Emelianov, S.Y. (2020). In vivo intraoperative guidance of stem cell 
delivery in the spinal cord using photoacoustic imaging augmented with Prussian blue 
nanocubes.  In preparation.   
Kubelick, K.P. & Emelianov, S.Y. (2020). In vivo longitudinal monitoring of stem cell 
therapy in the spinal cord using a trimodal imaging tool.  In preparation.  
 
4.1 Abstract 
 Translation of stem cell therapies to treat injuries and diseases of the spinal cord is 
hindered by lack of real-time monitoring techniques to guide regenerative therapies intra- 
and post-operatively.  Thus, we developed a trimodal ultrasound (US), photoacoustic (PA), 
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and magnetic resonance (MR) imaging approach augmented with Prussian blue nanocubes 
(PBNCs) to guide stem cell injections intraoperatively and monitor therapies in the spinal 
cord post-operatively.  Per the clinical procedure, a laminectomy was performed in rats.  
For intraoperative guidance, PBNC-labeled stem cells were injected directly into the spinal 
cord while US/PA images were acquired.  For post-operative guidance, US/PA/MR images 
were acquired up to 14 days after surgery.  Several features of the trimodal imaging 
approach were demonstrated including detection of low stem cell concentrations, real-time 
needle guidance and feedback on stem cell delivery, and agreement between US/PA/MRI.  
These benefits span intra- and post-operative environments to support further development 
of this trimodal imaging tool.  Although the ability to monitor stem cell location can 
provide useful information on stem cell migration in the spinal cord, this research is 
ultimately a building block on the road to functional monitoring in vivo.  To this end, the 
focus of future work is development of a photoacoustic probe for stem cell apoptosis 
detection in vivo.   
4.2 Introduction 
 Regenerative medicine holds great promise to offer novel treatment methods for 
injuries and neurodegenerative diseases of the spinal cord that otherwise have no cure.  
Stem cell therapy has received substantial interest, but has not yet reached its clinical 
potential.43,169–173  Development and translation of stem cell therapies for the spinal cord is 
hindered by lack of: 1) real-time guidance of stem cell injection; 2) noninvasive, 
longitudinal monitoring techniques to assess treatment progression and improve 
understanding of stem cell behavior; and 3) functional stem cell monitoring.2,43,174,175  
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Development of imaging tools to guide and detect stem cells in the spinal cord would 
expedite therapy development and clinical translation.   
 Others have recognized this need and substantial effort has been spent developing 
magnetic resonance imaging (MRI) tools to detect stem cells in the spinal cord.5,176–179  
MRI is the gold standard for central nervous system imaging.  Advantages include 
noninvasive, longitudinal, high-resolution, whole body imaging.  Although MRI is an 
excellent option for post-operative monitoring, challenges exist for intraoperative imaging, 
including high cost, slow acquisition, large foot print and lack of portability, and 
incompatibility with tools and instruments in the operating room (OR).180–182  For these 
reasons, the use of MRI to guide stem cell therapies throughout the entire course of 
treatment is challenging.  Other modalities can address this need, such as combined 
ultrasound/photoacoustic (US/PA) imaging.2,17,90,138,183–185   
 Ultrasound signals are produced by backscattering of acoustic waves to convey 
anatomical information at high resolution.  However, contrast is poor due to similar 
backscattering properties across many tissues.  Photoacoustic imaging can address this 
challenge.  In PA imaging, contrast is based on absorption of light rather than scattering of 
sound.  By irradiating an optical absorber with a pulsed laser, thermal deposition and 
compression of the surrounding tissue produces transient acoustic waves that can be 
detected by a traditional ultrasound transducer.115–117,184  Advantages of PA imaging 
include high contrast, high resolution, real-time imaging, and a variety of exogenous 
contrast agents exist to obtain cellular information. Furthermore, US/PA imaging systems 
are portable to facilitate intra- or post-operative imaging.   
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 We previously explored the use of US/PA imaging augmented with gold 
nanospheres (AuNSs) to provide real-time guidance of stem cell therapies in the spinal 
cord.174  Although results showed some intraoperative benefits, applicability to the post-
operative environment was not demonstrated.  In the current work, a trimodal US/PA/MR 
imaging approach was introduced to facilitate intra- and post-operative guidance in the 
spinal cord by labeling stem cells with Prussian blue nanocubes (PBNCs).  PBNCs are a 
unique nanoconstruct that simultaneously possess optical and magnetic properties to 
produce PA and MR contrast.148  By labeling stem cells with PBNCs, US/PA imaging can 
facilitate intraoperative imaging, and MRI can facilitate post-operative imaging per the 
current clinical standard.  This work demonstrated several features of the US/PA/MR 
imaging approach, including detection of stem cells at low concentrations, real-time needle 
guidance and injection monitoring, feedback on stem cell delivery, and strong agreement 
between PA/MR images, to lay the groundwork for a clinical multi-modal imaging 
protocol.    
4.3 Materials and methods 
4.3.1 Materials 
 Dextran-coated superparamagnetic iron oxide nanoparticles (SPIONs), 5 nm and 
10 nm diameter, were purchased from Ocean NanoTech (San Diego, CA). Small SPIONs 
(3 nm diameter) were synthesized in-house. Prior to use, all glassware and stir bars were 
washed with aqua regia (3:1 HCl:HNO3; Sigma-Aldrich).  All chemicals were used as 
received. 
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 Adipose-derived mesenchymal stem cells (MSCs) were cultured following 
methods described above in Chapter 3 (see Section 3.3.1).   
4.3.2 Synthesis of small SPION precursors and PBNCs 
A 1,000 ml three-neck round bottom flask containing an egg-shaped stir bar was 
suspended in a silicon oil bath placed on a heated stir plate. One neck was used as a gas 
inlet, and the second neck was connected to a condenser to keep the reaction under reflux. 
A 200 ml volume of triethylene glycol (TEG) was added to the round bottom flask, 
followed by 12.714 g of iron(III) acetylacetonate.  The iron was dissolved, and the solution 
was heated to 140 ˚C for one hour while stirring under argon or nitrogen gas. Next, an 
additional 200 ml of TEG was added to the flask to remove any iron deposited on the sides 
of the glassware.  The solution was then heated to 200 ˚C. After 2 hours the solution turned 
from a reddish color to a dark brown-black color indicating the formation of Fe3O4 
nanoparticles, commonly referred to as SPIONs. The SPION solution was cooled to room 
temperature while continuing to stir under argon or nitrogen gas overnight. The volumes 
and masses of reagents were carefully measured throughout the synthesis to keep track of 
Fe concentrations. The SPION solution was diluted 10x with deionized ultra-filtered 
(DIUF) water containing dextran at a concentration of 10 mg dextran/mg of Fe. The 
reaction was gently stirred overnight to allow the dextran to coat the SPIONs. Excess 
dextran was removed from the solution by centrifugation in 50 kDa filtered centrifuge tubes 
(Amicon).   
 Synthesis of PBNCs using iron oxide precursors was described in Chapter 3, and 
the same method was used here (see Section 3.3.14).   
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4.3.3 Characterization of nanoparticles  
 Transmission electron microscopy (TEM) (Hitachi HT7700 TEM, IEN/IMAT 
Materials Characterization Facility, Georgia Institute of Technology) was used to 
characterize PBNC morphology. Carbon formvar TEM grids (Electron Microscopy 
Sciences) were prepared by drop casting 3 l of particle solution and drying overnight at 
room temperature. Images were acquired at an accelerating voltage of 100 – 120 kV.  
PBNC edge length and SPION diameter were determined using ImageJ (NIH).   
 The optical absorption spectra of 20 nm, 40 nm, and 200 nm PBNCs was measured 
using UV-Vis spectrophotometry (Synergy HT microplate reader, BioTek Instruments).  
Readings were taken in 5 nm increments from 400 nm to 995 nm.   
 Magnetic properties of PBNCs were first assessed using superconducting quantum 
interference device (SQUID) magnetometry.  Prior to measurements, samples were 
concentrated by centrifugation using 50 kDA filtered centrifuge tubes (Amicon). The final 
concentrations were 8.7 mg/ml for PBNCs (20 nm edge length), and 20 mg/ml for SPIONs 
(3 nm diameter). Each sample was scanned separately. Briefly, 100 µl of the concentrated 
nanoparticle solution was added to a polycarbonate capsule (AGC3, Quantum Design). The 
capsule was sealed with non-magnetic tape and inserted in a non-magnetic straw to be held 
inside the magnetometer.  A capsule filled with DIUF water was used to confirm no 
significant background magnetization. The temperature was set to 5 K, and the magnetic 
field was varied from 5 T to −5 T twice to obtain a hysteresis curve of the magnetic 
moment.   
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Longitudinal and transverse relaxivity of all PBNCs (20 nm, 40 nm, and 200 nm 
edge length) were determined using a low-field 0.5T NMR spectrometer (Maran Ultra 23, 
Resonance).  Solutions at concentrations ranging from 533 to 16 µg of Fe/ml were 
prepared.  The average relaxation time was calculated using four scans per sample.   
 Further characterization of PBNCs was conducted using tissue-mimicking phantom 
experiments.  All particle phantom experiments were conducted following methods 
described above in Chapter 3 (see Section 3.3.6).  PBNCs (20 nm, 40 nm, and 200 nm edge 
length) were all at a concentration of 2 optical density (OD) in inclusions.   
4.3.4 Imaging Equipment 
 All US/PA imaging experiments were conducted using the Vevo LAZR and 20 
MHz transducer.  The imaging system was described in detail above (see Section 3.3.5).   
 A 7T preclinical MRI system (Bruker PharmaScan) was used to acquire all MR 
images. Samples were secured in a cylindrical holder and inserted in a 38 mm imaging coil 
for phantom studies.  In vivo studies were conducted using a 60 mm imaging coil.  Built-
in pulse sequences were used with slight modifications to the repetition (TR) and echo 
times (TE), described in detail below for each experiment, to improve nanoparticle 
contrast.  MR images were post-processed using the built-in Bruker Pharmascan image 
analysis software.   
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4.3.5 In vitro studies of PBNC-labeled stem cells 
 Stem cells were labeled with 200 nm PBNCs using the same incubation method 
described in Chapter 3 (see Section 3.3.3).  In this case, stem cells were labeled with 200 
nm PBNCs at a concentration of 2 OD.   
 Histology was used to verify PBNC uptake.  Microscopy coverslips were cleaned 
using 70% ethanol.  Once dried, each coverslip was placed in a well of a 6-well cell culture 
plate.  A monolayer of MSCs was grown on top of the coverslips.  MSCs were labeled with 
PBNCs (see Section 3.3.3). PBNC-labeled MSCs were fixed onto the coverslips, stained 
with eosin for 15 minutes (VWR; see Section 4.3.10), and mounted onto slides for 
brightfield microscopy.     
 Tissue-mimicking gelatin phantom experiments were conducted to assess PA and 
MR detection sensitivity of PBNC-labeled MSCs at known concentrations.  Phantom 
experiments of PBNC-labeled MSCs were conducted following the same phantom recipe 
described above (see Section 3.3.6).  In this case, each dome-shaped inclusion contained 
PBNC-labeled MSCs at 10k, 5k, 2.5k, 1.25k, 625, 313, 156, 78, 39, 20, and 0 cells/l.  The 
same exact phantom was imaged using US/PA and MRI.  Cross-sectional US/PA images 
of the cell inclusions were acquired at 740 nm wavelength, corresponding to the optical 
absorption peak of PBNCs, determined by UV-Vis spectrophotometry.  The average PA 
signal of the inclusion, manually isolated using ultrasound, was calculated over 20 frames 
to accommodate fluctuations in laser energy.  MR images were acquired using a multi-slice 
multi-echo (MSME) pulse sequence to determine T2 relaxation times starting with TR = 
1955.2 ms and TE = 20 ms.  TE increased by 20 ms increments for 32 steps.  Coronal views 
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were acquired and analyzed due to better visualization of inclusions.  Although different 
slice orientations were used for PA and MRI, PBNC-labeled MSCs appeared 
homogenously distributed throughout inclusions in either case.  Thus, slice orientation 
should not impact results.  For MR image analysis, the built-in Bruker Pharmascan 
software was used to define a circular region of interest corresponding to the inclusion.  
The average T2 relaxation time and standard deviation was calculated using the built-in 
parametric fit algorithm.   
4.3.6 Ex vivo spinal cord access and stem cell injection protocol  
 All studies involving animals were conducted following guidelines of the 
Institutional Animal Care and Use Committee (IACUC) of the Georgia Institute of 
Technology.  Spinal cord procedures followed previously reported methods.137,173,186,187  In 
brief, Sprague-Dawley rats (Charles River Laboratories) were sacrificed, and the spinal 
column was removed.  A multilevel laminectomy was performed to expose the underlying 
spinal cord.  Up to 5 l of PBNC-labeled MSCs suspended at 10k cells/l were directly 
injected into the spinal cord per the clinical procedure at a rate of 16 nL/sec using a 33G 
syringe attached to an ultra-micropump (World Precision Instruments).44  
4.3.7 Ex vivo intraoperative US/PA image-guidance  
 During needle insertion, single-wavelength US/PA datasets were acquired at 740 
nm wavelength and exported to MATLAB for post-processing.  Reverberation artifacts 
extending below the needle shaft were removed by creating a mask with a width of 2x the 
outer diameter of the 33G needle used for the injection and aligning the mask with the 
length of the needle shaft.  Small gaps in the PA signal were occasionally observed along 
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the needle shaft.  The MATLAB image processing toolbox and morphological operators, 
specifically image dilation followed by erosion, were used to connect gaps and display a 
continuous needle shaft.     
 During stem cell injections, single-wavelength US/PA datasets were similarly 
acquired at 740 nm wavelength and exported to MATLAB for post-processing.  PA signals 
from the needle shaft and PBNC-labeled MSCs were segmented to better visualize the 
injection.  To segment images, US/PA images were split into two regions of interest: 1) the 
region containing the needle, and 2) the region containing the stem cells.  In the needle 
shaft region of interest, reverberations artifacts were removed as described above.  In the 
stem cell region of interest, a threshold was applied to reduce background noise.  Any 
remaining pixels in the stem cell region of interest were identified as PBNC-labeled MSCs 
and were multiplied by a scaling factor.  As a result, PBNC-labeled MSCs were primarily 
colored red, and the needle shaft was primarily colored blue.  The average PA signal was 
calculated for the region containing the PBNC-labeled stem cells.   
4.3.8 Ex vivo trimodal US/PA/MR imaging 
Locations of PBNC-labeled MSC injections were marked by glass capillary tubes, 
which were visible in ultrasound and MRI, inserted in the surrounding muscle, to assure 
the same injections were compared across modalities.  US/PA datasets were acquired with 
and without a layer of muscle covering the spinal cord.  MR images were only acquired 
with a layer of muscle placed on top of the spinal cord.   
Three-dimensional (3D) US/PA datasets were created by attaching the transducer 
to a translational motor and compiling two-dimensional (2D) cross-sectional views 
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acquired at 133 m steps and 740 nm wavelength.  Datasets were then exported to 
MATLAB for post-processing.  Anatomical information provided by ultrasound was used 
to spatially distinguish PA signals from different species: 1) blood vessels/background 
signals that appeared on top of the spinal cord; 2) PBNC-labeled stem cells that appeared 
within the spinal cord.  PA signals from each species were further segmented by 
thresholding and scaling such that background signals were primarily colored blue and 
PBNC-labeled MSCs were primarily colored red.  Reverberation artifacts were 
occasionally observed below strong PA signals from blood vessels at the surface of the 
spinal cord.  These artifacts were removed by finding the local maximum PA signal, which 
corresponded to the vessel, and eliminating PA signals below a 0.5 mm vessel radius.  
Sagittal US/PA images were produced by integrating 3D datasets along the x-dimension, 
i.e. image width, and interpolating to display resulting images with square pixels (~40 m 
x ~40 m).     
MR images were acquired using several different pulse sequences.  T2-weighted 
images were produced using the T2-Turbo RARE pulse sequence with TR = 2500 ms and 
TE = 35 ms.  T2*-weighted images were produced using the T1-FLASH sequence with TR 
= 310 ms and TE = 5 ms for axial images or TE = 10 ms for sagittal images.  Four averages 
were acquired for all pulse sequences.   
 Following US/PA/MR imaging, spinal cord tissue was fixed in 10% neutral 
buffered formalin, followed by submersion in sucrose for one week.  Tissue was frozen in 
embedding medium for histology and sectioned into 20 m sagittal slices.  Sections were 
stained by submersion in eosin for 75 seconds.  Brightfield photomicrographs were 
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acquired using the Axio Observer microscope (Zeiss).  Wide-field views were produced 
by compiling tile scans.    
4.3.9 In vivo surgical procedure and imaging protocols 
 All studies involving animals were conducted following IACUC guidelines per the 
Georgia Institute of Technology.   
 First, the procedure room was prepared.  During room preparation, the PBNC-
labeled stem cells were prepared by a second person (see Section 3.3.3).   Three tables were 
cleaned with 70% ethanol or Sporcidin disinfectant solution (Contec Healthcare).  While 
still in the packaging, a surgical gown, surgical gloves, hair net, face mask, sterile hand 
towel, and scrub brush were placed directly onto Table 1, which was non-sterile.  The two 
remaining tables were covered with sterile drapes.  Table 2 was used to display all sterile 
surgical tools: small/medium/large scissors, small animal bone cutters, two glass syringes 
equipped with a 33G needle, needle grabbers, two forceps with teeth, retractor, curette, 
spatula, and Vannas scissors (World Precision Instruments).  Sterile Q-tips, sterile sutures 
(5-0 vicryl, undyed, braided, reverse cutting), and fenestrated drapes were also placed on 
Table 2.  Table 3 was used as the surgical table and contained the disinfected stereotax, 
heating pad, transducer holder, and ultra-microinjection pump (World Precision 
Instruments).   
 After the room was prepared, rats were anesthetized using either isoflurane or 
injectable anesthetics.  For isoflurane, anesthesia was induced with 5% isoflurane at 500 
ml/min and maintained with 1.0% - 2.5% isoflurane at the same flow rate.  For injectables, 
anesthesia was induced using a combination of dexdomitor (.5 mg/kg) and ketamine (75 
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mg/kg).  However, only half of the recommended dose was required to maintain a surgical 
plane for approximately 3 hours, which was enough time to complete the procedure.  Once 
anesthetized, an intramuscular or subcutaneous injection of sustained release 
buprenorphine (.6 - .8 mg/kg) was administered for pain relief.  The rat was then prepared 
for surgery by removing hair on the back between the shoulder blades and hips.  The 
exposed skin was sterilized by wiping the area with poviodine iodine swab sticks (Dynarex) 
followed by alcohol wipes (BD) for two cycles.  On the third cycle, the iodine was left on 
the skin to maintain sterility.  A hard toe pinch, i.e. nail on bone, confirmed the surgical 
plane was reached.  At this point, surgical garb was donned.   
 A lumbar laminectomy was performed to expose the spinal cord. An incision of 
approximately 2 cm was made in the skin along the spine.  A fenestrated drape was adhered 
to the skin with the incision centered in the drape hole.  The skin was held open with 
retractors or sutures.  Two cuts were made in the muscle on either side of the spinous 
process, and the muscle was removed with blunt dissection until the spinous processes and 
laminae were fully exposed and clear of muscle.  Finally, the bone was removed to expose 
the spinal cord for direct injection.  Up to 5 l of PBNC-labeled MSCs suspended at 10k 
cells/l were directly injected into the spinal cord per the clinical procedure at a rate of 16 
nL/sec using a 33G syringe attached to an ultra-micropump (World Precision 
Instruments).44  The needle remained in the spinal cord for 5 minutes after injection to 
prevent reflux.  After injection, the muscle was sutured back over the spinal cord, then the 
skin was sutured back over the muscle.  The bone was not replaced. 
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 For in vivo intraoperative studies, two strains of rats were used: Sprague-Dawley 
(Charles River Laboratories; n = 4) and nude rats (n = 2; Taconic) for a total of 6 rats.  All 
rats were female.  US/PA datasets were acquired intraoperatively with the Vevo LAZR 
during surgery following the imaging protocol described above in ex vivo studies (see 
Section 4.3.7).  Figure 26 depicts the surgical and intraoperative imaging set up.  After 24 
hours, MR images were acquired to validate US/PA results using the 7T preclinical MRI 
system (Bruker PharmaScan) and the T2-RARE sequence described in ex vivo studies (see 
Section 4.3.8).  Rats were then sacrificed, and the spinal cord was harvested for histology.   
US/PA datasets were exported to MATLAB for post-processing.  MR datasets were 
processed using the built-in Bruker Pharmascan software.   
 
Figure 26. Surgical and imaging set up for in vivo intraoperative studies.  The combined 
US/PA imaging transducer was positioned on top of the exposed cord while the needle was 
brought into position (A, B).  US/PA images were acquired as the needle was inserted, 
during, and immediately post-injection after needle removal.  Zoomed in photograph 
depicting the position of the transducer and syringe (B).     
 For longitudinal studies, nude rats (Taconic; n = 5) were imaged 3, 5, 7, 10, and 14 
days post-injection with US/PA imaging and MRI.  All rats were female.  The albino 
phenotype was preferred, but some black and white spotted nude rats were also used.  For 
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the spotted rats, a black patch was frequently observed on the spine.  In this case, the 
pigmented skin was moved outside the field of view during US/PA imaging.  For 
longitudinal imaging, the Vevo system was operated with an external laser (Phocus Mobile, 
Opotek) because higher laser energy was achievable to penetrate overlying muscle and skin 
post-operatively.  Otherwise US/PA and MR datasets were acquired using the same 
imaging protocol as in ex vivo studies (see Section 4.3.7 and 4.3.8) and in vivo 
intraoperative studies.  US/PA datasets were exported to MATLAB for post-processing.  
MR datasets were processed using the built-in Bruker Pharmascan software.  After 14 days, 
animals were sacrificed, and the spinal cord was harvested for histology.   
4.3.10 Histological analysis of PBNC-labeled stem cells 
 Spinal cord sections were stained with eosin (VWR) or DAPI (Thermo Fisher).  In 
both cases, slides were removed from the -80˚C freezer and air dried at room temperature 
for 30 minutes.   
For eosin staining, slides were submerged in PBS for 1 x 10 minutes, followed by 
1 x 1 minute in 95% EtOH, 75 seconds in diluted eosin (4:1 Eosin: 95% EtOH), 1 x 1 
minute in 95% EtOH, 2 x 1 minute in 100% EtOH, and 1 x 10 minutes in xylene.  Slides 
were mounted and dried in the fume hood for at least 24 hours.  Brightfield images were 
acquired (Axio Observer, Zeiss).  
 For DAPI staining, slides were rehydrated with PBS for 20 minutes.  A 1:1000 
dilution of DAPI was prepared in PBS per the manufacturer’s instructions.  Slides were 
stained with DAPI for 10 minutes in the dark at room temperature, followed by 3 x 5 minute 
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washes with PBS.  Slides were mounted and dried overnight at room temperature in the 
dark.  Confocal fluorescent microscopy images were acquired (LSM 700, Zeiss) 
4.3.11 Ex vivo porcine studies 
 A porcine spine was obtained from the slaughterhouse (Holifield Farms, 
Covington, GA).  Muscle was removed and a laminectomy was performed per the clinical 
procedure.44  A hand saw and bolt cutters were used to cut the thick porcine bones.  A 31G 
insulin syringe (BD) was used to inject 25 μl of highly concentrated 200 nm PBNCs (50 
OD).  Multi-wavelength US/PA datasets were acquired in this intraoperative mimicking 
situation using the 15 MHz and 20 MHz transducer.  Each transducer was coupled directly 
to the exposed spinal cord using ultrasound gel.  Data acquired using the 20 MHz 
transducer was further processed in MATLAB.  Anatomical information from ultrasound 
was used to identify the region of interest corresponding to the spinal cord, and background 
PA signals in surrounding tissue were suppressed.  Three-dimensional volumetric images 
were created in AMIRA.   
4.3.12 Stem cell viability probe 
 A caspase-3 sensitive photoacoustic imaging probe was synthesized to assess MSC 
apoptosis.188  The probe consisted of three components: (1) a hydrophilic DEVD peptide 
sequence (aspartate-glutamate-valine-asparate; Asp-Glu-Val-Asp); (2) an aggregating and 
quenching (AgQ) unit consisting of  2-cyano-6-aminobenzothiazole (CABT; Sigma-
Aldrich); and (3) a commercially-available fluorescent dye absorbing at 800 nm 
wavelength (IRDye 800 CW NHS ester; LI-COR Biotechnology).  The DEVD peptide 
motif is synthesized using well-established Fmoc chemistry methods.189  Briefly, after 
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synthesizing Fmoc-Lys(alkyne)-COOH (Sigma-Aldrich) and coupling to each amino acid 
in the sequence, the Fmoc group is deprotected using piperidine/DMF (VWR) to connect 
the DEVD peptide sequence.  The overall chemical structure of the imaging probe is 
depicted in Figure 27.   
 
Figure 27 Chemical structure photoacoustic imaging probe for sensing apoptosis.  The 
probe consisted of an aggregating/quenching unit (AgQ; red circle), IR800 dye (purple 
circles), and peptide sequence (green circle).  Cleavage of the DEVD peptide by caspase-
3 upon apoptosis induces aggregation of the probe through a condensation reaction that 
takes place between CABT (red circle) and the thiol and amino groups of cysteine (blue 
circle).  As a result of aggregation, fluorescent signal is quenched and PA signal is 
enhanced.  Thus, enhanced PA signal corresponds to cell death.    
4.4 Results 
4.4.1 Characterization of PBNCs 
 To demonstrate size control of the PBNC synthesis method, 3, 5, or 10 nm diameter 
SPIONs were used as the iron source to produce PBNCs with different edge lengths.  TEM 
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images confirmed that PBNC size varied with SPION precursor size (Figure 28).  Small 
PBNCs with ~20 nm edge length resulted from 3 nm diameter SPION precursors (Figure 
28A and 28D). Medium PBNCs with ~40 nm edge length resulted from 5 nm diameter 
SPION precursors (Figure 28B and 28E).  Large PBNCs with ~ 200 nm edge length 
resulted from 10 nm SPION precursors (Figure 28C and 28F). The plot summarizes the 
distribution of resulting PBNC edge length and SPION precursor diameter (Figure 28G).  
 
Figure 28. Characterization of size-controlled PBNCs synthesized from SPION precursors.  
TEM images of PBNCs. PBNCs with an edge length of (A) ~20 nm, (B) ~40 nm, and (C) 
~200 nm synthesized from 3 nm, 5 nm, and 10 nm diameter SPIONs, respectively.  (D – 
F) Images at increased magnification for 20 nm, 40 nm, and 200 nm PBNCs, respectively. 
(G) Scatter plot showing relationship between SPION diameter and resulting PBNC size. 
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 Optical and magnetic properties of PBNCs were assessed with UV-Vis 
spectrophotometry and SQUID, respectively.  The optical absorption spectrum of the 20 
nm, 40 nm, and 200 nm PBNCs were comparable, and each particle had a peak optical 
absorption at 685 nm, 720 nm, and 740 nm wavelength, respectively (Figure 29A).  
Spectral shifts likely resulted from increased optical scattering of larger PBNCs.  The 
magnetism of small 20 nm PBNCs and their 3 nm SPION precursors was analyzed with 
SQUID  (Figure 29B). PBNCs exhibited superparamagnetic behavior and had a magnetic 
saturation of 104.0 emu/g.  SPIONs had a magnetic saturation of 20.5 emu/g.  This 
corresponded to a 5-fold increase in magnetization.  Overall, UV-Vis and SQUID 
measurements supported further assessment of PBNCs as MR and PA contrast agents. 
 
Figure 29. Magnetic and optical properties of PBNCs. (A) UV-Vis spectrophotometry 
shows the peak absorption for the 20 nm, 40 nm, and 200 nm PBNCs, with a peak at 685 
nm, 720 nm, and 740 nm respectively.  (B) Magnetic moment curves show a 5-fold increase 
in magnetization for 20 nm PBNCs compared to the 3 nm SPIONs based on nanoparticle 
mass.  Results confirmed photomagnetic properties of PBNCs.   
 To test feasibility of our PBNCs as MRI contrast agents, relaxometry studies were 
performed using a 0.5 T NMR spectrometer. To calculate the molecular weights, Fe3O4 
and C18Fe7N18 were assumed for SPIONs and PBNCs, respectively. The measured 
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transverse relaxivity values are found in Table 2.  Transverse relaxivity was 1.11 mM−1s−1 
for 3 nm SPIONs. After synthesis, 20 nm PBNCs had a 10.05 mM−1s−1 transverse 
relaxivity, showing a 9-fold increase over the 3 nm SPION precursor. However, the size-
matched 20 nm SPIONs had a transverse relaxivity of 920 mM−1s−1. Thus, for the same 
particle size, SPIONs still provided better relaxivity than their PBNC counterparts. The 
large 200 nm PBNCs had a transverse relaxivity of 402.4 mM−1s−1, a 40-fold increase over 
the smaller 20 nm PBNCs, showing the scalable magnetic properties with increasing PBNC 
size. The r2/r1 ratio, an indicator for effective T2 contrast agents, ranged from 1.02 to 16.43 
for 20 nm to 200 nm PBNCs at 0.5 T. 
Table 2. Relaxometry measurements of PBNCs and SPIONs 
 
 To assess the feasibility of PBNCs as multi-modal contrast agents, nanoparticles 
were imaged in a tissue-mimicking phantom.  Dome-shaped inclusions contained PBNCs 
with 20 nm, 40 nm, or 200 nm edge length at 2 OD.  In the phantom, PBNCs of all sizes 
generated high contrast under T2-weighted MRI (Figure 30B–D). US/PA imaging at 740 
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nm laser light irradiation confirmed PA contrast (Figure 30J–L). Additionally, the PA 
spectra matched the expected absorption based on UV-Vis measurements (Figure 30M). 
 
Figure 30. Trimodal US/PA/MRI of PBNCs in a tissue-mimicking phantom.  All PBNCs 
were suspended at the same concentration based on optical density (OD = 2).  The phantom 
contained four dome-shaped inclusions.  One contained gelatin only, and the other three 
contained different types of PBNCs.  The same inclusion was imaged with all modalities: 
top row (A – D) T2-weighted MR images; middle row (E – H) US images; bottom row (I 
– L) PA images at 740 nm wavelength. Columns (left to right): gelatin control, 20 nm, 40 
nm, or 200 nm PBNCs.  All PBNCs produced MR (B – D) and PA (J – K) contrast.  Plot 
of PA spectra for all PBNC types (M).   
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4.4.2 Characterization of PBNC-labeled stem cells in vitro 
 Tissue-mimicking phantom experiments were repeated with PBNC-labeled MSCs.  
MSCs were incubated with PBNCs at 1 OD.  Each dome-shaped gelatin inclusion 
contained PBNC-labeled MSCs at known cell concentrations.  US/PA and MR images 
were acquired to compare detection sensitivity (Figure 31 and Figure 32).  First, the 
representative PA spectrum of PBNC-labeled MSCs (Figure 31B) was similar to UV-Vis 
spectrophotometry results of PBNCs alone (Figure 29). Qualitatively, ultrasound signal 
(top row; grayscale) and PA signal (bottom row; color scale) both decreased with 
decreasing cell concentration (Figure 31C).  The average PA signal was calculated for each 
inclusion and confirmed PA signal decreased with cell concentration (Figure 31D).  
Together, the US/PA images and average PA signal indicated a detection limit below ~100 
cells/μl.   
 106 
 
Figure 31. PA signal of PBNC-labeled MSCs in vitro.  (A) Brightfield microscopy of eosin-
stained cells verified successful labeling based on blue pigment, indicative of PBNCs, 
colocalized with pink cytoplasm.  (B) Representative PA spectrum of PBNC-labeled MSCs 
at 5k cells/μl. (C) Images of all dome inclusions.  Top row: ultrasound (grayscale) only.  
Bottom row: US/PA (color scale) overlays.  (D) Bar graph of comparing PA signal with 
cell concentration.  Scale bar = 2 mm.  
 Next, MR images were acquired for the same tissue-mimicking phantom to confirm 
PBNC-labeled MSCs produced MR contrast and compare detection limits of PA versus 
MRI.  The average T2 relaxation time at 7T was determined using the MSME sequence 
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and parametric fit function.  Relaxation time increased as PBNC-labeled MSC 
concentration decreased (Figure 32A).  PBNC-labeled MSCs at concentrations above ~300 
cells/μl had faster T2 relaxation times than the 0 cell/μl control at 354.5 ms and 368.6 ms, 
respectively.  However, qualitative differences were visible between the 78 cells/μl  
inclusion and 0 cells/μl  inclusion (Figure 32B). Overall the in vitro study indicated PA 
imaging was more sensitive to lower cell concentrations than MRI, but results will vary in 
vivo and both modalities successfully detected PBNC-labeled MSCs. 
 
Figure 32. MRI of stem cells labeled with PBNCs in vitro. MRI studies were conducted 
with the same phantom used in the PA studies. Coronal images were acquired using a 
MSME sequence to determine average T2 relaxation times (A).  T2 relaxation time 
increased with decreasing cell concentration.  Representative T2-weighted MR images (B; 
top row) and parametric fit images depicting relaxation time (B; bottom row).  
4.4.3 Intraoperative studies, ex vivo and in vivo 
 Feasibility of US/PA imaging as an intraoperative tool to guide needle insertion 
and injection of PBNC-labeled MSCs was first assessed ex vivo in Sprague-Dawley rats 
(Figure 33).  After performing a multilevel laminectomy, US/PA images were acquired in 
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real-time as the needle was advanced into the spinal cord.  Ultrasound (grayscale) imaging 
provided anatomical context for needle placement (Figure 33A–D).  Although the 33G 
needle shaft was difficult to detect with ultrasound at 20 MHz (Figure 33A–D), it was 
easily visualized with PA imaging (color scale) (Figure 33E–H).   
 
Figure 33. US/PA image guidance of real-time needle insertion in a rat spinal cord ex vivo.   
Top row: ultrasound (grayscale) only.  Bottom row: combined ultrasound (grayscale) and 
photoacoustic (color scale) images at 740 nm wavelength. Red arrows indicate the 33G 
needle tip. Scale bar = 2 mm.   
 Real-time US/PA images were acquired throughout a 4 μl injection of PBNC-
labeled MSCs (Figure 34) ex vivo.  PA images were post-processed so that the needle shaft 
primarily appeared blue and PBNC-labeled MSCs primarily appeared red.  PBNC-labeled 
MSCs suspended at 10k cells/μl, a clinically relevant cell concentration, were detected after 
only 1 μl was injected (Figure 34B).  The average PA signal increased as a function of 
injection volume (Figure 34E).  Results provided proof-of-concept that PA imaging 
augmented with PBNCs can provide real-time feedback on MSC delivery success, which 
is based on injection location, volume delivered, and stem cell retention in the spinal cord.   
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Figure 34. Injection of PBNC-labeled MSCs in a rat spinal cord ex vivo. Throughout the 
injection, combined ultrasound (grayscale) and photoacoustic (color scale) images were 
acquired using a 20 MHz transducer and a laser operating at 740 nm wavelength.  (A – D) 
US/PA images at 0, 1, 2, and 4 μl injected, respectively, at a concentration of 10k cells/μl.  
(E) Plot comparing PA signal with injection volume.  Scale bar = 2 mm.   
 Thus far, optical properties of PBNCs were utilized to implement PA imaging in 
the spinal cord.  However, PBNCs also possess magnetic properties, and the imaging 
approach can extend to post-operative MRI.  The spinal cord was injected at two locations 
in the spinal cord ex vivo with ~2 μl or 5 μl of PBNC-labeled MSCs suspended at 10k cells/ 
μl.  First, US/PA images were acquired and post-processed to distinguish PA signals from 
the background and PBNC-labeled MSCs (Figure 35A–C).  Next, a layer of muscle was 
placed on top of the spinal cord to mimic the transition from intraoperative to post-
operative imaging and MR images were acquired.  PBNC-labeled MSCs showed negative 
contrast in T2-weighted (Figure 35D–F) and T2*-weighted (Figure 35G–I) MR images.  
Both the ~2 μl (Figure 35B–H) and 5 μl (Figure 35C–I) injections were observed at similar 
locations in the US/PA and MR images. 
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Figure 35. Multi-modal detection of PBNC-labeled stem cells.  PBNC-labeled MSCs were 
suspended at 10k cells/μl. Top row: control, no cells injected.  Middle row: 2 μl injection 
of PBNC-labeled stem cells.  Bottom row: 5 μl injection of PBNC-labeled stem cells.  PA 
images (A - C) were acquired at 740 nm wavelength. Muscle was placed over the cord 
prior to MR imaging to mimic the clinical procedure and the post-operative imaging 
scenario. MR images were acquired using T2 (D - F) and T2* (G - I) pulse sequences. Red 
arrows indicate location of stem cells.  Scale bar = 2 mm.   
 Sagittal US/PA/MR images of the spinal cord were also created (Figure 36).  In this 
orientation ~2 μl and 5 μl injections of PBNC-labeled MSCs were visible in the same frame 
to allow further comparison of US/PA and MR detection of PBNC-labeled MSCs.  
Additionally, US/PA images were displayed without (Figure 36A) and with (Figure 36B) 
a layer of muscle on top of the spinal cord to mimic intraoperative and post-operative 
scenarios, respectively, and evaluate the feasibility of extending US/PA imaging to post-
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operative monitoring.  Both PBNC-labeled MSC injections were detected with PA imaging 
in either case.  T2*-weighted MR images confirmed PA results, and both stem cell 
injections were detected at similar locations (Figure 36C).  Brightfield photomicrographs 
further confirmed injection locations for PA/MRI (Figure 36D, E) and verified MSCs were 
still labeled with PBNCs, indicated by aggregated blue pigment speckles co-localized with 
pink cytoplasm (Figure 36F).   
 
Figure 36. Multi-modal detection of PBNC-labeled MSCs with overlying muscle.  PBNC-
labeled MSCs (red arrows) at 10k cells/μl were injected twice along the spinal cord.  
Sagittal US/PA (A, B) and T2* MR images (C) depicted the ~ 2 μl (left) and 5 μl (right) 
injections of PBNC-labeled MSCs before (A) and after (B, C) a layer of muscle was placed 
over the spinal cord.  Brightfield microscopy of eosin-stained tissue at 10x (D, E) and 40x 
(F) magnification further verified injection locations (D – F).   
 Ex vivo studies validated surgical techniques, imaging protocols, and detection 
algorithms.  Agreement between US/PA and MR data sets motivates progression to in vivo 
studies.  The first set of in vivo studies similarly assessed the ability to guide needle 
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insertion (Figure 37), visualize stem cell delivery intraoperatively (Figure 38), and detect 
PBNC-labeled stem cells post-operatively with MRI 24 hours after surgery (Figure 39).  In 
vivo US/PA datasets were acquired during real-time while the needle was inserted into the 
spinal cord following the methods used in ex vivo studies.  Ultrasound imaging provided 
anatomical context, while PA imaging clearly highlighted the needle shaft (Figure 37).  
Substantial reverberation artifacts from the needle were observed with both modalities.  PA 
artifacts could be removed with post-processing.  Real-time in vivo US/PA imaging also 
visualized breathing and resulting motion in the spinal cord.  This movement can change 
the location of the injection target, thus visualization with US/PA imaging during needle 
insertion can improve accuracy and safety of the procedure. 
 
Figure 37. In vivo US/PA image-guidance of needle insertion in the rat spinal cord.   
Combined ultrasound (grayscale) and PA (color scale) images were acquired with a 20 
MHz transducer at 740 nm wavelength in real-time.  Red arrows indicate the needle tip.  
Images from t = 0 seconds, 5 seconds, and 30 seconds (A – C), respectively.  Scale bar = 3 
mm.   
 After needle insertion, US/PA images were acquired during the stem cell injection 
in vivo (Figure 38).  PA signals from the needle and PBNC-labeled MSCs were segmented 
such that the needle was primarily colored solid red to better distinguish PBNC-labeled 
MSCs.  During the injection, accumulation of the PBNC-labeled stem cells was visible 
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from 0 to 4 μl (Figure 38A–C).  Real-time guidance also highlighted a problem with stem 
cell delivery in this case, specifically reflux of the injection out of the spinal cord.  Stem 
cell reflux would not have been visible without image guidance.  Thus, results can inform 
researchers or clinicians if another it is worth attempting another risky injection based on 
stem cell retention at the tissue target. 
 
Figure 38. In vivo US/PA imaging during PBNC-labeled MSC injection into the rat spinal 
cord.   Combined ultrasound (grayscale) and PA (color scale) images acquired with a 20 
MHz transducer at 740 nm wavelength during injection of PBNC-labeled MSCs at 10k 
cells/μl.  Images at t = 0, 2, and 4 μl injected (A – C), respectively.  Scale bar = 3 mm.   
 Once the needle was removed from the spinal cord, a final set of US/PA images 
were acquired prior to closing the incision for comparison to MR images acquired 24 hours 
after surgery (Figure 39).  Thus, this study mimicked the transition from intraoperative 
guidance with US/PA imaging to post-operative guidance with MRI, the gold standard for 
clinical spinal cord imaging.  PBNC-labeled stem cell injections were observed at similar 
locations with a similar footprint in US/PA (Figure 39A) and T2-weighted MR images 
(Figure 39B).  After completing MR data acquisition, rats were sacrificed, and the spinal 
cord was excised.  A photograph of the excised cord showed a superficial blue spot in the 
center of the spinal cord, indicative of PBNC-labeled MSCs (Figure 39C).   
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Figure 39. In vivo intraoperative US/PA and post-operative MRI.  (A) Combined 
ultrasound (grayscale) and PA (color scale) images were acquired intraoperatively with a 
20 MHz transducer at 740 nm wavelength after a 5 μl injection of PBNC-labeled MSCs at 
10k cells/μl.  Post-operative MR images were acquired 24 hours later (B).  Photograph of 
the excised spinal cord depicting PBNC-labeled MSCs (C).  Scale bar = 3 mm.   
 Histological analysis further verified presence of PBNC-labeled MSCs 24 hours 
after injection.  Blue PBNCs were visible on eosin-stained tissue sections with brightfield 
microscopy (Figure 40).  However, brightfield microscopy only confirmed presence of 
particles, not stem cells.  To confirm the latter, stem cells were double-labeled with a 
fluorescent dye in addition to PBNCs prior to injection.  Thus, green fluorescence 
confirmed presence of PBNC-labeled stem cells with confocal microscopy.   
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Figure 40. Histology of PBNC-labeled MSCs at 24 hours.  Stem cells were double-labeled 
with PBNCs and a fluorescent dye (CellTracker Green) in culture prior to injection into the 
spinal cord.  (A) Brightfield microscopy of eosin-stained spinal cord and blue PBNCs.  (B) 
Confocal microscopy of DAPI-stained spinal cord and green PBNC-labeled MSCs. 
4.4.4 In vivo longitudinal monitoring 
 The above in vivo studies highlighted the feasibility of intraoperative US/PA  
imaging and post-operative MRI to monitor PBNC-labeled MSCs at a single, early time 
point.  However, information is desired at multiple, later time points to more fully develop 
the imaging platform.  In addition, extending US/PA imaging to post-operative monitoring 
is of interest to add new opportunities for therapy assessment and provide complimentary 
information to MRI.  According to these goals, more extensive longitudinal monitoring 
studies were conducted.  
For longitudinal in vivo studies, PBNC-labeled MSCs (5 μl volume at 10k cells/μl) 
were similarly injected directly into the spinal cord of immune-compromised rats (n = 5).  
Multiple sites were injected, space permitting.  After stem cell delivery, the muscle and 
skin were sutured back over the cord, but the bone was not replaced per the clinical 
procedure.  Both US/PA and MR datasets were acquired at multiple time points – at most 
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3, 5, 7, 10, and 14 days post-injection.  In all US/PA datasets below, background PA signals 
outside of the spinal cord were suppressed using anatomical information from ultrasound.  
 Figure 41 displays post-operative axial views of a PBNC-labeled MSC injection 
in the spinal cord at 3, 5, 7, 10 and 14 days in vivo.  Axial views were first assessed because 
the orientation was most straightforward for image acquisition, processing, and visualizing 
injections.  PA signals from PBNC-labeled stem cells were visible at all time points (Figure 
41A–E).  The T2-weighted MR image at Day 14 confirmed presence of the PBNC-labeled 
stem cell injection.  Overall, results indicated extending US/PA imaging to post-operative 
stem cell monitoring in small animals seemed feasible.    
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Figure 41. Longitudinal monitoring of PBNC-labeled MSCs in vivo – axial views. Post-
operative combined ultrasound (grayscale) and PA (color scale) images were acquired 
using at 20 MHz transducer at 740 nm wavelength at 3, 5, 7, 10, and 14 days, respectively 
(A – E).  PBNC-labeled MSCs were still visible at day 14 with PA imaging (E).  T2-
weighted MR images confirmed presence of PBNC-labeled MSCs (F).  Scale bar = 3 mm.    
 To further establish a ground truth and compare detection with T2-weighted MRI, 
sagittal and coronal views were also acquired (Figure 42).  Sagittal and coronal orientations 
allow visualization of multiple injections in the spinal cord, which is common clinical 
practice.44  The spinal cord was injected with PBNC-labeled MSCs at three distinct 
locations.  By day 14, sagittal views did not clearly depict injections (Figure 42A–D).  
However, negative contrast indicative of PBNC-labeled MSCs from all three injections 
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was more clearly identifiable in coronal views (Figure 42E–H).  Coronal views may also 
better visualize stem cell migration from the injection site.   
 
Figure 42. Longitudinal monitoring of PBNC-labeled MSCs MRI in vivo – sagittal and 
coronal views.  PBNC-labeled MSCs (5 μl at 10k cells/μl) were injected into the spinal 
cord at three separate locations. Sagittal (top row; A – D) and coronal (bottom row; E – H) 
Post-operative T2-weighted MR images at 5 (A, E), 7 (B, F), 10 (C, G), and 14 days (D, 
H).  Blue arrows indicate injections of PBNC-labeled MSCs.   
 Given better visualization of PBNC-labeled MSC injections in coronal MRI views, 
three-dimensional US/PA datasets were processed to display images in a similar orientation 
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(Figure 43).  PA datasets were integrated with depth (y-dimension) to create a coronal view 
of the three PBNC-labeled MSC injections and visualize the injection footprint.  The red 
box indicates the approximate location of the spinal cord.  Changes in the injection location 
and footprint of PBNC-labeled stem cells were observed at each time point.  Some imaging 
artifacts may be present (Figure 43B), and results did not perfectly agree with MRI.  
However, expecting perfect agreement was unrealistic due to differences in exact spinal 
column orientation, MR image slice selection, contrast mechanisms of PA and MRI, and 
detection sensitivity.  In spite of this, three injection sites were depicted with both PA and 
MRI.  With further development, PA imaging may ultimately better visualize stem cell 
migration in the spinal cord in small animals in vivo as more subtle variations in the stem 
cell footprint were observed with PA imaging.   
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Figure 43. Longitudinal monitoring of PBNC-labeled MSCs with US/PA imaging in vivo 
– coronal views.  Three-dimensional PA datasets were integrated with depth (y-dimension) 
to create a maximum intensity projection and produce coronal maps of PBNC-labeled 
MSCs at day 5, 7, 10, and 14 post-operatively (A – D), respectively.  Red box indicates 
approximate location of the spinal cord.  Scale bar = 3 mm.   
 After 14 days, animals were sacrificed for histology to verify presence of PBNC-
labeled MSCs.  PBNCs were visible on eosin-stained tissue sections with brightfield 
microscopy due to their blue color (Figure 44A and 44B).  The large aggregates of PBNCs 
may indicate internalization in cells (Figure 44B).  However, as was the case for 
intraoperative studies, brightfield microscopy only confirmed presence of particles, not 
stem cells.  Stem cells were also double-labeled with a fluorescent dye, in addition to 
PBNCs in culture prior to injection into the cord.  Thus, presence of PBNC-labeled stem 
cells was confirmed with confocal microscopy by green fluorescence (Figure 44C).   
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Figure 44. Confirming presence of PBNC-labeled MSCs after 14 days post-injection.  Stem 
cells were double-labeled with PBNCs and a fluorescent dye, CellTracker Green.  (A, B) 
Brightfield microscopy of eosin-stained spinal cords and blue PBNCs.  (C) Confocal 
microscopy of DAPI-stained spinal cord and green fluorescent stem cells.   
4.5 Discussion 
 In previous work, we demonstrated use of AuNSs to detect stem cells in the spinal 
cord with US/PA imaging.174  Although AuNSs are a widely-used contrast agent for PA 
imaging, PBNCs have several benefits. Regarding optical properties, PBNCs have a peak 
optical absorption at longer wavelengths, ~740 nm wavelength compared to ~680 nm 
wavelength for AuNSs, which allows PA imaging at greater depths and may improve 
detection.  Regarding magnetic properties, PBNCs produce MR contrast, which is not 
possible with pure AuNSs.  Magnetic contrast may expedite translation due to 
compatibility with MRI, which is the gold standard for spinal cord imaging. Although 
PBNCs are in preclinical development, precursor components are FDA approved, which 
may further simplify regulatory hurdles and translation.  In addition, we previously 
explored PBNC cytocompatibility.126  No effects on stem cell potency or viability were 
observed, even when MSCs were exposed to higher concentrations of PBNCs compared to 
those used here.  Cytocompatibility over longer time periods remains to be assessed.  For 
these reasons, PBNCs are a promising contrast agent for stem cell imaging in the spinal 
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cord with clear benefits compared to previous studies with AuNSs.  The trimodal 
US/PA/MRI platform augmented with PBNCs provides a variety of options for intra- and 
post-operative detection of stem cells in the spinal cord in research and clinical settings.   
 PA and MRI detection capabilities of PBNC-labeled MSCs were compared in vitro.  
Results indicated PA imaging was able to detect less than 100 cells/µl.  MRI had a detection 
threshold of ~300 cells/µl.  Although in vitro results indicated PA imaging was more 
sensitive to PBNC-labeled MSCs, PA and MRI detection limits may vary in tissue.  More 
specifically, light penetration will reduce detection capabilities of PA imaging in vivo.  
However, for in vivo studies 10k cells/μl were injected per the clinical protocol, which is 
roughly a 30- and 100-fold increase over the MR and PA detection limits observed in 
phantom studies.  As a result, we were able to detect PBNC-labeled stem cells in vivo up 
to two weeks post-injection.  Considering the low detection threshold of phantom results, 
it may be possible to detect stem cells at even longer time points.  However, this may not 
be required based on clinician feedback.      
 Features of the US/PA/MR imaging platform augmented with PBNCs were 
demonstrated in experiments mimicking intra- and post-operative situations ex vivo and in 
vivo.  PA imaging was inherently well-suited for intraoperative imaging due to the smaller 
footprint, OR compatibility, lower cost, and fast image acquisition to allow real-time 
imaging.  Although intraoperative MRI exists, implementation is challenging and high cost 
is limiting.180–182 One feature of intraoperative US/PA imaging was real-time guidance of 
the direct stem cell injection into the spinal cord.  Research has shown that direct injection 
into the spinal cord has higher likelihood of therapeutic success.186  However, it comes 
with higher risk due to more likely damage to the spinal cord during needle insertion.  
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Intraoperative needle guidance can help assure safe needle placement and success of the 
stem cell injection, indicated by stem cell retention in the spinal cord, dose delivered, and 
accuracy of injection location.5,43,190   
 We previously investigated the use of ultrasound only to guide needle placement 
into the spinal cord.137  Here, the use of PA imaging was investigated for the same 
purpose.97  In the ex vivo study, the needle shaft was barely visible using ultrasound alone 
at 20 MHz imaging frequency, but was clearly highlighted with PA imaging at 740 nm 
wavelength.  One reason for this is the angular dependence of ultrasound.97  Compared to 
ultrasound, PA imaging is less dependent on the object angle relative to the transducer 
because contrast is based on light absorption, not backscattering.  As a result strong PA 
signals were generated from the needle regardless of orientation.97  Thus, intraoperative 
PA imaging may be a better option for needle guidance, while intraoperative ultrasound 
provides anatomical context.  Needle guidance was also possible during in vivo 
intraoperative imaging.  An additional benefit of real-time guidance with US/PA imaging 
was highlighted as movement in the spinal cord from breathing was also visible, which 
may change the injection location and have implications on injection safety.  In fact, 
neurosurgeons have developed a spinal cord derrick to guide and stabilize direct injections 
into the spinal cord for this very reason, which further highlights the importance and 
clinical need for image guidance 47.  
 After needle placement, the PBNC-labeled MSC injection was detected in real-time 
using US/PA imaging with both ex vivo and in vivo studies.  From a clinical perspective, 
results can provide physicians with immediate feedback on injection success 
intraoperatively.  Currently feedback on injection volume, location, and stem cell retention 
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would likely be confirmed with post-operative MRI due to limited availability of 
intraoperative MRI systems.  Thus, intraoperative information is often unavailable to 
indicate failed stem cell delivery in real-time, highlighting a benefit of the intraoperative 
US/PA imaging approach.  In a research setting, therapy development can also proceed 
more efficiently by immediately confirming delivery success.  US/PA results from 
intraoperative-mimicking studies were compared to MRI.  There was good agreement 
between modalities, and PBNC-labeled MSCs were detected at similar locations.  Some 
differences in injection morphology were observed and were suspected to result from 
differences in imaging slice, rat orientation, and detection sensitivity of PBNCs-labeled 
MSCs with PA and MRI.  
 To initially assess post-operative potential of the trimodal US/PA/MRI approach, a 
layer of muscle was replaced on top of the spinal cord post-injection to mimic the clinical 
procedure ex vivo.  Even in clinic, bone is not replaced after the surgery,173 providing a 
convenient US/PA imaging window.  PBNC-labeled MSCs were still detectable with PA 
imaging in spite of the additional muscle layer, indicating feasibility of post-operative 
US/PA imaging and motivating in vivo, longitudinal studies with US/PA/MRI.   
 For in vivo longitudinal studies, scattering from the skin and increased imaging 
depth due to swelling at the surgical site required use of higher laser energies.  In ex vivo 
studies, PBNC-labeled MSCs were visible with approximately 7 mJ/cm2 at 740 nm 
wavelength.  However, approximately 20 mJ/cm2 was required to visualize PBNC-labeled 
stem cells for in vivo studies.  PBNC-labeled MSCs were ultimately visible at 14 days post-
injection with both MRI and PA imaging in rats.  Although MRI still has the advantage for 
post-operative imaging due to ease of whole body penetration, detection of PBNC-labeled 
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stem cells with PA imaging for in vivo longitudinal studies brings a new opportunity to 
implement a low-cost alternative that provides complimentary information to MRI.    
 Results from in vivo longitudinal studies were confirmed with histology in addition 
to MRI.  Although MRI is the best comparison for verifying PA results, neither modality 
can distinguish the presence of PBNC-labeled MSCs versus PBNCs alone or PBNCs 
transferred to another cell type.  By double-labeling the PBNC-labeled MSCs with a 
fluorescent dye, CellTracker Green, presence of double-labeled MSCs in the spinal cord 
verified US/PA/MRI results with optical methods.  However, confirmation with confocal 
fluorescent microscopy was not ideal.  One issue was physical blockage of fluorescent 
signal from highly concentrated PBNCs within cells, which diminished green fluorescence 
from double-labeled MSCs.  In spite of this, optical microscopy still depicted some green 
fluorescent signal from PBNC-labeled MSCs.  Together with PA and MR results, histology 
further validated presence of PBNC-labeled MSCs at 14 days post-injection.        
4.6 Conclusions 
 Results showed proof-of-concept of a trimodal US/PA/MR imaging approach for 
intraoperative guidance of stem cell delivery in the spinal cord and longitudinal monitoring 
of stem cells up to 14 days post-operatively.  A key aspect of this approach was the use of 
a unique formulation of Prussian blue nanocubes, developed in-house,148 to produce multi-
modal PA/MR contrast.  MSCs were labeled with 200 nm PBNCs in culture.  Ex vivo and 
in vivo US/PA/MRI studies in rats demonstrated several features supporting intra- and post-
operative usability, including real-time needle and injection guidance, immediate feedback 
on stem cell delivery success, and longitudinal multi-modal stem cell detection.  PA and 
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MR images showed good agreement on stem cell location in intra- and post-operative 
scenarios.  In the future, long term effects of PBNCs must be assessed.  To fully evaluate 
PBNC cytocompatibility, impact on stem cell secretory profile should also be assessed, 
and particle clearance must also be evaluated.  Overall PBNCs may facilitate new 
opportunities to guide stem cell therapies in the spinal cord, and results lay the groundwork 
for a customizable trimodal imaging approach.   
4.7 Future work 
The key next steps to advance the trimodal imaging approach for applications in 
the spinal cord are large animal studies and implementation of functional imaging.  
Although in vivo studies in rodents were necessary to justify future work, studies in porcine 
models are critical to assess clinical feasibility.  Regarding functional imaging, detecting 
stem cell location was first required to provide foundational monitoring information.  Now 
that location was detected, the platform can be further developed for more sophisticated 
monitoring.  Specifically, functional monitoring is desired to provide functional 
information regarding stem cell status and therapy progression, such as stem cell viability, 
proliferation, and differentiation, or blood flow and oxygenation.  For these reasons, 
current efforts are focused on spinal cord imaging in porcine models and developing a 
sensor to detect stem cell apoptosis.  Both aspects have been explored in preliminary 
experiments detailed here.   
 Translation of intraoperative US/PA imaging to an ex vivo porcine spine was 
assessed.  A porcine spinal column was obtained from the slaughterhouse and was similarly 
prepared by performing a laminectomy to expose the underlying spinal cord.  In this case, 
 127 
PBNCs alone were injected at two sites along the spinal cord followed by US/PA imaging 
to mimic the intraoperative scenario.  The spinal cord was imaged with both a 15 MHz and 
20 MHz transducer.  It was initially expected that the 15 MHz transducer would be favored 
for large animal studies due to greater possible imaging depth of the lower frequency 
transducer.  However, the 20 MHz transducer was preferred.  The smaller footprint of the 
transducer allowed closer positioning to the spinal cord to maximize fluence at the PBNC 
injection sites and higher frequency better visualized anatomy.  Both injection sites were 
visible with US/PA imaging in 2D sagittal views (Figure 45A and 45B).  Although each 
site was theoretically injected with 25 μl of PBNCs, the injection footprint differed.  Three-
dimensional volumetric US/PA images confirmed this result, which highlighted variability 
in the procedure and an opportunity to improve consistency with image guidance (Figure 
45C).  After imaging, the spinal cord was excised from the spinal column and cut in half 
to confirm presence of PBNCs (Figure 45D).   
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Figure 45.  US/PA imaging of PBNCs in a porcine spine ex vivo.  A 25 μl volume of PBNCs 
(blue arrows) was injected directly into the spinal cord at two locations.  Two-dimensional 
US (grayscale) and PA (color scale) sagittal views before (A) and after (B) injection.  
Three-dimensional US/PA volumetric image visualized the injection bolus (C).  The spinal 
cord was excised and both injections were observed (D).  Scale bar = 3 mm.   
 Although a high concentration of PBNCs was injected in this case (~50 OD), results 
indicated feasibility of intraoperative US/PA imaging in a large animal model, which is an 
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important steps towards feasibility in patients.  However, many factors must be considered 
for translation of the trimodal imaging approach to large animals in vivo and humans for 
post-operative monitoring.  First, light penetration and imaging depth are concerns for post-
operative monitoring.  Currently, US and PA imaging depths of ~15 cm and  ~7 cm, 
respectively, can be reached.13,191  In humans, the distance from the spinous process to the 
spinal column is approximately 1 – 2 cm in the cervical region, 3 – 7 cm in the thoracic 
region, and 3 cm in the lumber region.  Dimensions are similar for pigs.187  Based on these 
dimensions, post-operative US/PA imaging may be feasible due to the imaging window 
created by lack of bone, but anatomical distance to the spinal cord will still challenge the 
penetration limit of current PA imaging hardware.  If the current PA imaging depth is 
insufficient, it may be possible to detect PBNC-labeled MSCs using more complex 
ultrasound detection mechanisms, such as magnetomotive imaging.192  Alternatively, 
technological advances in light delivery may eventually allow post-operative PA imaging 
of stem cell therapies in the spinal cord of large animals or humans.  In the meantime, the 
great advantage of PBNCs is that MRI can be used for post-operative monitoring 
immediately, while US/PA imaging can still benefit stem cell therapies with intraoperative 
guidance. 
 To address the need for functional stem cell monitoring, a PA imaging probe to 
assess stem cell apoptosis was developed.  Although substantial functional information 
related to cell and tissue status is desired, our initial focus is on apoptosis due to relevance 
to a wide range of stem cell tracking applications. A probe consisting of the DEVD peptide 
sequence, an optically-absorbing dye, and an aggregating/quenching (AgQ) unit was 
synthesized.  Note that the probe design does not include any nanoparticles.  The overall 
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detection scheme is illustrated in Figure 46.  While a cell is alive, the dye component of 
the probe is fluorescently active, and, as a result, the photoacoustic signal is low.  Upon 
cell apoptosis the DEVD peptide motif is cleaved by caspase-3, a key mediator of apoptosis 
that is activated by a variety of signals triggering programmed cell death.193  Cleavage 
allows the probe to self-polymerize and aggregate.  More specifically, aggregation of the 
dye quenches fluorescent activity and decreases quantum yield, which in turn increases PA 
signal.194,195  Therefore enhanced PA signal corresponds to cell apoptosis.196,197  
 
Figure 46. Detection scheme of the stem cell apoptosis probe.  The probe consists of the 
DEVD peptide sequence (green oval), dye (purple polygon), and an aggregating/quenching 
unit (AgQ; red triangle).  Upon cell apoptosis, caspase-3 cleaves the DEVD motif, allowing 
the probe to aggregate and enhance PA signal corresponding to cell apoptosis.  
 After synthesis, probe function was tested in tissue-mimicking phantom 
experiments.  MSCs were incubated with the probe overnight in cell culture.  The next day, 
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the media was collected, and MSCs were washed with PBS to remove any residual probe.  
The media was replaced and supplemented with .2 μg/ml of doxorubicin.  After four hours, 
the cells and media were collected for phantom preparation and US/PA imaging.  Dome-
shaped inclusions consisted of the naïve live cells, probe-labeled dead cells, and the probe 
alone.  Representative US/PA images showed dead cells  labeled with the probe produced 
a PA signal at 700 nm wavelength (Figure 47B).  Analysis of the PA spectrum of each 
inclusion showed an increased PA signal and spectral shift upon cell death (Figure 47B 
and C).  While it is difficult to make conclusions based on changes in magnitude of the PA 
signal, the spectral shift observed from ~800 nm wavelength to ~700 nm wavelength in the 
probe alone versus the probe-labeled MSCs may better distinguish cell apoptosis.    
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Figure 47. Assessing stem cell apoptosis detection in vitro in a tissue-mimicking phantom.  
Combined ultrasound (grayscale) and PA (color scale) images of live, unlabeled MSCs (A) 
and dead MSCs incubated with the probe (B).  (C) PA spectra of dead cells (red line), live 
cells (green line), and the probe alone (black line).   
 Although results demonstrated changes in the PA signal from the probe upon cell 
death, there were many issues identified in this study.  First, cell death was primarily caused 
by the probe itself.  After overnight incubation with the probe alone, many MSCs were 
discovered floating and lysed in the media the following day before any doxorubicin was 
added.  To salvage the experiment, the media containing the dead, lysed cells incubated 
with the probe was also collected and imaged in the tissue mimicking phantom.  This 
sample is identified as “Dead cells – w/ probe” above (Figure 47).  In later studies, further 
purification steps during probe synthesis eliminated cell death and lysis caused by the 
probe.  However, once the probe no longer caused cell lysis, there was also no longer any 
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change in the PA signal upon cell apoptosis.  Thus, cells did not efficiently endocytose the 
probe to allow PA detection of caspase activation in the cytoplasm.  Overall, initial success 
(Figure 47) was observed because cell lysis allowed caspase-3 to access the probe external 
to the cells.  
 To address this problem, laser delivery of the probe using perfluorocarbon 
nanodroplets was attempted.  The idea is similar to sonoporation, but instead laser light 
irradiation of nanodroplets provides the mechanical stimulus to open the cell 
membrane.198,199  The labeling scheme is depicted in Figure 48A.  Briefly, stem cells were 
incubated with a cocktail of the apoptosis probe and light-activated nanodroplets, which 
contained a dye absorbing at 1064 nm wavelength.  Upon laser irradiation at 1064 nm, the 
droplets vaporized to generate acoustic waves, which can mechanically stimulate transient 
opening of the cell membrane to allow the probe to enter.  In tissue-mimicking phantom 
studies, results indicated delivery of photoacoustic absorbers into the cells (Figure 48B–
E); however, substantial background signal was observed in the light-irradiated cells 
incubated with nanodroplets only (Figure 48D and 48E). Thus, it appeared that the 1064 
nm dye more favorably crossed the cell membrane rather than the apoptosis probe.  
Although development of this laser-based delivery technique would be beneficial for 
various applications, use of existing technologies, such as electroporation, may be a better 
immediate solution to deliver the apoptosis probe to MSCs in culture.    
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Figure 48.  Apoptosis probe delivery using light-activated nanodroplets.  Laser light-
activated nanodroplets may be able to temporarily permeabilize the cell membrane through 
acoustic stimulation to improve delivery efficiency (A). Combined ultrasound (grayscale) 
and PA (color scale) images of live (B, D) and dead stem cells treated with doxorubicin 
(C, E).  Top row (B, C):  stem cells incubated with the probe and nanodroplets.  Bottom 
row (D, E): stem cells incubated with nanodroplets only.  All groups were irradiated with 
300 laser pulses for duration of 10 ns at a frequency of 10 Hz.     
4.8 Contributions from collaborators 
 In this chapter, specific contributions were made by Eleanor Donnelly, Diego 
Dumani, Jisha V.S., Andrew Zhao, and Johannes Leisen.  Eleanor Donnelly provided 
training to execute the in vivo surgeries.  Diego Dumani conducted the SQUID experiment 
for PBNCs.  Jisha V.S. synthesized the apoptosis probe.  Andrew Zhao synthesized light-
activated nanodroplets and tested laser parameters to deliver the caspase-3 probe.  Johannes 
Leisen provided expertise and training to execute magnetic resonance imaging studies.  
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CHAPTER 5. TRACKING PARTICLES TO INFORM VACCINE 
DESIGN 
This work was presented at two conferences:  
Kubelick, K.P., Pradhan, P., Roy, K., & Emelianov, S. Ultrasound and Photoacoustic 
Imaging to Aid Design, Optimization, and Validation of Pathogen-like Particle Vaccines. 
IEEE International Ultrasonics Symposium, Kobe, Japan, October 2018.  
Kubelick, K.P., Pradhan, P., Roy, K., & Emelianov, S. Tracking Vaccine Particle 
Trafficking to the Lymph Node using Ultrasound/Photoacoustic Imaging Tools. 
Biomedical Engineering Society (BMES) Annual Meeting, Atlanta, GA, October 2018.  
 
5.1 Abstract 
Development of particulate vaccines, termed pathogen-like particles (PLPs), is of 
interest to stimulate a more robust immune response compared to traditional, small 
molecule formulations.  Physical properties of PLPs can be tailored to impact trafficking 
to the lymph node, cell-particle interactions, and ultimately vaccine mechanism of action.  
To expedite development of PLPs, a minimally invasive, longitudinal monitoring tool is 
needed to understand the impact of vaccine particle design on the immune response in vivo.  
Thus, we have developed an ultrasound/photoacoustic (US/PA) imaging platform to track 
PLPs during trafficking to the lymph node, which can provide insight on how to effectively 
design PLPs to stimulate a robust immune response.  Several types of PLPs, composed of 
poly(lactide-co-glycolic acid) (PLGA), were synthesized using a water-oil-water double 
emulsion method.  Different optical absorbers for PA or fluorescent imaging were 
encapsulated within the PLPs.  The most promising formulation, nano-sized PLPs (nPLPs), 
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~300 nm diameter and loaded with dye absorbing at 950 nm wavelength, was assessed with 
US/PA imaging in vivo.  BALBL/c mice received subcutaneous injections of Dye950-
nPLPs, and the inguinal lymph node was imaged at multiple time points up to 48 hours 
post-injection.  Dye950-nPLPs were then coated with an adjuvant, CpG, to mimic vaccine 
particles and compare differences in PLP trafficking.  Spectroscopic analysis of multi-
wavelength PA datasets detected presence of uncoated and adjuvant-coated Dye950-
nPLPs.  Accompanying changes in lymph node swelling and blood accumulation were also 
observed.  Several technical challenges remain, including sensitivity of particle detection, 
and crosstalk between particles and endogenous absorbers due to overlapping optical 
spectra, which motivate research areas for further development.  Overall, initial results 
indicated the potential of the US/PA imaging platform to inform particulate vaccine design, 
which may be applicable to particle tracking in other applications in the future.     
5.2 Introduction 
Development of particulate vaccines, termed pathogen-like particles (PLPs), is of 
interest to stimulate a more robust immune response compared to traditional, small 
molecule formulations.58,59  Physical properties of PLPs can be tailored to control vaccine 
delivery and ultimately mechanism of action by manipulating trafficking to the lymph node 
and cell-particle interactions.54  Particle size, composition, and surface coating can all be 
tailored to engineer immunity, leading to endless design combinations.58,200,201  For 
example, considering surface coating alone, the type of coating, surface molecule density, 
resulting particle charge, and hydrodynamic radius all impact immune response. Though 
an incredible variety of particles have been developed to date, outcomes are not well 
understood.58  This can be partly attributed to the lack of in vivo monitoring techniques to 
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evaluate particle interactions with the immune system.  To expedite development of PLPs, 
a minimally invasive longitudinal monitoring tool is needed to understand the relationship 
between vaccine particle design and the resulting immune response in vivo.   
Other than histology, one existing option to address this need is two-photon 
intravital imaging.  Two-photon intravital imaging has drastically advanced understanding 
of the immune system in vivo.60,61  This purely optical method is an excellent option for 
cellular and molecular-level imaging due to high resolution and compatibility with existing 
optical dyes to monitor complex cellular and molecular responses.  Although certain lymph 
nodes are quite superficial, two-photon microscopy still lacks sufficient imaging depth for 
in vivo monitoring, which is why two-photon intravital imaging was developed.  Intravital 
imaging requires a highly invasive, specialized surgical procedure, where the skin is 
removed and replaced with a transparent viewing window to facilitate optical imaging.  
Thus, two-photon intravital imaging increases imaging depth by eliminating light 
scattering and attenuation at the skin.  An alternative option is the commercially available 
fluorescent in vivo imaging system (IVIS; PerkinElmer).  However, resolution is poor and 
sensitivity and imaging depth are limited by optical scattering from the skin.   
Although current optical imaging techniques are not ideal, the desirable attributes 
of these systems are clear, specifically high resolution, high contrast, and the potential to 
detect many cellular or molecular events simultaneously using the wide variety of available 
optical absorbers.  Considering the characteristics of an ideal system, ultrasound (US)- 
guided photoacoustic (PA) imaging is an excellent alternative.  As a combined optical and 
acoustic modality, PA imaging captures the best of both worlds for lymph node imaging 
by providing high resolution, optical-based contrast at greater imaging depths than purely 
 138 
optical methods.  For this reason, PA imaging has been widely used for other applications 
of lymph node imaging using nanodroplets, metallic nanoparticles, endogenous optical 
absorbers, and dyes.12,62–65.  However, US/PA imaging tools have not been specifically 
developed to monitor vaccine particle trafficking to the lymph node.    
In this chapter, nano-sized PLPs (nPLPs) with a diameter of approximately 300 nm 
were synthesized.54,55,57  An optically absorbing dye, Dye950, was encapsulated within the 
nPLPs to generate PA contrast. The first batch of Dye950-nPLPs received no further 
surface modification.  A second batch of Dye950-nPLPs was coated with an adjuvant, 
CpG, to mimic a vaccine particle.  BALB/c mice received subcutaneous injections of 
uncoated or adjuvant-coated particles while US/PA datasets were acquired up to 48 hours 
post-injection.  Spectroscopic PA analysis was implemented to distinguish Dye950-nPLPs 
from the background.  Results provided information on particle trafficking to the lymph 
node, particle localization within the lymph node, and morphological changes at the lymph 
node.  Furthermore three-dimensional (3D) US/PA volumetric images visualized particle 
distribution from the injection site to the inguinal lymph node.  Together, these pieces of 
information can indicate passive drainage or active cellular transport of PLPs to the lymph 
node.  If and how PLPs arrive to the lymph node ultimately impact the immune response 
and vaccine mechanism of action.54,202–204  Thus, results lay the groundwork for developing 
a US/PA imaging platform to inform vaccine design and monitor more complex cell-
particle interactions in the future. 
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5.3 Materials and methods   
5.3.1 Particle synthesis and characterization 
 All materials were used as received.  PLGA (RG502H, Sigma-Aldrich) PLPs were 
synthesized via a water-oil-water double emulsion and all subsequent coating steps 
followed previously established methods described elsewhere.54–57  Small modifications 
were made to the protocol to incorporate photoacoustic or fluorescent dye.   
 Briefly, to synthesize micron-sized PLPs (mPLPs) with ~ 1 micron diameter, 200 
mg of PLGA and 8 mg of hydrophobic dye, either DiI (Sigma-Aldrich), Epolight 9151 
(Epolin; referred to as Dye750), or Epolight 3832 (Epolin; referred to as Dye950), were 
dissolved in 10 ml of dichloromethane (Sigma-Aldrich) and added to 300 μl of deionized 
ultra-filtered (DIUF) water.  The solution was homogenized at ~10,000 rpm (SL2T) for 2 
minutes.  The first emulsion was then added to 50 ml of 1% polyvinyl alcohol (PVA; 
Sigma-Aldrich) and homogenized at the same speed for 2 minutes.  The second emulsion 
was added to a beaker containing 100 ml of 1% PVA and stirred gently for 3 hours in a 
fume hood.  Following solvent evaporation, particles were centrifuged at 3500 rpm for 20 
minutes.  The pellet was resuspended in 2 ml of DIUF water, and the process was repeated 
three times.  After the final centrifugation step, the resuspended PLPs were flash frozen in 
liquid nitrogen, and the sample was lyophilized (FreeZone, Labconco) for at least 3 days.  
After drying, the sample was weighed and stored at -20˚C.   
 Methods to synthesize nPLPs with ~300 nm diameter were also previously 
established elsewhere.54–57   Briefly, the same amount of PLGA and hydrophobic dye was 
dissolved in 4 ml of dichloromethane and sonicated (Q700, QSonica) at approximately 85 
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W for 2 minutes in the presence of 1 ml DIUF water.  In the second emulsion, the sample 
was added to 16 ml of 5% PVA and sonicated at the same power for 5 minutes.  The double 
emulsion was poured into a beaker and gently stirred for 3 hours in a fume hood.  Following 
solvent evaporation, particles were centrifuged at 3500 rpm for 20 minutes to remove large, 
pelleted PLPs.  The supernatant was then centrifuged at 20,000 G for 20 minutes.  The 
pellet was resuspended in DIUF water and centrifuged two additional times.  After the final 
spin, the pellet was lyophilized following the above protocol.   
 In preparation for adjuvant-coating, nPLPs were coated with branched 
polyethylenimine (bPEI; Polysciences) via well-established surface activation methods 
described by others.56,57  Briefly, 200 mg of PLPs were resuspended in 3 ml of ice cold 0.1 
M MES (Sigma-Aldrich) buffer.  Two separate solutions of 40 molar excess EDC (Sigma-
Aldrich) and 25 molar excess sulfo-NHS (Sigma-Aldrich) in 1 ml of 0.1 M MES were 
prepared.  The sulfo-NHS solution was added to the PLPs, followed by the EDC solution.  
Samples were covered in aluminum foil followed by gentle shaking at room temperature.  
After 2 hours a bPEI solution consisting of 14.1 ml bPEI, 28.2 ml of 0.2 M MES buffer, 
and 1.8 ml HCl (37%, VWR) was added to the PLP solution.  The solution was stirred for 
2 hours.  The PEI-nPLPs were centrifuged at 22,000 G for 20 minutes at 4˚C.  The pellet 
was resuspended in 20 ml of 1M NaCl and centrifuged again using the same parameters.  
The pellet was resuspended in 20 ml of DIUF water and centrifuged again using the same 
parameters.  After the final spin, the pellet was resuspended in 5 ml of RNAse/DNAse free 
water and lyophilized following the above protocol.   
 PEI-nPLPs were next coated with an adjuvant, CpG (tlrl-1826; Invivogen), 
according to methods previously described elsewhere.54  A sodium phosphate loading 
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buffer (pH 6) was obtained from collaborators in the Roy Lab.  Two centrifuge tubes 
containing reaction components were prepared.  In Tube 1, 50 μg of CpG was added to 1 
ml of loading buffer in a 2 ml low adhesion centrifuge tube (USA Scientific).  In Tube 2, 
5 mg of PEI-PLPs were added to 1 ml of loading buffer in a 2 ml low adhesion centrifuge 
tube.  Tube 2 was briefly sonicated for 5 – 10 seconds to resuspend PEI-nPLPs.  Tube 1 
was then secured in a vortex.  While Tube 1 was continually vortexed at low speed, the 
solution from Tube 2 was added dropwise to Tube 1 over one minute.  Once the entire 
solution from Tube 2 was added to Tube 1, the lid on Tube 1 was closed, and the solution 
was vortexed at high speed for 30 seconds.  Tube 1 was wrapped in foil and rotated 
overnight at 4˚C.  The following day the CpG-nPLPs were centrifuged at 3000 G for 20 
minutes.  The supernatant was kept to determine CpG surface loading on the CpG-nPLPs 
(Synergy HT microplate reader, BioTek Instruments; single-stranded DNA setting).  The 
pelleted CpG-nPLPs were resuspended at 1 μg CpG/μl in sterile PBS to prepare for in vivo 
injections.   
PLP hydrodynamic diameter and surface charge was measured with DLS and zeta-
potential, respectively (Malvern Zetasizer Nano ZS).  Prior to measurements, PEI-nPLPs 
were sonicated in a bath sonicator for 10 minutes.     
5.3.2 PA assessment of PLPs in a tissue-mimicking phantom 
 A tissue mimicking phantom was prepared and imaged with US/PA imaging 
according to the methods described above (see Section 3.3.6).  In this case, the dome-
shaped inclusions contained uncoated m- and nPLPs loaded with Dye750 or Dye950.  
Seven different domes were prepared for each type of PLP containing different particle 
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concentrations: 12.5 mg/ml, 6.3 mg/ml, 3.1 mg/ml, 1.6 mg/ml, 0.78 mg/ml, 0.39 mg/ml, 
and 0.195 mg/ml.     
5.3.3 In vivo studies 
 In vivo studies were conducted following the Institutional Animal Care and Use 
Committee (IACUC) guidelines per the Georgia Institute of Technology.  Female, BALB/c 
mice (Charles River Laboratories) were used in these studies.   
 For US/PA imaging experiments, mice received Dye950-nPLPs with different 
coatings. More specifically, two mice received uncoated Dye950-nPLPs, and two mice 
received CpG-coated Dye950-nPLPs (henceforth referred to as “CpG-Dye950-nPLPs”).  
Anesthesia was induced with 5% isoflurane at a flow rate of 500 ml/min and maintained at 
1 - 2% isoflurane at the same flow rate.  Hair was removed on the abdomen between the 
legs and ribs.  Mice were injected on the left side near the mammary fat pad with 20 μl of 
Dye950-nPLPs or CpG-Dye950-nPLPs, which corresponded to 20 mg of nPLPs and 20 μg 
of CpG, where applicable.  Three-dimensional multi-wavelength US/PA datasets were 
acquired using the Vevo LAZR (see Section 2.3.2 and 3.3.5).  Datasets were exported to 
MATLAB (Mathworks, Inc.) and post-processed with spectroscopic analysis (see Section 
2.3.5) to distinguish PA signals from endogenous and exogenous absorbers, in this case 
blood and Dye950-nPLPs or CpG-Dye950-nPLPs.  Three-dimensional volumes were 
created in AMIRA (Thermo Fisher).    
 Fluorescent imaging experiments using the in vivo imaging system (IVIS Lumina, 
PerkinElmer) and fluorescent microscopy were conducted to establish a ground truth for 
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comparison of photoacoustic results.  For in vivo fluorescent experiments, female, BALB/c 
mice received DiI-loaded nPLPs (referred to as “DiI-nPLPs”) with different coatings.  
More specifically, three mice received uncoated DiI-nPLPs, and three mice received CpG-
DiI-nPLPs.  Mice were similarly anesthetized for hair removal and particle injections.  In 
this case, a 20 μl subcutaneous injection was administered on the underside of the left leg, 
further away from the left inguinal lymph node compared to the injection with 
photoacoustic particles.  After 24 hours, mice were anesthetized again for fluorescent 
imaging with IVIS.  After in vivo fluorescent images were acquired, mice were sacrificed 
for acquisition of ex vivo fluorescent images with IVIS.  In this case, the skin was removed 
to expose both inguinal lymph nodes, and the injection site was covered with a piece of 
gauze to suppress the high fluorescent signal from the injection site to allow detection of 
low concentrations of particles at the lymph node.   
 After sacrifice, both inguinal lymph nodes were harvested from all mice.  Lymph 
nodes were sectioned and stained with eosin for brightfield microscopy (Axio Observer, 
Zeiss) or DAPI for confocal fluorescent microscopy (LSM 700, Zeiss).  The staining 
protocol followed methods described above (see Section 4.3.10).   
5.4 Results 
5.4.1 Particle synthesis and characterization 
 Seven different types of photoacoustic PLPs were synthesized with different 
photoabsorbers, diameters, and particle coatings, as described in Table 3.  The original 
formulation of PLPs, composed of PLGA, does not optically absorb for tracking with 
photoacoustic imaging, IVIS, or fluorescent confocal microscopy.  Thus, various 
 144 
photoabsorbers were encapsulated within the PLP by adding hydrophobic dyes to the oil 
phase during the double emulsion synthesis.   
Table 3.  Description of PLP formulations.  The size column indicates target diameter of 
~1 µm (micro) or ~300 nm (nano).  The absorber column indicates type of dye 
encapsulated.  The coating column indicates whether the PLP has no coating or an adjuvant 
(CpG) coating.  The modality column indicates PA or fluorescent contrast.   
 
 The optical properties of uncoated photoacoustic PLPs, which contained Dye750 
or Dye950, were assessed with UV-Vis spectrophotometry (Figure 49).  First, the 
absorbance spectra of free Dye750 and Dye950 was measured and compared to the known 
spectra of endogenous absorbers, specifically HbO2 and Hb.
106–112  Both photoacoustic 
dyes had a distinct optical signature compared to endogenous absorbers, which indicated 
potential to distinguish Dye950- or Dye750-PLPs in vivo with multi-wavelength PA 
imaging and spectroscopic analysis.  The extinction spectra of Dye950- and Dye750-
mPLPs (Figure 49B) or nPLPs (Figure 49C) had similar spectral signatures to the free dye, 
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indicating successful encapsulation of absorber.  Optical scattering was apparent in 
measurements of Dye950- and Dye750-mPLPs, indicated by noise in the spectra (Figure 
49B).  Less optical scattering was observed in the measurements of Dye950- and Dye750-
nPLPs due to their smaller size (Figure 49C).  Unlike, PA imaging, UV-Vis measurements 
were susceptible to scattering.  Spectral shifts were also observed in the dye-loaded PLPs 
compared to free dye because the optical signature can vary based on concentration of 
encapsulated dye. 
 
Figure 49. Characterization of PLPs with UV-Vis spectrophotometry.  (A) Absorbance 
spectra of free Dye750 (green), free Dye950 (pink), and relevant endogenous absorbers for 
lymph node imaging in BALB/c mice, Hb (blue) and HbO2 (red).  Extinction spectra of 
mPLPs (B) and nPLPs (C) loaded with Dye750 or Dye950.  Similar spectral signatures 
were observed for the free dye and dye encapsulated in the PLPs; however, some 
differences were observed.  Noise in the spectra of mPLPs resulted from scattering of the 
larger particle.  Differences in the ratios between extinction peaks can result from 
differences in concentration of dye encapsulated in each particle type. 
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 The PA signal of uncoated PA-tagged PLPs was assessed in tissue-mimicking 
phantom experiments.  Seven domes with decreasing concentrations were prepared for 
each type of PA-tagged PLP to determine the detection limit.  PA signal was detected from 
all four types of PA-tagged PLPs at the lowest concentration of 0.195 mg/ml: Dye950-
mPLPs, Dye750-mPLPs, Dye950-nPLPs and Dye750-nPLPs.  However, a higher PA 
signal was observed from the nano-sized formulations.  Furthermore, compared to 
endogenous absorbers Dye950 had a more distinct spectral signature than Dye750, which 
has a shared peak with Hb (Figure 49).  For these reasons, the following in vivo studies 
described hereafter were conducted with Dye950-nPLPs because characterization 
determined this was the most promising formulation to allow US/PA detection.  
 Dye950-nPLPs were further characterized with DLS to determine the 
hydrodynamic radius (Table 4).  Results were compared to uncoated PLPs that were not 
loaded with any dye, and DiI-nPLPs for fluorescent imaging.  Additional measurements 
were acquired after coating the Dye950- and DiI-nPLPs with PEI.  The uncoated nPLPs 
had a smaller hydrodynamic diameter of 277.5 nm compared to that of the Dye950-nPLPs 
or DiI-nPLPs, at 301.7 nm and 330.9 nm, respectively.  This may indicate some dye coating 
the PLP surface.  As expected, hydrodynamic diameter increased when the particles were 
coated with PEI.  Particles also tended to aggregate after the PEI coating step.  The PEI-
Dye950-nPLPs seemed more susceptible to aggregation than the PEI-DiI-nPLPs with a 
hydrodynamic diameter of 2654 nm compared to 479.7 nm.  
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Table 4. Average diameter of different types of nPLPs.  PDI = polydispersity index. 
 
 Particle surface charge was assessed with zeta-potential (Table 5).  The surface 
charge changed after each coating step as expected based on previous results from others 
54.  The uncoated particles had a negative surface charge.  After PEI-coating the surface 
charge became more positive.  Finally, the surface charge became more negative after CpG 
coating.  Plate reader measurements determined the CpG surface loading was ~10 μg of 
CpG/mg of particles for both CpG-Dye950-nPLPs and CpG-DiI-nPLPs. 
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Table 5. Comparing surface charge of nPLPs after each coating step 
 
 
5.4.2 In vivo studies using uncoated nPLPs  
 For the first set of in vivo experiments, Dye950-nPLPs (uncoated) were 
subcutaneously injected near the left mammary fat pad.  Uncoated PLPs were initially 
studied to assess feasibility of PA detection prior to studying a more realistic and complex 
adjuvant-coated vaccine particle.   Multi-wavelength US/PA datasets were acquired 
continuously for the first 2 hours post-injection and at 24 hours post-injection followed by 
spectroscopic analysis.   
Prior to injection of Dye950-nPLPs, only Hb and HbO2 were identified, indicating 
minimal crosstalk between optical absorbers (Figure 50A–C).  Crosstalk between 
endogenous and exogenous absorbers creates detection inaccuracies due to overlapping 
spectral signatures, which ultimately leads to incorrect identification of blood or particles.  
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As expected no Dye950-nPLPs were detected prior to injection.  Thus, there appeared to 
be minimal crosstalk between absorbers, and results gave confidence in particle detection 
at later time points.  By 2 hours post-injection, some PLPs were observed at the lymph 
node periphery (pink arrow; Figure 50L).  By 24 hours, more substantial accumulation of 
PLPs was detected surrounding the lymph node and in surrounding vessels (Figure 50O).  
Changes in blood spatial distribution were also observed at each time point (Figure 50D 
and E, G and H, J and K, M and N).  However, the difference between signal from Hb and 
HbO2  at 2 hours and 24 hours post-injection could result from differences in the imaging 
frame acquired, as mice were allowed to wake up at 2 hours post-injection and were 
anesthetized again for US/PA imaging 24 hours later.  Note that the injection site was not 
visible in the same frame as the lymph node in any of the images in Figure 50.  Overall 
results indicated feasibility of detecting Dye950-nPLPs and some accompanying 
physiological responses.   
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Figure 50. In vivo US/PA imaging of Dye950-nPLP trafficking to the lymph node.  
Ultrasound (grayscale) and PA (color scale) overlay images after spectroscopic analysis to 
distinguish Hb, HbO2, and Dye950-nPLPs (columns left to right).  Maps of absorber 
distribution before injection (A – C), 30 minutes (D – F), 1.5 hours (G – I), 2 hours (J – L), 
and 24 hours (M – O) after injection.  PLPs were detected near the lymph node by 2 hours 
post-injection (L) and more substantial accumulation was observed by 24 hours post-
injection (O).  Pink arrows point to particles.  Scale bar = 3 mm.   
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 To establish a ground truth for in vivo PA results, fluorescent experiments were 
conducted with fluorescent IVIS of DiI-nPLPs, a fluorescent analog for the photoacoustic 
Dye950-nPLPs.  DiI-nPLPs were injected subcutaneously on the underside of the left leg.  
The inguinal lymph nodes were imaged after 24 hours with IVIS in vivo (Figure 51A).  
Particle accumulation was not visible at the inguinal lymph node with IVIS in vivo.  The 
mouse was sacrificed and fluorescent IVIS images were acquired ex vivo after peeling back 
the skin to expose both inguinal lymph nodes and covering the injection site (Figure 51B).  
Fluorescent signal was visualized at the left inguinal lymph node, i.e. the injected side 
(ipsilateral), providing some confirmation of PA results.  However, the exact distribution 
of DiI-nPLPs within the lymph node could not be determined due to poor resolution of 
IVIS.  This result highlighted two immediate advantages of the US/PA imaging platform.  
First, in vivo IVIS detection of nPLPs was not possible.  Mice had to be sacrificed, and the 
skin pulled back to allow detection with IVIS.  Second, poor resolution prevented IVIS 
detection of exact nPLP location within the lymph node, even ex vivo.  US/PA imaging of 
nPLPs addressed both shortcomings of IVIS as longitudinal in vivo monitoring was 
possible and high resolution specifically depicted particles at the lymph node periphery 
(Figure 50).   
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Figure 51. In vivo and ex vivo fluorescent imaging of DiI-nPLPs.  BALB/c mice received 
subcutaneous injections of DiI-nPLPs and were imaged 24 hours later with IVIS.  DiI-
nPLP accumulation was not apparent at the left inguinal lymph node in vivo while the skin 
was intact (A).  Increased fluorescent signal was present at the left inguinal lymph node ex 
vivo (B). 
 To further assess nPLP detection capabilities of in vivo PA imaging, the inguinal 
lymph nodes were harvested for histology from mice that received Dye950-nPLPs or DiI-
nPLPs.  The Dye950-nPLPs appeared dark green in solution, thus it was suspected that 
particles could be visualized under brightfield microscopy.  Eosin-stained tissue may have 
depicted Dye950-nPLP accumulation based on dark greenish/brown coloration throughout 
the lymph node (Figure 52A and 52B).  Compared to in vivo PA imaging results, where 
Dye950-nPLPs were only detected at the lymph node periphery, brightfield microscopy 
indicated sensitivity of the current in vivo US/PA imaging platform can be improved.  
Confocal fluorescent microscopy showed DiI-nPLPs (red fluorescence) were primarily 
localized to the lymph node periphery (Figure 52C and 52D), similar to in vivo PA imaging 
results.  Overall, it is important to recognize the standards for success of in vivo US/PA 
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detection of particles cannot be solely based on optical microscopy of tissue sections from 
harvested lymph nodes.  The imaging modalities are far too different, and histology will 
always be more sensitivity than minimally invasive, US/PA imaging.  Thus, it would be 
unrealistic to aim to design a US/PA imaging system based on the sensitivity of a highly 
invasive method, such as histology.   Results from ex vivo IVIS, brightfield microscopy, 
and confocal fluorescent microscopy also highlight the challenge of establishing a fair 
ground truth for development of the US/PA imaging platform for particle tracking, as each 
modality showed slightly different results.  In spite of this technical challenge, results have 
already indicated one benefit of the US/PA platform, the ability for high resolution, 
minimally invasive, longitudinal detection of particles in vivo, which was not possible with 
any of the other modalities, including in vivo IVIS.     
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Figure 52. Histology of Dye950-nPLPs and DiI-nPLPs at 24 hours.  Brighfield and 
confocal microscopy from the left inguinal lymph node from the mouse injected with 
Dye950-nPLPs (A, B) or DiI-nPLPs (C, D), respectively.  Dye950-nPLPs may be indicated 
by dark green/brown speckles throughout the eosin-stained lymph node (A, B; black 
arrows).  (C, D) DiI-nPLPs (red) were visible at the DAPI-stained lymph node periphery   
5.4.3 In vivo studies using adjuvant-coated particles 
 To assess trafficking in a vaccine-mimicking particle, Dye950- and DiI-nPLPs 
were next coated with an adjuvant, CpG.  BALB/c mice were similarly prepared and 
injected.  In this case, US/PA imaging time points were staggered between mice to 
visualize trafficking over a longer range of time.  The first mouse was imaged from 0 – 4 
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hours post-injection and at 48 hours post-injection.  The second mouse was imaged from 4 
– 8 hours post-injection and at 24 hours post-injection.  To more fully evaluate trafficking 
of a vaccine-mimicking particle, two-dimensional (2D) and 3D multi-wavelength US/PA 
datasets were acquired over a wider field-of-view.  However, system limitations allowed 
acquisition of fewer wavelengths for 3D datasets, which impacted spectroscopic 
processing.  More specifically, compared to analysis of uncoated Dye950-nPLPs, which 
separated the PA signals into three absorber maps (Hb, HbO2, and particles), the best 
approach to minimize artifacts for CpG-Dye950-nPLPs was to separate signals into two 
absorber maps (total blood and particles).  Although this was only a requirement for 3D 
datasets, for consistency purposes, 2D datasets of adjuvant-coated particles were processed 
using the same approach, i.e. two absorber maps were produced.  For this reason, some 
differences were observed in the 2D results of uncoated particles (Figure 50) and adjuvant-
coated particles (Figure 53).   
In this case, 2D cross-sectional views of the ipsilateral inguinal lymph node showed 
some crosstalk was between the CpG-Dye950-nPLPs and blood (Figure 53A and 53F), 
indicated by detection of CpG-Dye950-nPLPs before injection (Figure 53A).  Thus, some 
misidentification of optical absorbers occurred.  However, the map of CpG-Dye950-nPLP 
distribution before injection (Figure 53A) can be used to identify imaging artifacts at later 
time points (Figure 53B–E).  In addition, artifacts were isolated to tissues outside of the 
lymph node.  Thus, particle accumulation within the lymph node can still be assessed, and 
spectroscopic PA analysis was conducted with caution.  For the adjuvant-coated particles, 
no PLP accumulation was observed at the lymph node by 24 or 48 hours post-injection 
(Figure 53B–E).  Changes in blood spatial distribution were observed (Figure 53F–J).  
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Although this may be indicative of an immune response, the result can also be explained 
by acquisition of different imaging frames at each time point, as mice were anesthetized 
again for US/PA imaging at 24 hours and 48 hours post-injection.  Ultrasound depicted 
some response to the particles as lymph node swelling was visible at 48 hours post-
injection (Figure 53E), which was confirmed by photographs of harvested inguinal lymph 
nodes (Figure 53K).  Swelling was suspected to primarily result from presence of the CpG 
adjuvant because US/PA images of the lymph node after injection of uncoated particles 
loaded with dye did not show the same response (Figure 50).  Note that the injection site 
was not visible in any US/PA images in Figure 53. 
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Figure 53. In vivo US/PA imaging of CpG-Dye950-nPLP trafficking to the lymph node.  
PA datasets were post-processed using spectroscopic analysis to distinguish absorbers: 
CpG-Dye950-nPLPs (A – E; left column) and blood (F – J; right column).  Absorber 
distribution maps immediately (A, F), 4 hours (B, G), 8 hours (C, H), 24 hours (D, I), and 
48 hours (E, J) after injection.  (K) Photographs of excised lymph nodes.  Scale bar = 3 
mm.   
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 To better understand results from 2D cross-sectional lymph node images, 3D multi-
wavelength US/PA datasets were processed to depict CpG-Dye950-nPLP trafficking over 
a larger field-of-view from the injection site to the ipsilateral inguinal lymph node.  After 
spectroscopic analysis, topographic maps were created by integrating spectroscopic PA 
datasets with depth (y-dimension) (Figure 54).  Although crosstalk was again observed 
between the CpG-Dye950-nPLPs and blood (Figure 54A and 54F), this was localized to 
the injection site.  Thus, insights can still be gained about particle trafficking since the 
location of the imaging artifacts was clearly identified and isolated to a specific region.  
Minimal changes in CpG-Dye950-nPLP distribution were observed up to 8 hours post-
injection (Figure 54A–C).  At 24 and 48 hours post-injection the size and shape of the 
injection footprint changed, indicating particle movement away from the injection site, and 
CpG-Dye950-nPLPs appeared in a branched pattern resembling vessels in surrounding 
tissue (Figure 54D and 54E).  Thus, CpG-Dye950-nPLPs appeared trapped in vessels 
outside of the lymph node.  However, the intertwined arrangement of blood and lymphatic 
vessels and shortcomings of the current processing techniques, prevents conclusions on 
whether particles are specifically trapped within the vasculature or lymphatics.       
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Figure 54. Topographic maps of absorbers from the injection site to the lymph node. 
Spectroscopic PA analysis of 3D volumetric datasets distinguished CpG-Dye950-nPLPs 
(A – E; left column) and blood (F – J; right column).  Images were integrated over depth 
(y-dimension).  Over time the size of the injection footprint decreased, and particles were 
distributed in a branched pattern extending from the injection site (B – E).  Scale bar = 3 
mm.   
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 Three-dimensional volumetric US/PA overlay images of the CpG-Dye950-nPLPs 
provided additional anatomical context (Figure 55).  Similar to topographic maps, the 
footprint of the injection site decreased from 4 hours to 48 hours post-injection, indicating 
particle trafficking away from the injection site.  However, particles did not appear to be 
traveling towards the ipsilateral inguinal lymph node, located along the outer left edge of 
ultrasound images.  CpG-Dye950-nPLPs were localized to superficial vessels extending 
towards the midline of the mouse (Figure 55C and 55D).   
 
Figure 55. Three-dimensional volumetric images of CpG-Dye950-nPLP trafficking from 
the injection site.  Ultrasound (grayscale) depicts anatomy and spectroscopic PA analysis 
(color scale) distinguished CpG-Dye950-nPLPs at 4 hours (A, B) and 48 hours (C, D) post-
injection.  The size of the injection site decreased by 48 hours post-injection and PLPs 
appeared to be in superficial vessels (C, D).   
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 To again attempt to establish a ground truth for comparison of in vivo PA results, 
CpG-DiI-nPLP localization was assessed with fluorescent IVIS experiments at 24 hours 
post-injection.  Particle accumulation was still not visible at the lymph node with in vivo 
fluorescent imaging using IVIS.  However, some increase in fluorescent signal was visible 
in the abdomen (Figure 56A), which may indicate CpG-Dye950-nPLP accumulation in 
superficial vessels.  However, considering the poor resolution of IVIS, this signal cannot 
be conclusively identified as being within the lymphatic or blood vessels.  The mouse was 
sacrificed and fluorescent images were acquired ex vivo using IVIS by again cutting open 
the skin to expose both inguinal lymph nodes and covering the injection site. Fluorescent 
signal from CpG-DiI-nPLPs was visible at the ipsilateral lymph node, which indicates 
sensitivity of in vivo PA results can be improved.  However, the best comparison to assess 
current advantages of the in vivo US/PA platform is in vivo fluorescent imaging using IVIS 
(Figure 56A).  Unlike the US/PA platform, in vivo fluorescent imaging with IVIS did not 
visualize particle localization within superficial vessels or swelling at the lymph node and 
could not detect particles at the lymph node.  With this in mind, improvements are needed 
with the US/PA platform to better track adjuvant-coated particles; however, there are 
already clear benefits compared to the most similar minimally invasive alternative, in vivo 
fluorescent imaging with IVIS, which failed to provide any information on particle 
localization and trafficking to the lymph node in vivo.   
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Figure 56. In vivo and ex vivo fluorescent imaging of CpG-DiI-nPLPs at 24 hours.  Particle 
accumulation was not apparent at the left inguinal lymph node in vivo while the skin was 
intact (A).  Increased fluorescent signal was present at the left inguinal lymph node ex vivo 
(B). 
 Both inguinal lymph nodes were again harvested for histology from both PA and 
fluorescent studies of adjuvant-coated particles at 24 hours post-injection.  Eosin-stained 
tissue sections depicted CpG-Dye950-nPLPs throughout the lymph node, indicated by 
appearance of dark greenish/brown speckles (Figure 57A and 57B). Confocal fluorescent 
microscopy confirmed presence of CpG-DiI-nPLPs (red fluorescence) at the lymph node 
periphery (Figure 57C and 57D).  Both sets of microscopy also indicated a need for 
increased imaging sensitivity of the US/PA platform.  However, discrepancies remain as 
to whether the standard for US/PA sensitivity should be based on brightfield microscopy, 
confocal microscopy, or fluorescent imaging with IVIS, as each depicted differences in 
particle localization.  Brightfield microscopy showed accumulation of CpG-Dye950-
nPLPs throughout the lymph node.  Confocal microscopy showed accumulation of CpG-
DiI-nPLPs at the lymph node periphery only.  In vivo IVIS showed no accumulation of 
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CpG-DiI-nPLPs at the lymph node.  Thus, there are three different “ground truths.”   
Overall, the best comparison is again in vivo fluorescent imaging with IVIS, but the current 
US/PA platform already outperforms this modality.  Thus, the key question for future work 
is how to define the standards for the ideal US/PA platform for tracking particle in vivo.  
The best approach is to set standards based on quantification using histological analysis, 
but the target detection limit will need to be adjusted due to inherently lower sensitivity of 
minimally invasive, longitudinal monitoring methods.  
 
Figure 57. Histology of CpG-Dye950-nPLPs and CpG-DiI-nPLPs at 24 hours.  Brighfield 
and confocal microscopy from the left inguinal lymph node from the mouse injected with 
CpG-Dye950-nPLPs (A, B) or CpG-DiI-nPLPs (C, D), respectively.  CpG-Dye950-nPLPs 
may be indicated by dark green/brown speckles throughout the eosin-stained lymph node 
(A, B).  (C, D) Some CpG-DiI-nPLPs (red) were visible at the periphery of the DAPI-




Our results demonstrated several beneficial features of the US/PA imaging platform.  
First, high resolution and greater penetration depth of US/PA imaging compared to purely 
optical methods allowed minimally invasive monitoring of particle localization, which was 
not possible with currently available fluorescent imaging methods, including IVIS.  
Second, particle trafficking to the lymph node could be longitudinally monitored with 2D 
cross-sectional images.  Accompanying changes in blood spatial distribution and lymph 
node morphology were also detected.  Lastly, 3D volumetric US/PA datasets depicted 
particles over a wide field-of-view from the injection site to the inguinal lymph node, which 
may help to further understand particle trafficking and cell-particle interactions.   
 Although two specific PA-tagged PLP formulations were ultimately used for in 
vivo studies, Dye950-nPLPs and CpG-Dye950-nPLPs, many other formulations were 
developed and assessed in tissue-mimicking phantom studies.  Specifically, both m- and 
nPLPs were loaded with indocyanine green dye, copper sulfide nanoparticles, gold 
nanospheres, Prussian blue nanocubes, BODIPY dyes, croconic acid dyes, and infrared 
1048 dye (Sigma-Aldrich).  The key factor for encapsulation was use of a hydrophobic 
optical absorber.  Dye950 and Dye750, commercially identified as Epolight 3832 and 
Epolight 9151, respectively, produced the highest PA signal at the lowest PLP 
concentration in phantom studies (.195 mg/ml).  DiI was also a hydrophobic dye and was 
easily encapsulated in the PLPs for control experiments using fluorescent microscopy.   
 Although the same synthesis protocol was used for all particle types, differences in 
particle diameter and surface charge were observed based on the dye encapsulated.  For 
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example, compared to uncoated, unloaded nPLPs, which had a hydrodynamic diameter of 
277 nm, the DiI-nPLPs and Dye950-nPLPs measured ~301 nm and ~330 nm, respectively.  
Unloaded nPLPs and Dye950-nPLPs had similar surface charges of -31 +/- 5.73 mV and -
34.3 +/- 5.83 mV, respectively.  However, the DiI-nPLPs had a surface charge of -19.5 +/- 
4.06 mV.  After the final adjuvant coating step, the surface charge of CpG-Dye950-nPLPs 
and CpG-DiI-nPLP was 9.86 +/- 3.09 mV and -3.31 +/- 5.60 mV, respectively.  These 
differences may impact trafficking to the lymph node,58,201 which raises concerns for 
assessing the mechanism of action of a particular vaccine formulation as the dye itself may 
impact immune response.   
 In the case of the Dye950-nPLPs (uncoated), particles were detected at early time 
points and accumulation at the periphery of the left inguinal lymph node was observed by 
24 hours post-injection.  Furthermore, no crosstalk was observed between endogenous and 
exogenous absorbers prior to injection, which indicates correct identification of absorbers 
and gives confidence in PA detection at later time points.  In vivo US/PA imaging results 
were compared to in vivo results using IVIS.  Unlike in vivo US/PA imaging results, IVIS 
was unable to detect DiI-nPLPs in vivo at the left inguinal lymph node at 24 hours post-
injection.  Thus, mice were sacrificed and both inguinal lymph nodes were exposed by 
peeling back the skin to make another attempt at validating the US/PA platform.   Ex vivo 
fluorescent results using IVIS showed DiI-nPLP accumulation at the left inguinal lymph 
node, which agreed with in vivo US/PA imaging results.  However, poor image resolution 
of IVIS made it impossible to determine if DiI-nPLPs were localized only at the lymph 
node periphery, which was the case in PA results.  These shortcomings of IVIS highlight 
clear advantages of the US/PA tool, specifically minimally invasive, high resolution, in 
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vivo longitudinal imaging.  However, results also highlight the challenge of setting 
detection standards and establishing a ground truth for the US/PA imaging platform.   
 After sacrifice, lymph nodes were harvested for histology.  Brightfield microscopy 
was used to visualize Dye950-nPLPs, which appeared dark green in solution.  Confocal 
fluorescent microscopy was used to detect DiI-nPLPs.  Fluorescent microscopy depicted 
the DiI-nPLPs at only the periphery of the lymph node and agreed with in vivo US/PA 
imaging results.  However, brightfield microscopy showed Dye950-nPLP accumulation 
throughout the lymph node.  Thus, brightfield microscopy seemed to indicate that PA 
image analysis techniques lacked sufficient sensitivity to detect all Dye950-nPLPs within 
the lymph node.  However, although unlikely, the dark greenish/brown speckles observed 
from brightfield microscopy were faint and perhaps did not result from the Dye950-nPLPs.  
This again highlights the broader challenge of establishing an accurate ground truth for 
these studies.  Although ex vivo IVIS or confocal microscopy images were less ambiguous 
and seem to be the most reasonable comparisons, a separate set of particles was required 
to incorporate a fluorescent dye, and the DiI-nPLPs were injected in a different mouse.  
Furthermore, the image resolution of IVIS and sensitivity of confocal fluorescent 
microscopy make detailed comparison with the US/PA platform somewhat invalid.  To 
minimize variability in the ground truth, ideally one type of PLP would be synthesized that 
simultaneously encapsulates a fluorescent and PA absorber.   
 In vivo studies were repeated with adjuvant-coated particles.  The addition of an 
adjuvant was a better representation of a vaccine particle, and further analysis was 
conducted to assess the US/PA platform.  Thus, three-dimensional multi-wavelength 
US/PA datasets were acquired.  However, due to hardware limitations, it was not possible 
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to acquire as many wavelengths, which in turn impacted spectroscopic analysis results.  In 
this case, more crosstalk was observed between the CpG-Dye950-nPLPs and endogenous 
absorbers.  In spite of this inaccuracy, artifacts were identifiable and allowed some insight 
to be gained regarding particle trafficking.  However, improved processing techniques will 
be required.  Three-dimensional US/PA images of CpG-Dye950-nPLPs showed particles 
were localized to surrounding vessels, possibly be indicative of the lymphatics, but were 
not visible at the lymph node.  This type of information provides a direct example of how 
the US/PA platform may be used to help inform particle design.  Without localization 
within the lymph node, a robust immune response to this formulation was unlikely.   
5.6 Conclusions 
 Overall, the US/PA imaging platform has many advantages compared to existing 
technologies for monitoring vaccine particle trafficking to the lymph node, and some of 
the potential benefits were demonstrated in these studies.  Dye950-nPLPs and CpG-
Dye950-nPLPs, were synthesized and a variety of outcomes were monitored with US/PA 
imaging tools.   US/PA imaging allowed longitudinal monitoring, high resolution 
anatomical imaging of the lymph node, and three-dimensional volumetric images provided 
more complete information on particle trafficking over a wide field-of-view.   Changes in 
blood spatial distribution and lymph node morphology following particle injection were 
also detected.  Together these pieces of information may provide valuable data to aid 
vaccine design.  Overall, in its current state the in vivo US/PA platform for vaccine particle 
tracking already outperforms the most equivalent alternative technology, which is in vivo 
fluorescent imaging using IVIS.  IVIS could not detect particles at the lymph node in vivo, 
whereas the US/PA platform did allow minimally invasive particle detection in vivo.  
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However, further development is required to develop the US/PA platform into a highly 
sensitive, turn-key tool for vaccine particle detection. 
5.7 Future work 
 In its current state, results have shown enough beneficial features to motivate 
further development of the US/PA imaging platform for monitoring vaccine particles.  
However, many technical challenges were identified for future work.   
 Related to study design, a more accurate ground truth needs to be established.  It 
was difficult to validate PA imaging results with the current strategy of injecting a second 
set of fluorescent particles in a separate mouse.  Furthermore, inherent differences between 
US/PA imaging and fluorescent confocal microscopy or IVIS make it challenging to 
compare results and conclusively inform changes to the US/PA system.  Ideally, the 
fluorescent and PA absorber should be incorporated within the same particle.  Given the 
poor resolution and inability to detect particles at the lymph node in vivo using IVIS, 
confocal microscopy may be the better option for verification.   
 The greatest hurdles for future development is increasing PA imaging sensitivity 
and minimizing high background signals from endogenous absorbers.  Further analysis and 
modifications to spectroscopic processing algorithms may lead to some improvement.  
Additional particle formulations using other photoacoustic absorbers may also be 
investigated.  Although many other dyes and hydrophilic nanoparticles were tried in the 
current studies, another option would be to add hydrophobic coatings on nanoparticles, 
which was only briefly attempted.   
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 However at this point a more drastic change may be required.  Rather than 
continuing to investigate spectroscopic processing techniques, a switch to dynamic contrast 
mechanisms may be warranted.  Dynamic contrast agents, which change in relation to a 
stationary background PA signals, can allow highly sensitive imaging and suppression of 
background signals,205 which was clearly identified as a key requirement for detecting low 
concentrations of vaccine particles at the lymph node.  The drawback of dynamic contrast 
agents is susceptibility to motion artifacts.  
 Outside of addressing these technical challenges, the broader vision for this project 
is to implement multiplex imaging, meaning simultaneous detection of many different 
photoabsorbers.  The motivation from an immunotherapy perspective is that 
simultaneously delivering several different types of PLPs with different roles eliminates 
the need to design the one perfect particle to stimulate a holistic immune response.  
However, understanding the resulting outcome becomes more complex with more 
particles, even further affirming the need for longitudinal, minimally invasive, in vivo 
monitoring techniques.  Thus, the US/PA imaging platform may ultimately be applied by 
tagging different types of PLPs with different absorbers for simultaneous monitoring.   
5.8 Contributions from collaborators 
 In this chapter, specific contributions were made from Jardin Leleux, Randall Toy, 
Pallab Pradhan, and Diego Dumani.  Jardin Lelux, Pallab Pradhan, and Randall Toy shared 
expertise and provided training on synthesis of the unloaded PLPs and CpG-coated PLPs.  
Diego Dumani shared his expertise and advice related to lymph node imaging.   
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CHAPTER 6. CONCLUSIONS 
 This thesis described development of a US/PA imaging toolbox, consisting of 
optically-absorbing contrast agents, imaging hardware, imaging protocols and algorithm 
development.  Different individual tools were combined to create custom imaging 
platforms for tracking, which were applicable to a variety of in vivo applications: 1) stem 
cell tracking in the anterior segment and spinal cord; and 2) particle tracking for vaccine 
development.  The US/PA imaging toolbox was assessed in three very different 
applications to demonstrate versatility and motivate later extension to other applications.  
Although each application was met with unique individual technical challenges, there were 
several common themes observed throughout all results, which lay the pathway for overall 
future research plans. 
 One major research endeavor should be implementation of functional imaging.  In 
its current state, these platforms focused on providing information on location to assess 
stem cell delivery, retention, and migration.  Knowing where the stem cells were located 
was a critical first step on the longer path of providing functional information.  A variety 
of types of functional information can be provided, some of which were noted in 
developing the vaccine particle tracking platform, such as changes in blood accumulation 
or blood oxygen saturation at the lymph node.  A metric like blood oxygen saturation would 
be relevant to a variety of applications, whether that be assessing disease state, tissue 
healing and revascularization, inflammatory response, or immune response.   
 Specific to the stem cell tracking applications investigated herein, a key piece of 
functional information is to determine stem cell status, which may include stem cell 
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proliferation, viability, or differentiation.  In this case, photoacoustic nanosensors can 
address this need.  Related to the spinal cord aim, we are already developing a 
photoacoustic probe to assess stem cell apoptosis induced by caspase-3.  The same probe 
is relevant to ophthalmic applications.  However, one drawback of the current detection 
scheme is stem cell apoptosis is indicated by an increase in PA signal.  Changes in 
amplitude tend to be less reliable and sensitive than spectroscopic changes, i.e. amplitude 
may change due to variations in the imaging system itself.  Another drawback is that the 
current probe only detects stem cell apoptosis; however, there are many other mechanisms 
and classifications of cell death, including entosis, mitotic catastrophe, necrosis, 
necroptosis, and pyroptosis.206  Although detecting caspase-3-mediated stem cell apoptosis 
is a good starting point, a complete viability sensor should account for all mechanisms of 
cell death.   
  A second major research endeavor should be investigation of background-free 
photoacoustic imaging techniques, where PA signals from endogenous absorbers can be 
completely eliminated with confidence to improve detection sensitivity of cells or particles.  
This was a common theme throughout all applications.  Herein, spectroscopic analysis was 
the primary method used for separating photoacoustic signals from endogenous and 
exogenous absorbers.  The spinal cord represented the simplest image-processing scenario 
for several reasons: 1) minimal background signals were observed in the spinal cord; 2) the 
basic vicinity of the stem cell injection was known a priori; and 3) the spinal cord has a 
well-defined, consistent location.  The eye represented a more difficult image-processing 
scenario. Extremely high background signals from melanin were present in the eye; 
however, similar to the spinal cord, imaging geometry and location of endogenous 
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absorbers was well-established.  However, stem cell delivery location was not well-
controlled in the eye as cells were injected into the aqueous humor and allowed to passively 
accumulate at the TM.  Vaccine particle tracking at the lymph node represented the most 
challenging image-processing scenario.  Vaccine particle trafficking combined challenges 
from the eye and spinal cord and also introduced some new issues:  1) high background 
signals were observed from endogenous absorbers; 2) imaging geometry was not 
consistent; 3) very low PA signals must be distinguished due to low particle accumulation 
at the lymph node; 4) particle delivery to the lymph node was uncertain; 5) there was no 
ideal ground truth.  For these reasons, each application may benefit from custom light 
delivery systems or more sophisticated detection algorithms to facilitate background-free 
PA imaging techniques.   
 Custom focused-light delivery systems can minimize unnecessary irradiation of 
tissues outside of the region of interest.  Thus, background signals from endogenous 
absorbers outside the region of interest will no longer be irradiated and, in turn, no longer 
produce PA signals.  However, this approach may not be feasible depending on the 
application.  Focused-light delivery is particularly relevant for ophthalmic applications of 
PA imaging.  From a clinical perspective, focused light delivery systems improve patient 
safety, imaging accuracy, and ultimately facilitate translation.  However during the 
developmental phase, irradiating the entire anterior segment is important for visualizing 
off-target stem cell delivery.  In the case of lymph node imaging, focusing light at one 
specific lymph node may be useful to assess particle accumulation at the lymph node with 
high sensitivity; however, it is again not an ideal approach for visualizing particle 
trafficking through the lymphatics, which cover a wide field-of-view.   
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 An alternative is implementing background-free PA imaging techniques.  These 
techniques utilize dynamic contrast agents that repeatedly change state.  Examples include 
magnetomotive ultrasound or photoacoustic imaging, pump-probe techniques, or phase-
change agents.192,199,207,208  Magnetomotive imaging requires use of magnetic contrast 
agents, like PBNCs.  By cycling a magnetic field on and off, magnetically-tagged cells or 
particles oscillate and the background remains stationary.  This magnetic movement causes 
changes in the speckle pattern of US/PA datasets for highly-sensitive imaging at increased 
imaging depths.192,207  Pump-probe contrast agents, such as Rose Bengal dye, generate PA 
signals at one wavelength, but only after first being activated at a different wavelength.208  
Phase-change contrast agents use a similar strategy by oscillating between on/off states to 
create “blinking” contrast upon acoustic or optical activation.199,209  These more 
sophisticated contrast mechanisms may greatly improve sensitivity and imaging depth, 
which is a benefit for any application of the US/PA imaging toolbox developed here. 
 Finally, therapeutic tools can be added to the US/PA imaging toolbox.  The entire 
purpose of the US/PA toolbox developed here was to inform therapy design, aid 
development, and expedite clinical translation.  Thus, therapeutic strategies should be 
implemented in addition to monitoring.  One example was the use of PBNCs for image-
guided magnetic delivery.  Other opportunities include therapeutic heating, laser-triggered 
therapeutic delivery, nanoparticle-induced electrical stimulation, and many others.  
Overall, the current work demonstrated a variety of benefits and successes of the US/PA 
imaging toolbox for tracking cells and particles in vivo, and results lay the groundwork to 
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